

Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 3, 2004, 11:59:10 ; Search time 39 Seconds  
(without alignments)

Scoring table: US-09-852-261\_4\_COPY\_26\_111  
Perfect score: 86  
Sequence: 1 NPKTVGGSIRRAPQGIVD.....THKKKLQRKKSTLEEHK 86

Scanned: 1017041 seqs, 315518202 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 100 summaries

Database : SPREMBL 25,\*

1: sp\_archea:\*

2: sp\_bacteria:\*

3: sp\_fungi:\*

4: sp\_human:\*

5: sp\_invertebrate:\*

6: sp\_mammal:\*

7: sp\_mhc:\*

8: sp\_organelle:\*

9: sp\_phage:\*

10: sp\_plnt:\*

11: sp\_rhodet:\*

12: sp\_virus:\*

13: sp\_vertebrate:\*

14: sp\_unclassified:\*

15: sp\_rvirus:\*

16: sp\_bacteria:\*

17: sp\_archeap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES				
Result No.	Score	Query	% Match Length	DB ID
1	31	36 0	69	6 002807
2	31	36 0	127	11 P97899
3	31	36 0	153	11 Q8C4U6
4	31	36 0	155	11 Q8CA06
5	26	30 2	57	6 Q28236
6	26	30 2	66	6 Q9N1S6
7	26	30 2	130	4 Q9NP10
8	26	30 2	133	6 Q9N1C1
9	26	30 2	137	4 Q14620
10	26	30 2	139	4 Q13429
11	26	30 2	139	6 P79167
12	11	12 8	153	13 Q93380
13	9	10 5	53	13 Q901K0
14	9	10 5	62	6 Q9X888
15	9	10 5	92	13 Q8TMW9
16	9	10 5	104	6 Q86287

17	9	10.5	13	077107	077107 dicentrus
18	9	10.5	13	080056	09myz5 trichosurus
19	9	10.5	13	080050	Q80050 morone chry
20	9	10.5	13	080059	Q80059 morone saxa
21	9	10.5	13	080058	Q80058 morone chry
22	9	10.5	13	080057	Q80057 morone amer
23	9	10.5	13	09N155	Q9nis capreolus c
24	9	10.5	13	116	091111 oncorhynchus
25	9	10.5	13	117	091476 salmo salar
26	9	10.5	13	123	08M015 sus scrofa
27	9	10.5	13	129	08pu30 oreochromis
28	9	10.5	13	135	09ptp0 gallus gall
29	9	10.5	141	6	08p261 bos taurus
30	9	10.5	145	13	091475 salmo salar
31	9	10.5	149	6	09myx4 bos indicus
32	9	10.5	149	13	091231 oncorhynchus
33	9	10.5	154	11	063265 ractus norv
34	9	10.5	155	13	091162 oncorhynchus
35	9	10.5	159	13	093607 paralichthys
36	9	10.5	161	13	091230 oncorhynchus
37	9	10.5	167	13	09det4 myoxocephalus
38	9	10.5	177	13	072216 gallus gallus
39	9	10.5	185	13	057436 paralichthys
40	9	10.5	185	13	09yi57 acanthocephalus
41	9	10.5	186	13	09pks5 paralichthys
42	9	10.5	186	13	093527 paralichthys
43	9	10.5	186	13	090055 sianus aca
44	9	10.5	186	13	090055 sianus aca
45	9	10.5	187	13	071747 perca fluviatilis
46	9	10.5	187	13	077687 taenopygia
47	9	10.5	188	13	091268 gallus gallus
48	9	10.5	188	13	091965 oncorhynchus
49	9	10.5	210	13	091443 squalius aca
50	9	10.5	210	13	091443 squalius aca
51	9	10.5	215	13	073721 tilapia sp.
52	9	10.5	215	13	042429 latipes calceatus
53	9	10.5	215	13	090054 siganus guttatus
54	8	10.5	215	13	090056 paralichthys
55	8	10.5	218	13	091965 oncorhynchus
56	8	10.5	218	13	091443 squalius aca
57	8	10.5	218	13	073721 tilapia sp.
58	8	10.5	218	13	042429 latipes calceatus
59	8	10.5	218	13	098sr6 megalobrama
60	8	10.5	218	13	09y182 carassius a
61	8	10.5	218	13	091965 oncorhynchus
62	8	10.5	218	13	091443 squalius aca
63	8	10.5	218	13	091965 oncorhynchus
64	8	10.5	218	13	090055 sianus aca
65	8	10.5	218	13	090055 sianus aca
66	8	10.5	218	13	090055 sianus aca
67	8	10.5	218	13	090055 sianus aca
68	7	9.3	197	13	090055 sianus aca
69	7	9.3	197	13	090055 sianus aca
70	7	9.3	197	13	090055 sianus aca
71	7	9.3	197	13	090055 sianus aca
72	7	9.3	197	13	090055 sianus aca
73	7	9.3	197	13	090055 sianus aca
74	7	9.3	197	13	090055 sianus aca
75	7	9.3	197	13	090055 sianus aca
76	7	9.3	197	13	090055 sianus aca
77	7	9.3	197	13	090055 sianus aca
78	7	9.3	197	13	090055 sianus aca
79	7	9.3	197	13	090055 sianus aca
80	7	9.3	197	13	090055 sianus aca
81	7	9.3	197	13	090055 sianus aca
82	7	9.3	197	13	090055 sianus aca
83	7	9.3	197	13	090055 sianus aca
84	7	9.3	197	13	090055 sianus aca
85	7	9.3	197	13	090055 sianus aca
86	7	9.3	197	13	090055 sianus aca
87	7	9.3	197	13	090055 sianus aca
88	7	9.3	197	13	090055 sianus aca
89	7	9.3	197	13	090055 sianus aca
90	7	9.3	197	13	090055 sianus aca
91	7	9.3	197	13	090055 sianus aca
92	7	9.3	197	13	090055 sianus aca
93	7	9.3	197	13	090055 sianus aca
94	7	9.3	197	13	090055 sianus aca
95	5	9.3	197	13	090055 sianus aca
96	5	9.3	197	13	090055 sianus aca
97	5	9.3	197	13	090055 sianus aca
98	5	9.3	197	13	090055 sianus aca
99	5	9.3	197	13	090055 sianus aca
100	5	9.3	197	13	090055 sianus aca
101	5	9.3	197	13	090055 sianus aca
102	5	9.3	197	13	090055 sianus aca
103	5	9.3	197	13	090055 sianus aca
104	5	9.3	197	13	090055 sianus aca
105	5	9.3	197	13	090055 sianus aca
106	5	9.3	197	13	090055 sianus aca
107	5	9.3	197	13	090055 sianus aca
108	5	9.3	197	13	090055 sianus aca
109	5	9.3	197	13	090055 sianus aca
110	5	9.3	197	13	090055 sianus aca
111	5	9.3	197	13	090055 sianus aca
112	5	9.3	197	13	090055 sianus aca
113	5	9.3	197	13	090055 sianus aca
114	5	9.3	197	13	090055 sianus aca
115	5	9.3	197	13	090055 sianus aca
116	5	9.3	197	13	090055 sianus aca
117	5	9.3	197	13	090055 sianus aca
118	5	9.3	197	13	090055 sianus aca
119	5	9.3	197	13	090055 sianus aca
120	5	9.3	197	13	090055 sianus aca
121	5	9.3	197	13	090055 sianus aca
122	5	9.3	197	13	090055 sianus aca
123	5	9.3	197	13	090055 sianus aca
124	5	9.3	197	13	090055 sianus aca
125	5	9.3	197	13	090055 sianus aca
126	5	9.3	197	13	090055 sianus aca
127	5	9.3	197	13	090055 sianus aca
128	5	9.3	197	13	090055 sianus aca
129	5	9.3	197	13	090055 sianus aca
130	5	9.3	197	13	090055 sianus aca
131	5	9.3	197	13	090055 sianus aca
132	5	9.3	197	13	090055 sianus aca
133	5	9.3	197	13	090055 sianus aca
134	5	9.3	197	13	090055 sianus aca
135	5	9.3	197	13	090055 sianus aca
136	5	9.3	197	13	090055 sianus aca
137	5	9.3	197	13	090055 sianus aca
138	5	9.3	197	13	090055 sianus aca
139	5	9.3	197	13	090055 sianus aca
140	5	9.3	197	13	090055 sianus aca
141	5	9.3	197	13	090055 sianus aca
142	5	9.3	197	13	090055 sianus aca
143	5	9.3	197	13	090055 sianus aca
144	5	9.3	197	13	090055 sianus aca
145	5	9.3	197	13	090055 sianus aca
146	5	9.3	197	13	090055 sianus aca
147	5	9.3	197	13	090055 sianus aca
148	5	9.3	197	13	090055 sianus aca
149	5	9.3	197	13	090055 sianus aca
150	5	9.3	197	13	090055 sianus aca
151	5	9.3	197	13	090055 sianus aca
152	5	9.3	197	13	090055 sianus aca
153	5	9.3	197	13	090055 sianus aca
154	5	9.3	197	13	090055 sianus aca
155	5	9.3	197	13	090055 sianus aca
156	5	9.3	197	13	090055 sianus aca
157	5	9.3	197	13	090055 sianus aca
158	5	9.3	197	13	090055 sianus aca
159	5	9.3	197	13	090055 sianus aca
160	5	9.3	197	13	090055 sianus aca
161	5	9.3	197	13	090055 sianus aca
162	5	9.3	197	13	090055 sianus aca
163	5	9.3	197	13	090055 sianus aca
164	5	9.3	197	13	090055 sianus aca
165	5	9.3	197	13	090055 sianus aca
166	5	9.3	197	13	090055 sianus aca
167	5	9.3	197	13	090055 sianus aca
168	5	9.3	197	13	090055 sianus aca
169	5	9.3	197	13	090055 sianus aca
170	5	9.3	197	13	090055 sianus aca
171	5	9.3	197	13	090055 sianus aca
172	5	9.3	197	13	090055 sianus aca
173	5	9.3	197	13	090055 sianus aca
174	5	9.3	197	13	090055 sianus aca
175	5	9.3	197	13	090055 sianus aca
176	5	9.3	197	13	090055 sianus aca
177	5	9.3	197	13	090055 sianus aca
178	5	9.3	197	13	090055 sianus aca
179	5	9.3	197	13	090055 sianus aca
180	5	9.3	197	13	090055 sianus aca
181	5	9.3	197	13	090055 sianus aca
182	5	9.3	197	13	090055 sianus aca
183	5	9.3	197	13	090055 sianus aca
184	5	9.3	197	13	090055 sianus aca
185	5	9.3	197	13	090055 sianus aca
186	5	9.3	197	13	090055 sianus aca
187	5	9.3	197	13	090055 sianus aca
188	5	9.3	197	13	090055 sianus aca
189	5	9.3	197	13	090055 sianus aca
190	5	9.3	197	13	090055 sianus aca
191	5	9.3	197	13	090055 sianus aca
192	5	9.3	197	13	090055 sianus aca
193	5	9.3	197	13	090055 sianus aca
194	5	9.3	197	13	090055 sianus aca
195	5	9.3	197	13	090055 sianus aca
196	5	9.3	197	13	090055 sianus aca
197	5	9.3	197	13	090055 sianus aca
198	5	9.3	197	13	090055 sianus aca
199	5	9.3	197	13	090055 sianus aca
200	5	9.3	197	13	090055 sianus aca
201	5	9.3	197	13	090055 sianus aca
202	5	9.3	197	13	090055 sianus aca
203	5	9.3	197	13	090055 sianus aca
204	5	9.3	197	13	090055 sianus aca
205	5	9.3	197	13	090055 sianus aca
206	5	9.3	197	13	090055 sianus aca
207	5	9.3	197	13	090055 sianus aca
208	5	9.3	197	13	090055 sianus aca
209	5	9.3	197	13	090055 sianus aca
210	5	9.3	197	13	090055 sianus aca
211	5	9.3	197	13	090055 sianus aca
212	5	9.3	197	13	090055 sianus aca
213	5	9.3	197	13	090055 sianus aca
214	5	9.3	197	13	090055 sianus aca
215	5	9.3	197	13	090055 sianus aca
216	5	9.3	197	13	090055 sianus aca
217	5	9.3	197	13	090055 sianus aca
218	5	9.3	197	13	090055 sianus aca
219	5	9.3	197	13	090055 sianus aca
220	5	9.3	197	13	090055 sianus aca
221	5	9.3	197	13	090055 sianus aca
222	5	9.3	197	13	090055 sianus aca
223	5	9.3	197	13	090055 sianus aca
224	5	9.3	197	13	090055 sianus aca
225	5	9.3	197	13	090055 sianus aca
226	5	9.3	197	13	090055 sianus aca
227	5	9.3	197	13	090055 sianus aca
228	5	9.3	197	13	090055 sianus aca
229	5	9.3	197	13	090055 sianus aca
230	5	9.3</			

OX NCBI\_TAXID=10118;  
 RN [1]  
 RP PARTIAL SEQUENCE FROM N.A.  
 MEDLINE:87222423; PubMed=3034909;  
 RA Shimatsu A.; Rotwein P.;  
 "Mosaic evolution of the insulin-like growth factors.";  
 RT J. Biol. Chem. 262:7894-7900(1987).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 MEDLINE=91103966; PubMed=1368571;  
 RA Kato H.; Okochi A.; Miura Y.; Noguchi T.;  
 "A new cDNA clone relating to larger molecular species of rat insulin-  
 like growth factor-I mRNA.";  
 RT Agric. Biol. Chem. 54:1599-1601(1990).  
 RL "I."  
 CC -  
 CC -  
 CC -  
 RESULT 1  
 PRELIMINARY; PRT; 69 AA.  
 ID Q02807  
 AC 002807;  
 DT 01-JUN-1997 (TREMBLrel. 04. Last sequence update)  
 DT 01-JUL-1997 (TREMBLrel. 04. Last annotation update)  
 DT 01-JUN-2003 (TREMBLrel. 24. Last annotation update)  
 OS Bubalus bubalis (Domestic water buffalo).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Butheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;  
 OC Bovidae; Bovinae; Bubalus.  
 RN NCBI\_TAXID=89462;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE:Dung;  
 RA Dabiri M.; Appa Rao K.B.C.; Kaur G.; Garg S.; Patil S.; Totev S.M.;  
 RT "The expression of growth factor ligand and receptor genes in  
 preimplantation stage buffalo embryos and oviductal epithelial  
 cells";  
 RL Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.  
 CC -  
 CC -  
 CC -  
 DR EMBL; Y10691; CA071694.1; -.  
 DR HSSP; P01343; 2GFL  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0005179; F:hormone activity; IEA.  
 DR InterPro; IPR00825; Ins/IGF/relax.  
 DR Pfam; PF00049; Insulin; 1.  
 DR PRINTS; PR00049; INSULIN.  
 DR SMART; SM0078; IIGF\_1.  
 DR PROSITE; PS0062; INSULIN; 1.  
 FT CHAIN 23 92 PROST  
 SQ SEQUENCE 127 AA; 14106 MW; 104E126BCFCA5CB7 CRC64;  
 RN Query Match 36.0%; Score 31; DB 11; Length 127;  
 RC Best Local Similarity 100.0%; Pred. No. 9.8e+25;  
 RA Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OQ 6 YGSSIRRAPQTGIVDECCFRSDQRLRLEMYC 36  
 DB 53 YGSSIRRAPQTGIVDECCFRSDQRLRLEMYC 83  
 RESULT 3  
 PRELIMINARY; PRT; 153 AA.  
 ID Q8C4U6  
 AC Q8C4U6;  
 DT 01-MAR-2003 (TREMBLrel. 23. Last sequence update)  
 DT 01-MAR-2003 (TREMBLrel. 23. Last annotation update)  
 DE Unknown EST.  
 GN C730016709Rik.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Butheria; Rodentia; Sciuromorphi; Muridae; Murinae; Mus.  
 RN NCBI\_TAXID=10190;  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=CB7L6G; TISSUE=Cerebellum;  
 RX MEDLINE=2234683; PubMed=12466851;  
 RA The FANTOM Consortium,  
 RA The RIKEN Genome Exploration Research Group Phase I & II Team;  
 RT "Analysis of the mouse transcriptome based on functional annotation of  
 RT 60,770 full-length cDNAs.;"  
 RL Nature 420:563-572(2002).  
 DR EMBL; AK081019; BAC38117.1; -.  
 DR MGDB; MG12444166; C730016709Rik.  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0005576; F:hormone activity; IEA.  
 DR GO; GO:007592; P:physiological processes; IEA.  
 DR InterPro; IPR004825; Ins/IGF/relax.  
 DR Pfam; PF00049; Insulin; 1.  
 DR PRINTS; PR00077; INSULIN.  
 DR SMART; SM0078; IIGF\_1.  
 DR PROSITE; PS0062; INSULIN; 1.  
 SQ SEQUENCE 153 AA; 17093 MW; 967596AEAC0A387 CRC64;  
 RC Query Match 36.0%; Score 31; DB 11; Length 153;



PT NON-TER 66 66 MW; 4BD5ACFADDF73E51 CRC64;  
 SQ SEQUENCE 66 AA; 7422 MW; 4BD5ACFADDF73E51 CRC64;  
 Query Match 30.2%; Score 26; DB 6; Length 66;  
 Best Local Similarity 100.0%; Pred. No. 1.1e-19; 0; Mismatches 0;  
 Matches 26; Conservative 0; Indels 0; Gaps 0;  
 RT "A primary screen of the bovine genome for quantitative trait loci  
 affecting twinning rate,"  
 RT submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.  
 QY 11 RRAPQGIVDCCFRSCDLRLLEMVC 36  
 DB 25 RRAPQGIVDCCFRSCDLRLLEMVC 50  
 RESULT 7  
 Q9NP10 PRELIMINARY; PRT; 130 AA.  
 ID Q9NP10; AC; 01-OCT-2000 (TREMBrel. 15, 'Created)  
 DT 01-OCT-2000 (TREMBrel. 15, 'Last sequence update)  
 DR 01-JUN-2003 (TREMBrel. 24, 'Last annotation update)  
 DE IGFL1 protein precursor.  
 GN IGFL1.  
 OS Homo sapiens (Human).  
 OC Bovaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;  
 Mammalia; Buterria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TAXID=9606;  
 RN [1]  
 RF SEQUENCE FROM N.A.  
 RX MEDLINE=88065102; PubMed=3683205;  
 RA Rall L.B., Scott J., Bell G.I.;  
 RT "Human insulin-like growth factor I and II messenger RNA: isolation of complementary DNA and analysis of expression.,";  
 RL Meth. Enzymol. 146:239-248(1987).  
 CC !- SUBCELLULAR LOCATION: SECRETED (BY SIMILARITY).  
 CC !- SIMILARITY: BELONGS TO THE INSULIN/IGF/RELAXIN FAMILY.  
 DR EMBL; M22644; AA52543.1; .  
 DR HSSP; P01343; 2GFL.  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0005179; F:hormone activity; IEA.  
 DR GO; GO:0007582; P:physiological processes; IEA.  
 DR InterPro; IPR004825; Ins/IGF/relax.  
 PRIM; PF00049; Insulin; 1.  
 SMART; SM00078; INSULINB.  
 PROSITE; PS00262; INSULIN; 1.  
 KW Signal.  
 FT CHAIN 1 25 POTENTIAL.  
 SQ SEQUENCE 130 AA; 14406 MW; 970FBAACFA0352D CRC64;  
 Query Match 30.2%; Score 26; DB 4; Length 130;  
 Best Local Similarity 100.0%; Pred. No. 1.9e-19; 0; Mismatches 0;  
 Matches 26; Conservative 0; Indels 0; Gaps 0;  
 RT "A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells.,"  
 RT Mol. Endocrinol. 4(1):14-19(201990).  
 CC !- SUBCELLULAR LOCATION: SECRETED (BY SIMILARITY).  
 DR EMBL; M37484; AA5289.1; .  
 DR PIR; A36552; A36552.  
 DR HSSP; P0143; 2GFL.  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0007582; P:physiological processes; IEA.  
 DR InterPro; IPR004825; Ins/IGF/relax.  
 PRIM; PF00049; Insulin; 1.  
 SMART; SM00078; INSULINB.  
 PROSITE; PS00262; INSULIN; 1.  
 KW Signal.  
 FT CHAIN 1 32 POTENTIAL.  
 SQ SEQUENCE 137 AA; 15177 MW; BRC0D1B32AB75D CRC64;  
 Query Match 30.2%; Score 26; DB 4; Length 137;  
 Best Local Similarity 100.0%; Pred. No. 2e-19; 0; Mismatches 0;  
 Matches 26; Conservative 0; Indels 0; Gaps 0;



EMBL; AY074980; AAC26006.1; - .  
 DR HSSP; P01343; 2GFL.  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0005179; F:hormone activity; IEA.  
 DR InterPro; IPR004125; Ins/IGF/relax.  
 DR Pfam; PF00049; Insulin; 1.  
 DR PRINTS; PR00277; INSULINB.  
 DR SMART; SM00078; IIGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 KW Signal. POTENTIAL.  
 FT SIGNAL 1 48 INSULIN-LIKE GROWTH FACTOR-I.  
 FT CHAIN 49 118 MW; 5AF1EB8D13C70B5 CRC64;  
 SQ SEQUENCE 153 AA; ||||||| 109

Query Match Best Local Similarity 100.0%; Score 11; DB 13; Length 153; Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0; CC 25 SCDIIRRLEMNC 36 SCDIIRRLEMNC 109

Qy DR 99 NCBI\_TaxID=9796; RQ SEQUENCE FROM N.A.  
 RX RX  
 RA Caetano A.R., Pomp D., Murray J.D., Bowling A.T.;  
 RT "Comparative mapping of 18 equine type I genes assigned by somatic cell hybrid analysis.";  
 RL Mamm. Genome 10:271-276 (1999).  
 CC -!- SUBCELLULAR LOCATION: SECRETED (BY SIMILARITY).  
 CC -!- SIMILARITY: BELONGS TO THE INSULIN/IGF/RELAXIN FAMILY.  
 DR EMBL; AF097586; AAD25989.1; - .  
 DR HSSP; P01344; IIGL.  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0005179; F:hormone activity; IEA.  
 DR InterPro; IPR004125; Ins/IGF/relax.  
 DR Pfam; PF00049; Insulin; 1.  
 DR SMART; SM00078; IIGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 DR NON\_TER 1 1 1  
 FT NON\_TER 62 62 62  
 SQ SEQUENCE 7037 MW; F00C3FE300B4793C CRC64;  
 DR 21 BCCFRSCDL 29  
 Db 14 BCCFRSCDL 22

RESULT 13  
 Q9YXK0 PRELIMINARY; PRT; 53 AA.  
 AC Q9YXK0;  
 DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)  
 DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)  
 DE Insulin-like growth factor II (Fragment).  
 OS Gallus gallus (Chicken).  
 OC Gallus, Metazoa, Chordata, Craniata, Vertebrata, Euteleostomi, Archosauria, Aves, Neognathae, Galliformes, Phasianidae, Phasianinae, OX NCBI\_TaxID=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Yan B., Li N.;  
 RT Single Nucleotide Polymorphism Analysis in Chicken Insulin-like Growth Factor-II Gene and its Association with Growth and Carcass Traits.;  
 RT Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.  
 RL -!- SUBCELLULAR LOCATION: SECRETED (BY SIMILARITY).  
 CC -!- SIMILARITY: BELONGS TO THE INSULIN/IGF/RELAXIN FAMILY.  
 EMBL; AY043225; AAK85304.1; - .  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0005179; F:hormone activity; IEA.  
 GO; GO:0007582; P:physiological processes; IEA.  
 DR InterPro; IPR004825; Ins/IGF/relax.  
 DR Pfam; PF00049; Insulin; 1.  
 DR SMART; SM00078; IIGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 FT NON\_TER 1 1  
 SQ SEQUENCE 53 AA; 5843 MW; 263970BF5D9467DF CRC64;

Query Match Best Local Similarity 100.0%; Score 9; DB 13; Length 53; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0; CC 21 ECCFRSCDL 29 SCDIIRRLEMNC 23

Qy DR 15 NCBI\_TaxID=9796; RQ SEQUENCE FROM N.A.  
 RX RX  
 RA Radetic F., Malek R.;  
 RT "Effects of 4-hydroxyphenol on ovarian gene expression in juvenile Atlantic salmon (Salmo salar).";  
 RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.  
 CC -!- SUBCELLULAR LOCATION: SECRETED (BY SIMILARITY).  
 CC -!- SIMILARITY: BELONGS TO THE INSULIN/IGF/RELAXIN FAMILY.  
 DR EMBL; AY09955; AAL29956.1; - .  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0005179; F:hormone activity; IEA.  
 DR GO; GO:0007582; P:physiological processes; IEA.  
 DR InterPro; IPR04825; Ins/IGF/relax.  
 DR Pfam; PF00049; Insulin; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 DR NON\_TER 1 1  
 FT NON\_TER 92 92 92  
 SQ SEQUENCE 92 AA; 10716 MW; 4818P230A1929634 CRC64;  
 DR Query Match Best Local Similarity 100.0%; Score 9; DB 13; Length 92; DT 01-NOV-1999 (TREMBLrel. 12, Created)  
 DT 01-NOV-1999 (TREMBLrel. 12, Last sequence update)

RESULT 14  
 Q9XSB8 PRELIMINARY; PRT; 62 AA.  
 ID Q9XSB8;  
 AC Q9XSB8;  
 DT 01-NOV-1999 (TREMBLrel. 12, Created)  
 DT 01-NOV-1999 (TREMBLrel. 12, Last sequence update)

Matches	9;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;	Query Match	10.5%	Score	9;	DB	13;	Length	104;		
Qy	21	ECCFRSCDL	29							Best Local Similarity	100.0%			No.	0.15;				
Db	6	ECCFRSCDL	14							Matches	9;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
RESULT 16																			
ID	Q862B7			PRELIMINARY;			PRT;		104 AA.	Q9MYZ6				PRELIMINARY;		PRT;		106 AA.	
AC	Q862B7;									ID	Q9MYZ6								
DT	01-JUN-2003	(TREMBLrel.	24,	Created)						AC	Q9MYZ6;								
DT	01-OCT-2003	(TREMBLrel.	25,	Last annotation update)						DT	01-OCT-2000	(TREMBLrel.	15,	Created)					
OS	Bos taurus	(Bovine).								DT	01-OCT-2000	(TREMBLrel.	15,	Last sequence update)					
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Butheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovidae; Bovinae; Bos.									DT	01-JUN-2003	(TREMBLrel.	24,	Last annotation update)					
OC	NCBI_TaxID=9913;									DB	92	RAQRHTDMP	100						
RN	[1]									RESULT 17									
RP	SEQUENCE FROM N.A.									Q9MYZ6									
RX	MEDLINE=22544902;	PubMed=12656828;								ID	Q9MYZ6								
RA	Ishiwata H., Ratsuma S., Kikuchi K., Patel O.V., Nakano H.,									AC	Q9MYZ6;								
RA	Takahashi T., Imai K., Hirashima A., Shiozawa S., Ikeda H., Suzuki Y., Tsujimoto G., Iizuka Y., Todoroki J., Hashizume K.,									DT	01-OCT-2000	(TREMBLrel.	15,	Created)					
RT	"Characterization of gene expression profiles in early bovine pregnancy using a custom cDNA microarray."									DT	01-OCT-2000	(TREMBLrel.	15,	Last sequence update)					
RL	Mol. Reprod. Dev. 65:9-18 (2003).									DT	01-JUN-2003	(TREMBLrel.	24,	Last annotation update)					
DR	EMBL: AB99052; BADG5352; 1/-.									DB	49	RAQRHTDMP	57						
DR	GO; GO:0005575; C:extracellular; IEG.									RN	92	RAQRHTDMP	100						
DR	GO; GO:0005179; P:hormone activity; IEG.									RESULT 18									
DR	GO; GO:0007582; P:Physiological processes; IEG.									Q9MYZ6									
DR	InterPro; IPR04825; Ins/IGFrelax.									ID	Q9MYZ6								
DR	PROSITE; PS00262; INSULIN; 1.									AC	Q9MYZ6;								
FT	NON_TER	1								RT	01-OCT-2000	(TREMBLrel.	15,	Created)					
FT	NON_TER	104	104							RA	92	RAQRHTDMP	100						
SQ	SEQUENCE	104 AA;	11708 MW;	BBBB8781F13EEE3 CRC64;						RT	01-OCT-2000	(TREMBLrel.	15,	Last sequence update)					
Query Match	10.5%;	Score	9;	DB	6;	Length	104;			DB	49	RAQRHTDMP	57						
Best Local Similarity	100.0%;	Pred.	No.	0.15;						RN	92	RAQRHTDMP	100						
Matches	9;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;	RP	SEQUENCE FROM N.A.								
Db	3	ECCFRSCDL	11							RX	MEDLINE=21100219;	PubMed=11161776;							
RESULT 17										RA	Saunders M.C., Gemmell R.T., Cullieus J.D.;								
QT107	PRELIMINARY;		PRT;	104 AA.						RT	"Insulin-like growth factor 2 cDNA cloning and ontogeny of gene expression in the liver of the marsupial brushtail possum (Trichosurus vulpecula)."								
AC	QT107;									RL	Gen. Comp. Endocrinol. 121:14-14 (2001).								
DT	01-OCT-2003	(TREMBLrel.	25,	Created)						CC	-- SIMILARITY BELONGS TO THE INSULIN/IGF/RELAXIN FAMILY.								
DT	01-OCT-2003	(TREMBLrel.	25,	Last sequence update)						CC	SECRETED (BY SIMILARITY).								
DT	01-OCT-2003	(TREMBLrel.	25,	Last annotation update)						CC	1- SUBCELLULAR LOCATION: SECRETED (BY SIMILARITY).								
DE	01-OCT-2003	(TREMBLrel.	25,	Last annotation update)						CC	1- SIMILARITY BELONGS TO THE INSULIN/IGF/RELAXIN FAMILY.								
GN	IGFL.									DR	EMBL: AF276074; AAFF69001; -.								
OS	Dicentrarchus labrax	(European sea bass).								DR	HSSP; P01444; IIGL.								
OC	Bukaryote; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Actinopterygii; Neopterygii; Teleostei; Buteleosteii; Neoteleosteii; Acanthomorpha; Acanthopterygii; Perciformes; Percoidei; Moronidae; Dicentrarchus.									DR	GO; GO:0005179; P:hormone activity; IEG.								
OC	NCBI_TaxID=13489;									DR	InterPro; IPR04825; Ins/IGF/relax.								
RN	[1]	SEQUENCE FROM N.A.								DR	Pfam; PF0004; Insulin, 1.								
RP	Gibert E., Villeneuve L.A.N., Cahu C., Zambonino-Infante J.L.; "Effect of vitamin A level during the development of sea bass (Dicentrarchus labrax) larvae"; Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.									DR	PRINTS; PRO0277; INSULINB.								
RT	NON_TER	1								DR	SMART; SW00078; IIGF, 1.								
FT	NON_TER	1								DR	PROSITE; PS00262; INSULIN; 1.								
FT	NON_TER	106	106							FT	NON_TER	1							
SQ	SEQUENCE	106 AA;	12021 MW;	804BB2A66FCB7D6D CRC64;						FT	NON_TER	106	106						
Query Match	10.5%;	Score	9;	DB	6;	Length	106;			FT	NON_TER	106	106						
Best Local Similarity	100.0%;	Pred.	No.	0.15;						FT	NON_TER	106	106						
Matches	9;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;	FT	NON_TER	106	106						
Db	51	ECCFRSCDL	59							FT	NON_TER	106	106						
RESULT 19										FT	NON_TER	106	106						
OB0ONO	OB0ONO			PRELIMINARY;			PRT;		108 AA.	FT	NON_TER	106	106						
AC	OB0ONO;									FT	NON_TER	106	106						
DT	01-JUN-2003	(TREMBLrel.	24,	Created)						FT	NON_TER	106	106						
DT	01-JUN-2003	(TREMBLrel.	24,	Last sequence update)						FT	NON_TER	106	106						
DE	01-OCT-2003	(TREMBLrel.	25,	Last annotation update)						FT	NON_TER	106	106						
OS	Morone chrysops x Morone saxatilis (White bass x Striped bass).									FT	NON_TER	106	106						
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Actinopterygii; Neopterygii; Teleostei; Buteleosteii; Neoteleosteii; Acanthomorpha; Acanthopterygii; Perciformes; Percoidei; Moronidae; Morone.									FT	NON_TER	106	106						
OC	NCBI_TaxID=4552;									FT	NON_TER	106	106						
RN	[1]	SEQUENCE FROM N.A.								FT	NON_TER	106	106						
RP	Fruchman S., Hawkins M.B., Borski R.J.; "Cloning of IGF-I and the type I IGF receptor cDNAs from temperate									FT	NON_TER	106	106						
RT	NON_TER	1								FT	NON_TER	106	106						
FT	NON_TER	104	104							FT	NON_TER	106	106						
SQ	SEQUENCE	104 AA;	11339 MW;	5CC569aa80B8F6FF2 CRC64;						FT	NON_TER	106	106						



us-09-852-261-4 copy 26 111.rsppt

DR SMART; SM00078; IIGF; 1.  
DR PROSITE; PS00262; INSULIN; 1.  
KW Signal; 1.  
FT NON\_TMR 1 1  
FT SIGNAL <1 18 POTENTIAL.  
FT CHAIN 19 88 INSULIN-LIKE GROWTH FACTOR I.  
FT SEQUENCE 117 AA; 12867 MW; A976563E2F526EAC CRC64;  
SQ Query Match 10.5%; Score 9; DB 13; Length 117;  
Best Local Similarity 100%; Pred. No. 0.15;  
Matches 9; Conservative 0; Mismatches 0; Indels 0;  
Gaps 0;  
Qy 49 RAQRHDMP 57  
Db 92 RAQRHDMP 100

Search completed: March 3, 2004, 12:02:38  
Job time : 40 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 3, 2004, 11:55:55 ; Search time 14 Seconds  
Sequence: 1 NKPTVYGSIRRAPQTGIVD.....THKKRKLUQRRKGSTLZEHK 86  
319.860 Million cell updates/sec

Scoring table: OLIGO

Gapop 60.0 , Gapext 60.0

Perfect score: US-09-852-261-4\_COPY\_26\_111

Score: 86

Sequence: 1 NKPTVYGSIRRAPQTGIVD.....THKKRKLUQRRKGSTLZEHK 86  
(without alignments)

Word size : 0

Searched: 141681 seqs, 52070155 residues

Post-processing: Listing first 100 summaries

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Database : SwissProt\_42.2\*

%  
SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	40	46.5	181	IGFB RAT
2	31	36.0	127	1 IGA_MOUSE
3	31	36.0	133	1 IGPB_MOUSE
4	31	36.0	153	1 IGPB RAT
5	26	30.2	81	1 IGP1_SUMMU
6	26	30.2	122	1 IGP1_CANFA
7	26	30.2	122	1 IGP1_HORSE
8	26	30.2	130	1 IGP1_CAVPO
9	26	30.2	143	1 IGP1_RABIT
10	26	30.2	153	1 IGP1_PIG
11	26	30.2	153	1 IGP1_HUMAN
12	26	30.2	154	1 IGP1_BOVIN
13	26	30.2	154	1 IGP1_CAPII
14	26	30.2	154	1 IGP1_SHEEP
15	16	12.8	195	1 IGP1_HUMAN
16	11	12.8	124	1 IGP1_CONJA
17	11	12.8	153	1 IGP1_CHICK
18	10	11.6	153	1 IGP1_XENIA
19	9	10.5	66	1 IGP2_CHICK
20	9	10.5	128	1 IGP2_CAVPO
21	9	10.5	129	1 IGP2_CAVPO
22	9	10.5	155	1 IGP2_BOVIN
23	9	10.5	176	1 IGP1_ONCII
24	9	10.5	176	1 IGP1_ONCIV
25	9	10.5	179	1 IGP2_SHEEP
26	9	10.5	180	1 IGP2_HUMAN
27	9	10.5	180	1 IGP2_MOUSE
28	9	10.5	180	1 IGP2_RAT
29	9	10.5	181	1 IGP2_HORSE
30	9	10.5	181	1 IGP2_PIG
31	9	10.5	214	1 IGP2_ONCIV
32	8	9.3	161	1 IGP1_CIFCA
33	8	9.3	161	1 IGP1_CIFCA

ALIGNMENTS

RESULT 1

IGFB-RAT  
ID: IGFB-RAT  
AC: P08024;  
DT: 01-FEB-1991 (Rel. 17, last sequence update)  
DE: Insulin-like growth factor IB precursor (IGF-IB) (Somatomedin).  
GN: IGF1 OR IGF-1.  
OS: Rattus norvegicus (Rat).  
OC: Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
NCBI\_TaxID:10116;  
RN: [1]  
RP: SEQUENCE FROM N.A.  
RX: MEDLINE=9722423; PubMed=3034909;  
RT: "Mosaic evolution of the insulin-like growth factors. Organization, sequence, and expression of the rat insulin-like growth factor I gene.";  
RL: J. Biol. Chem. 262:7894-7900(1987).  
RN: [2]  
RP: SEQUENCE FROM N.A.  
RX: MEDLINE=8915672; PubMed=3658684;  
RT: "Sequence of two rat insulin-like growth factor I mRNAs differing within the 5' untranslated region.";  
RL: Nucleic Acids Res. 15:7196-7196(1987).  
RN: [3]  
RP: SEQUENCE FROM N.A.  
RX: MEDLINE=8912259; PubMed=3221878;  
RA: Roberts C.T., Lasky S.R., Lowe W.L., Seaman W.T., Leroith D.;  
RT: "Structure of the rat insulin-like growth factor II transcriptional unit: heterogeneous transcripts are generated from two promoters by use of multiple polyadenylation sites and differential ribonucleic acid splicing";  
RL: Mol. Endocrinol. 2:1115-1126(1988).  
RN: [4]  
RP: SEQUENCE OF 49-118.  
RX: MEDLINE=8917603; PubMed=2538424;  
RA: Nakamura K., Kobayashi M., Ishii Y., Tamura T., Hashimoto K.,  
RA: Niwa M., Zapf J.;  
RT: "Primary structure of rat insulin-like growth factor-I and its biological activities.";  
RL: J. Biol. Chem. 264:5616-5621(1989).  
CC: --!- FUNCTION: The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity.  
CC: --!- SUBCELLULAR LOCATION: Secreted.  
CC: --!- ALTERNATIVE PRODUCTS: Event=Alternative splicing; Named isoforms=2;  
CC: IsoId=P08024-1; Sequence=Displayed;  
CC: Name=IGF-IB;  
CC: IsoId=P08025-1; Sequence=External;  
CC: --!- SIMILARITY: Belongs to the insulin family.  
CC: -----  
CC: This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).  
CC: -----  
DR: EMBL; M15647; AAA1214\_1; JOINED.  
DR: EMBL; M15648; AAA1214\_1; JOINED.  
DR: EMBL; M15649; AAA1214\_1; JOINED.  
DR: X06107; CAA29480\_1; ALT\_SEQ.  
DR: EMBL; M15480; AAA1385\_1; ALT\_SEQ.  
DR: PIR; A27804; A27804.  
DR: HSSP; P01343; IGF1.  
DR: InterPro; IPRO04825; Ins/IGF/relax.  
DR

RESULT 2

IGFB-MOUSE  
ID: IGFB-MOUSE  
AC: P05017;  
DT: 13-AUG-1987 (Rel. 05, Last sequence update)  
DT: 10-OCT-2003 (Rel. 42, Last annotation update)  
DE: Insulin-like growth factor IA precursor (IGF-IA) (Somatomedin).  
GN: IGF1 OR IGF-1.  
OS: Mus musculus (Mouse).  
OC: Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
NCBI\_TaxID:10090;  
RN: [1]  
RP: SEQUENCE FROM N.A.  
RX: MEDLINE=87040760; PubMed=3774549;  
RA: Bell G.I., Stempin M.M., Fong N.M., Rall L.B.;  
RT: "Sequences of liver cDNAs encoding two different mouse insulin-like growth factor I precursors.";  
RL: Nucleic Acids Res. 14:7873-7882(1986).  
CC: --!- FUNCTION: The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity.  
CC: --!- SUBCELLULAR LOCATION: Secreted.  
CC: --!- ALTERNATIVE PRODUCTS:  
CC: Event=Alternative splicing; Named isoforms=2;  
CC: Name=IGF-IB;  
CC: IsoId=P05017-1; Sequence=Displayed;  
CC: IsoId=P05018-1; Sequence=External;  
CC: Name=IGF-IB;  
CC: -----  
CC: This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).  
CC: -----  
DR: EMBL; X04480; CAA28168\_1; -.  
DR: PIR; A25540; A25540.  
DR: HSSP; P01343; IGF1.  
DR: MGI:96432; IGF1.

DR GO; GO:0010001; P:glial cell differentiation; IMP.  
 DR GO; GO:00739; P:neurogenesis; IMP.  
 DR InterPro:IPR00825; Ins/IGF/relax.  
 DR PRINTER; PR00277; INSULINB.  
 DR SMART; SNO078; IIGF:1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 FT SIGNAL; 1 22  
 FT CHAIN 23 92  
 FT DOMAIN 23 51  
 FT DOMAIN 52 63  
 FT DOMAIN 64 84  
 FT DOMAIN 85 92  
 FT PROPEP 93 127  
 FT DISULFD 28 70  
 FT DISULFD 40 83  
 FT DISULFD 69 74  
 SQ SEQUENCE 127 AA; 14120 MW; 1054B8CAG72DC2D7 CRC4;  
 36.0%; Score 31; DB 1; Length 127;  
 Best Local Similarity 100.0%; Pred. No. 1.6e-25; Mismatches 0; Indels 0; Gaps 0;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 6 YGSSIRRAPQGIVDCCFRSCDLRLEMVC 36  
 Db 53 YGSSIRRAPQGIVDCCFRSCDLRLEMVC 83

RESULT 3

IGFB\_MOUSE

ID IGFB\_MOUSE STANDARD; PRT; 133 AA.  
 AC P0518; 13-AUG-1987 (Rel. 05, Created)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Insulin-like growth factor IB precursor (IGF-IB) (Somatomedin).  
 GN IGF1 OR IGF-1.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Buterria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10990;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Liver;  
 RX MEDLINE:87040760; PubMed=3774549;  
 RA Bell G.I., Stempkin M.M., Fong N.M., Ball L.B.;  
 RT "Sequences of liver cDNAs encoding two different mouse insulin-like  
 growth factor I precursors.". Nucleic Acids Res. 14:7873-7882(1986).  
 RL [2]  
 RP STRAIN=FVB/N; TISSUE=Liver;  
 RX MEDLINE:22389257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins P.S., Wagner L., Shonman C.M., Schuler G.D., Altchul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh R., Diatchenko L., Matsunaga K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soakes M.B., Bonaldo M.F., Casavant T.L., Scheetz T.B., Brownstein M.J., Usdin T.B., Yoshihiko S., Carninci P., Prange C., Rana S.S., Loqueland N.A., Peters G.J., Abramson R.D., Mullally S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Heaton E., Kettman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blatesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grinwood J., Schmitz J., Myers R.M., Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smilus D.E., Schneich A., Schein J.E., Jones S.J.M., Maira M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". DR GO; GO:0010001; P:glial cell differentiation; IMP.  
 DR GO; GO:00739; P:neurogenesis; IMP.  
 DR InterPro:IPR00825; Ins/IGF/relax.  
 DR PRINTER; PR00277; INSULINB.  
 DR SMART; SNO078; IIGF:1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 FT SIGNAL; 1 22  
 FT CHAIN 23 92  
 FT DOMAIN 23 51  
 FT DOMAIN 64 84  
 FT DOMAIN 85 92  
 FT PROPEP 93 127  
 FT DISULFD 28 70  
 FT DISULFD 40 83  
 FT DISULFD 69 74  
 SQ SEQUENCE 133 AA; 14915 MW; B8B5C05B88D62502 CRC64;  
 36.0%; Score 31; DB 1; Length 133;  
 Best Local Similarity 100.0%; Pred. No. 1.6e-25; Mismatches 0; Indels 0; Gaps 0;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 6 YGSSIRRAPQGIVDCCFRSCDLRLEMVC 36  
 Db 53 YGSSIRRAPQGIVDCCFRSCDLRLEMVC 83

RESULT 4

IGFA\_RAT

ID IGFA\_RAT STANDARD; PRT; 153 AA.  
 AC P0805; 01-AUG-1988 (Rel. 08, Created)  
 DT 01-FEB-1991 (Rel. 17, Last annotation update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Insulin-like growth factor IA precursor (IGF-IA) (Somatomedin).  
 GN IGF1 OR IGF-1.  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Buterria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxID=10116;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE:87222423; PubMed=3034909;  
 RA Shimatsu A., Rotwein P.;  
 RT "Mosaic evolution of the insulin-like growth factors. Organization, sequence, and expression of the rat insulin-like growth factor I









RT "Characterization of two cDNAs encoding insulin-like growth factor 1  
(IGF-1) in the human fetal brain."; R.  
RL Brain Res. Mol. Brain Res. 12:275-277(1992).  
RN [7]  
RP SEQUENCE OF 24-50 AND 119-153 FROM N.A.  
RX MEDLINE=84295593; PubMed=6382022;  
RA Dull T.J.; Gray A.; Haylick J.S.; Ulrich A.; organization in  
RT "Insulin-like Growth Factor II precursor gene organization in  
RT relation to insulin gene family.";  
RL Nature 310:777-781(1984).  
RN [8]  
RP SEQUENCE OF 49-118.  
RX MEDLINE=8130171; PubMed=6323200;  
RA Rinderknecht E.; Humbel R.E.;  
RT "The amino acid sequence of human insulin-like growth factor I and  
RT its structural homology with proinsulin.";  
RL J. Biol. Chem. 253:2769-2776(1978).  
RN [9]  
RP 3D-STRUCTURE MODELING.  
RX MEDLINE=83210259; PubMed=6189745;  
RA Blundell T.L.; Bedarkar S.; Humbel R.E.;  
RT "Tertiary structures, receptor binding, and antigenicity of  
RT insulin-like growth factors.";  
RL Fed. Proc. 42:2592-2597(1983).  
RN [10]  
RP STRUCTURE BY NMR.  
RX MEDLINE=9124244; PubMed=2036417;  
RA Cooke R.M.; Harvey T.S.; Campbell I.D.;  
RT "Solution structure of human insulin-like growth factor I: a nuclear  
RT magnetic resonance and restrained molecular dynamics study.";  
RL Bichemistry 30:5484-5491(1991).  
RN [11]  
RP STRUCTURE BY NMR.  
RX MEDLINE=9316933; PubMed=1319992;  
RA Sato A.; Nishimura S.; Okubo T.; Kyogoku Y.; Koyama S.; Kobayashi M.;  
RT Yasuda T.; Kobayashi Y.;  
RT "1H-NMR assignment and secondary structure of human insulin-like  
RT growth factor-I (IGF-I) in solution.";  
RL Biochem. 111:529-536(1992).  
RN [12]  
RP DISULFIDE BONDS  
RX MEDLINE=8920780; PubMed=3242681;  
RA Raschdorf F.; Dahinden R.; Maerkli W.; Richter W.J.; Merryweather J.P.;  
RT "Location of disulphide bonds in human insulin-like growth factors  
(IGFs) synthesized by recombinant DNA technology.";  
RL Biomed. Environ. Mass Spectrom. 16:3-8(1988).  
CC -!- FUNCTION: The insulin-like growth factors, isolated from plasma,  
CC are structurally and functionally related to insulin but have a  
CC much higher growth-promoting activity.  
CC -!- SUBCELLULAR LOCATION: Secreted.  
CC -!- ALTERNATIVE PRODUCTS:  
CC Event-Alternative splicing; Named isoforms=2;  
CC Name=IGF-IA;  
CC IsoID=P01343-1; Sequence=Displayed;  
CC  
CC -!- SIMILARITY: Belongs to the insulin family.  
-----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce>  
CC or send an email to license@isb-sib.ch).  
CC

DR EMBL; X03420; CAA27152.1; -.  
DR EMBL; X03421; CAA27153.1; -.  
DR EMBL; X03422; CAA27154.1; -.  
DR EMBL; X57025; CAA4042.1; -.  
DR EMBL; X56773; CAA4092.1; -.  
DR PIR; A92581; IGHU.  
DR PDB; 1GFL; 15-OCT-94.  
DR PDB; 2GFL; 15-APR-93.  
DR PDB; 3GFL; 15-APR-93.  
DR PDB; 1B9G; 23-FEB-99.  
DR PDB; 1GZR; 02-OCT-02.  
DR PDB; 1GZY; 02-OCT-02.  
DR PDB; 1H02; 25-JUL-02.  
DR PDB; 1H59; 16-MAY-02.  
DR PDB; 1IMX; 03-OCT-01.  
DR Genew; HGNC:5464; IGF1.  
DR MTM; 147440; -.  
DR 265550; -.  
DR GO; GO:0003159; P:insulin-like growth factor receptor binding; TAS.  
DR GO; GO:0003180; P:peptide hormone; TAS.  
DR GO; GO:0005928; P:cell motility; TAS.  
DR GO; GO:0008680; P:DNA replication; TAS.  
DR GO; GO:003441; P:glycolate metabolism; TAS.  
DR GO; GO:007517; P:muscle development; TAS.  
DR GO; GO:0007284; P:positive regulation of cell proliferation; TAS.  
DR GO; GO:0007165; P:signal transduction; TAS.  
DR GO; GO:0001501; P:skeletal development; TAS.  
DR InterPro; IPR004825; Ins|IGF/relax.  
DR Pfam; PF0049; Insulin\_1.  
DR PRINTS; PRO077; INSULINB.  
DR SMART; SM0078; IGF\_1.  
DR PROSITE; PS00262; INSULIN\_1.  
DR Insulin family; Growth factor; Plasma; 3D-structure;  
KW Alternative splicing; Signal; POTENTIAL.  
FT SIGNAL 1  
FT 21  
FT PROPEP 22  
FT CHAIN 48  
FT DOMAIN 49  
FT DOMAIN 77  
FT DOMAIN 78  
FT DOMAIN 90  
FT DOMAIN 111  
FT PROPEP 118  
FT DISULFID 119  
FT DISULFID 153  
FT DISULFID 118  
FT DISULFID 154  
FT STRAND 54  
FT TURN 96  
FT HELIX 66  
FT TURN 109  
FT HELIX 100  
FT TURN 95  
FT HELIX 88  
FT TURN 87  
FT HELIX 91  
FT TURN 95  
FT STRAND 97  
FT HELIX 99  
FT SEQUENCE 99  
SQ 153 AA; 17026 MW; C6ECD92DCA9B37BC CRC64;

Query Match 30.2%; Score 26; DB 1; Length 153;  
Best Local Similarity 10.0%; Pred. No. 3.5e+20;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAQQTGIVDECCFRSCLRLREMYC 36  
Db 84 RRAQQTGIVDECCFRSCLRLREMYC 109

RESULT 12  
IGFL\_BOVIN  
ID\_IGFL\_BOVIN  
AC\_P01455;  
DT 01-APR-1988 (Rel. 07, Created)  
DT 01-NOV-1991 (Rel. 20, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Insulin-like growth factor I precursor (IGF-I) (Somatomedin).  
 DE IGF1.  
 OS Bos taurus (Bovine).  
 OC Chordata; Craniata; Vertebrata; Euteleostomi;  
 Bovidae; Bovinae; Bos.  
 OC Mammalia; Buteraria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;  
 OC NCBi\_TaxID=9913;  
 RN [1] SEQUENCE OF 2-154 FROM N.A.  
 RX MEDLINE=00175014; PubMed=2308858;  
 RA Fotsis T., Murphy C., Gannon P.;  
 RT "Nucleotide sequence of the bovine insulin-like growth factor I  
 (IGF-1) and its IGF-1A precursor";  
 RL Nucleic Acids Res. 18:676-676(1990).  
 RN [2] SEQUENCE OF 50-119 FROM N.A.  
 RX MEDLINE=95172127; PubMed=7867698;  
 RA Schmidt A., Erismaner K., Amselegreber W., Sinowitz F., Schams D.;  
 RT "Expression of insulin-like growth factor I (IGF-1) in the bovine  
 oviduct during the oestrous cycle";  
 RL EXP. Clin. Endocrinol. 102:364-369(1994).  
 RN [3] SEQUENCE OF 50-119.  
 RX MEDLINE=8608581; PubMed=3941093;  
 RA Honegger A., Humber R.E.;  
 RT "Insulin-like growth factors I and II in fetal and adult bovine  
 serum. Purification, primary structures, and immunological  
 cross-reactivities";  
 RL J. Biol. Chem. 261:569-575(1986).  
 RN [4] SEQUENCE OF 50-119.  
 RX MEDLINE=88268820; PubMed=3390164;  
 RA Francis G.L., Upton P.M., Ballard F.J., McNeil K.A., Wallace J.C.;  
 RT "Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences  
 and biological activities compared with those of a potent truncated  
 RT form";  
 RL Biochem. J. 251:95-103(1988).  
 CC --!- FUNCTION: The insulin-like growth factors, isolated from plasma,  
 CC are structurally and functionally related to insulin but have a  
 CC much higher growth-promoting activity.  
 CC --!- SUBCELLULAR LOCATION: Secreted.  
 CC --!- SIMILARITY: Belongs to the insulin family.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
 CC or send an email to license@isb-sib.ch).  
 CC  
 DR EMBL; X15726; CAA31746.1; --.  
 DR EMBL; S7122; AD14209.1; --.  
 DR PIR; S12622; IGB01.  
 DR HSSP; P01343; IGF1.  
 DR IPR04425; Ins/IGF/relax.  
 DR Pfam; PF0049; Insulin; 1.  
 DR PRINTS; PR00277; INSULINB.  
 DR SMART; SM00078; IGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 KW Insulin family; Growth factor; Plasma; Signal.  
 FT PROPEP ? 49 INSULIN-LIKE GROWTH FACTOR I.  
 FT DOMAIN 50 119 B. SIGNAL  
 FT DOMAIN 50 78 C. SIGNAL  
 FT DOMAIN 79 90  
 FT DOMAIN 91 111 A. SIGNAL  
 FT DOMAIN 112 119 D. SIGNAL  
 FT PROPEP 120 154 E. PEPTIDE.  
 FT DOMAIN 55 97 BY SIMILARITY.  
 FT DISUFLID 67 110 BY SIMILARITY.  
 FT DISUFLID 96 101 BY SIMILARITY.  
 SQ SEQUENCE 154 AA; 17066 MW; 64201B6AF3140999 CRC64;

Query Match 30.2%; Score 26; DB 1; Length 154;  
 Best Local Similarity 100.0%; Pred. No. 3.5e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Ov 11 RRAPOGIVDCCGFRGCDLRLLEMYC 36  
 Db 85 RRAPOGIVDCCGFRGCDLRLLEMYC 110

RESULT 13  
 IGF1\_CAPHI  
 IGF1\_CAPHI STANDARD; PRT; 154 AA.  
 ID PS1457;  
 DT 01-OCT-1996 (Rel. 34, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE IGF1-like growth factor I precursor (IGF-I) (Somatomedin).  
 OS Capra hircus (Goat).  
 OC Bovidae; Caprinae; Capra.  
 OC Mammalia; Buteraria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;  
 OC Bovidae; Caprinae; Capra.  
 RN NCBI\_TaxID=9925;  
 RN [1] SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.  
 RC STRAIN=Shiba; TISSUE=Liver;  
 RX MEDLINE=95290780; PubMed=772848;  
 RA Mikawa S., Yoshikawa G.-I., Yamano Y., Sakai H., Romano T., Hosoi Y.,  
 RA Utsumi K.;  
 RT "Tissue" and development-specific expression of goat insulin-like  
 growth factor-I (IGF-I) mRNA";  
 RL Biosci Biotechnol. Biochim. 59:759-761(1995).  
 CC --!- FUNCTION: The insulin-like growth factors, isolated from plasma,  
 CC are structurally and functionally related to insulin but have a  
 CC much higher growth-promoting activity.  
 CC --!- SUBCELLULAR LOCATION: Secreted.  
 CC --!- TISSUE SPECIFICITY: Expressed in all tissues examined: brain,  
 CC lung, liver, spleen, uterus, ovary, testis, heart and skeletal  
 CC muscle.  
 CC --!- SIMILARITY: Belongs to the insulin family.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration -  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
 CC or send an email to license@isb-sib.ch).  
 CC  
 DR EMBL; D11378; BAB01976.1; --.  
 DR EMBL; D26119; BAB7724.1; ALT SEQ.  
 DR EMBL; D26116; BAB7724.1; JOINED.  
 DR EMBL; D26117; BAB7724.1; JOINED.  
 DR EMBL; D26118; BAB7724.1; JOINED.  
 DR PIR; JCC2483; JCC2483.  
 DR HSSP; P01343; IGF1.  
 DR InterPro; IPR004825; Ins/IGF/relax.  
 DR Pfam; PF00049; Insulin; 1.  
 DR PRINTS; PR00277; INSULINB.  
 DR SMART; SM00078; IGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 KW Insulin family; Growth factor; Plasma; Signal.  
 FT SIGNAL ? 49 BY SIMILARITY.  
 FT PROPEP ? 49 BY SIMILARITY.  
 FT CHAIN 50 119 INSULIN-LIKE GROWTH FACTOR I.  
 FT DOMAIN 50 78  
 FT DOMAIN 79 90  
 FT DOMAIN 91 111 A.  
 FT DOMAIN 112 119 D.  
 FT PROPEP 120 154 E. PEPTIDE.  
 FT DOMAIN 55 97 BY SIMILARITY.  
 FT DISUFLID 67 110 BY SIMILARITY.

FT	DISURPID	95	101	BY SIMILARITY.
SQ	SEQUENCE	154 AA;	17082 MW;	07238B6AF3068422 CRC64;
Query Match		30.2%	Score 26;	DB 1; Length 154;
Best Local Similarity		100.0%	Pred. No. 3.5e-20;	
Matches 26;	Conservative	0;	Mismatches 0;	Indels 0; Gaps 0;
QY	11	RRAPOQTIVDVECCFRSCDLRLLEMVC 36		
Db	85	RRAPOQTIVDVECCFRSCDLRLLEMVC 110		
RESULT 14				
ICGF1_SHEEP	STANDARD;	PRT;	154 AA.	
ID	ICGF1_SHEEP			
AC	P10763;			
DT	01-JUL-1989 (Rel. 11, Created)			
DT	01-FEB-1991 (Rel. 17, Last sequence update)			
DT	10-OCT-2003 (Rel. 42, Last annotation update)			
DE	Insulin-like growth factor I precursor (IGF-I) (Somatomedin).			
IGF1				
OS	Ovis aries (Sheep).			
OC	Bukarota; Metzcoa; Chordata; Craniata; Vertebrata; Buteleostomi;			
OC	Mammalia; Butchoria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;			
OC	Bovidae; Caprinae; Ovis.			
OX	NCBI_TAXID=9940;			
RN	{1}			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Liver;			
RX	MEDLINE=90126234; PubMed=2575490;			
RA	Wong E.A., Ohlsen S.M., Godfredson J.A., Dean D.M., Whatton J.E.,			
RT	Dickson M.C., Saunders J.C., Gilmour R.S.,			
RT	"Cloning of ovine insulin-like growth factor-I cDNAs: heterogeneity			
RT	in the mRNA population.";			
RL	RA 8:649-657(1989).			
RN	{2}			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Liver;			
RX	MEDLINE=91197361; PubMed=2015053;			
RA	Ohlsen M.C., Saunders J.C., Gilmour R.S.,			
RT	"The ovine insulin-like growth factor-I gene: characterization,			
RT	expression and identification of a putative promoter.";			
RL	J. Mol. Endocrinol. 6:17-31(1991).			
RN	{3}			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Liver;			
RX	MEDLINE=93221682; PubMed=8466647;			
RA	Ohlsen M., Dean D.M., Wong E.A.,			
RT	"Characterization of multiple transcription initiation sites of the			
RT	ovine insulin-like growth factor-I gene and expression profiles of			
RT	three alternatively spliced transcripts.";			
RL	DNA Cell Biol. 12:243-251(1993).			
RN	{4}			
RP	SEQUENCE OF 55-135 FROM N.A.			
RA	STRAIN=Coopworth; TISSUE=Liver;			
RC	MEDLINE=9325051; PubMed=8485157;			
RX	Demmer J., Hill D.P., Peersen G.B.,			
RT	"Characterization of two sheep insulin-like growth factor II cDNAs			
RT	with different 5'-untranslated regions.";			
RL	Biochim. Biophys. Acta 1173:79-80(1993).			
RN	{5}			
RP	SEQUENCE OF 50-119.			
RX	MEDLINE=8913687; PubMed=253774;			
RA	Francis G.L., McNeil K.A., Wallace J.C., Ballard F.J., Owens P.C.,			
RT	"Sheep insulin-like growth factors I and II: sequences, activities			
RT	and assays";			
RL	Endocrinology 124:1173-1183(1993).			
RN	{6}			
RP	SEQUENCE OF 50-79.			
RX	MEDLINE=89323215; PubMed=2752053;			
RA	Hey A.W., Browne C.A., Simpson R.J., Thorburn G.D.,			
RT	"Simultaneous isolation of insulin-like growth factors I and II from			
RT	adult sheep serum";			
RL	Biophys. Acta 997:27-35(1993).			
RP	SEQUENCE OF 50-79.			
RX	MEDLINE=89323215; PubMed=2752053;			
RA	Hey A.W., Browne C.A., Simpson R.J., Thorburn G.D.,			
RT	"Simultaneous isolation of insulin-like growth factors I and II from			
RT	adult sheep serum";			
RL	Biophys. Acta 997:27-35(1993).			
CC	-!- FUNCTION: The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity.			
CC	-!- SUBCELLULAR LOCATION: Secreted.			
CC	-!- ALTERNATIVE PRODUCTS: Event=Alternative splicing; Named isoforms=3;			
CC	NameB; IsoId=P10763-1; Sequence=Displayed;			
CC	NameA; IsoId=P10763-2; Sequence=VSP_002707;			
CC	NameC; IsoId=P10763-3; Sequence=VSP_002706;			
CC	-!- SIMILARITY: Belongs to the insulin family.			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation at the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a> or send an email to license@isb-sib.ch).			
DR	EMBL; M30653; AAA80532.1; -.			
DR	EMBL; M30653; AAA80533.1; -.			
DR	EMBL; M31734; AAA80535.1; -.			
DR	EMBL; M31734; AAA80534.1; -.			
DR	EMBL; M31736; AAA31545.1; -.			
DR	EMBL; M31735; AAA31546.1; -.			
DR	EMBL; M31735; AAA31547.1; -.			
DR	EMBL; X69472; CAA4230.1; -.			
DR	EMBL; X69473; CAA4230.1; JOINED.			
DR	EMBL; X69474; CAA4230.1; JOINED.			
DR	EMBL; X69475; CAA4230.1; JOINED.			
DR	EMBL; X69472; CAA4231.1; -.			
DR	EMBL; X69473; CAA4231.1; JOINED.			
DR	EMBL; X69474; CAA4231.1; JOINED.			
DR	EMBL; X69475; CAA4231.1; -.			
DR	EMBL; X69475; CAA4231.1; JOINED.			
DR	EMBL; X69473; CAA4232.1; -.			
DR	EMBL; X69474; CAA4232.1; JOINED.			
DR	EMBL; X69472; CAA4232.1; JOINED.			
DR	EMBL; X69473; CAA4232.1; JOINED.			
DR	EMBL; X69474; CAA4232.1; JOINED.			
DR	EMBL; X69475; CAA4232.1; -.			
DR	DR InterPro; IPR004825; InsP/IGF/relax.			
DR	DR Pfam; PF00049; Insulin_1.			
DR	DR PRINTS; PRO0077; INSULIN.			
DR	DR SMART; SW00078; IIGF_1.			
DR	DR PROSITE; PS00262; INSULIN_1.			
DR	DR Insulin family; Growth factor; Plasma; Signal; Alternative splicing.			
FT	SIGNAL 1	?		
FT	PROPEP	49		
FT	CHAIN	50	119	INSULIN-LIKE GROWTH FACTOR I.
FT	DOMAIN	50	78	B.
FT	DOMAIN	79	90	C.
FT	DOMAIN	91	111	A.
FT	DOMAIN	112	119	D.
FT	PROPEP	120	154	E. PEPTIDE.
FT	DISURPID	55	97	BY SIMILARITY.
FT	DISURPID	67	110	BY SIMILARITY.
FT	DISURPID	96	101	BY SIMILARITY.
FT	VARSPIC	1	21	MGKISLIPTQKCCPCDFLK -> MVTPTP (in isoform C).
FT				/FTid=VSP_002706; Missing (in isoform A).
FT	CONFFLICT	57	57	A -> V (in FTid 4).
SQ	SEQUENCE	154 AA;	17012 MW;	E226CE6AF653CF3F CRC64;
QY	11	RRAPOQTIVDVECCFRSCDLRLLEMVC 36		

Db 85 RRAPOGIVDECCFRSCDRLIEMYC 110

RESULT 15

IGFB-HUMAN

ID -IGFB HUMAN STANDARD: PRT; 195 AA.

AC P05019; RT

DT 13-AUG-1987 (Rel. 05, Created) RN [9]

DT 13-AUG-1987 (Rel. 05, last sequence update) RT

DT 10-OCT-2003 (Rel. 42, last annotation update) RN

DE Insulin-like growth factor IB precursor (IGF-IB) (Somatomedin C). DR

GN IGFI OR IUPI. RT

OS Homo sapiens (Human); Chordata; Craniata; Vertebrata; Buteleostomi; RN

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. DR

NCBI\_TaxID=9606; RN

[1] PRT

SEQUENCE FROM N.A. DR

RX MEDLINE=80168194; PubMed=2937782; RN

RA Rotwein P., Pollock K.M., Didier D.X., Krivi G.C. RX

RT Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides." RT

RL J. Biol. Chem. 261:4828-4832(1986). RN [2]

RP SEQUENCE FROM N.A. DR

RX MEDLINE=66094355; PubMed=3455760; RN

RA Rotwein P.; "Two insulin-like growth factor I messenger RNAs are expressed in human liver"; DR

Proc. Natl. Acad. Sci. U.S.A. 83:77-81(1986). RN [3]

RP SEQUENCE FROM N.A. DR

RX MEDLINE=8610862; PubMed=3002851; RN

RA de Pagter-Holthuizen P., van Schaik F.M.A., Verduin J.S., van Ommen G.J.B., Bouma B.N., Jansen M., Sijselebach J.M., "Organization of the human genes for insulin-like growth factors I and II"; DR

RL FEBS Lett. 195:179-184(1986). RN [4]

RP SEQUENCE OF 22-50 FROM N.A. DR

RX MEDLINE=84129593; PubMed=6392022; RN

RA Dull T.J., Gray A., Hayflick J.S., Ulrich A.; "Insulin-like growth factor II precursor gene organization in relation to insulin gene family"; DR

RT Nature 310:777-781(1984). RN [5]

RP SEQUENCE OF 49-118. DR

RX MEDLINE=78130171; PubMed=632300; RN

RA Rinderknecht E., Humber R.E.; "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin"; DR

RT J. Biol. Chem. 253:2769-2776(1978). RN [6]

RP 3D-STRUCTURE MODELING. DR

RX MEDLINE=83210559; PubMed=6189745; RN

RA Blundell T.L., Bedkar S., Humber R.E.; "Tertiary structures, receptor binding, and antigenicity of insulin-like growth factors"; DR

RT insulin-like growth factors"; DR

RL Ped. Proc. 42:2592-2597(1983). RN [7]

RP STRUCTURE BY NMR. DR

RX MEDLINE=9122464; PubMed=2036417; RN

RA Cooke R.M., Campbell I.D.; "Solution structure of human insulin-like growth factor 1: a nuclear magnetic resonance and restrained molecular dynamics study"; DR

RL Biochemistry 30:5484-5491(1991). RN [8]

STRUCTURE BY NMR. DR

RX MEDLINE=93316903; PubMed=1319992; RN

RA Sato A., Nishimura S., Ohkubo T., Kyogoku Y., Koyama S., Kobayashi M., Yasuda T., Kobayashi Y.; "Signal transduction; DR

"1H-NMR assignment and secondary structure of human insulin-like growth factor-I (IGF-I) in solution."; RT

J. Biochem. 111:529-536(1992). RN

RP DISULFIDE BONDS DR

RX MEDLINE=8907850; PubMed=324681; RN

RA Raschdorf F., Bahnsen R., Maerkli W., Richter W.J., Merryweather J.P.; "Location of disulphide bonds in human insulin-like growth factors (IGFs) synthesized by recombinant DNA technology."; DR

Biomed. Environ. Mass Spectrom. 16:3-8(1988). RN [10]

RP VARIANT ASN-187. DR

RX MEDLINE=99118093; PubMed=10391209; RN

RA Cargill M., Alshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim B.P., Kalanaraman N., Namesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipschutz R., Daley G.Q., Lander E.S.; "Characterization of single-nucleotide polymorphisms in coding regions of human genes"; Nat. Genet. 22:231-238(1999). RN [11]

RP ERRATUM. DR

RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Friedland L., Rolfe A., Warrington J., Lipschutz R., Daley G.Q., Lander E.S.; Nat. Genet. 23:373-373(1999).

CC -- FUNCTION: The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity. DR

CC -- SUBCELLULAR LOCATION: Secreted. DR

CC -- ALTERNATIVE PRODUCTS: Event; Alternative splicing; Named isoforms=2; Name=IGF-IB; IsoID=P05019-1; Sequence=Displayed; DR

CC -- ISoID=P01343-1; Sequence=External; DR

CC -- SIMILARITY: Belongs to the insulin family. DR

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See [http://www.isb-sib.ch/announce/or\\_send\\_an\\_email\\_to\\_licensee@ibb-sib.ch](http://www.isb-sib.ch/announce/or_send_an_email_to_licensee@ibb-sib.ch)). DR

CC -- EMBL; M14155; AAA5237.1; JOINED. DR

DR EMBL; M12659; AAA5237.1; JOINED. DR

DR EMBL; M14153; AAA5237.1; JOINED. DR

DR EMBL; M14154; AAA5237.1; JOINED. DR

DR EMBL; M11588; AAA5239.1; ALT\_SEQ. DR

DR EMBL; X03533; CAA27750.1; ALT\_SEQ. DR

DR EMBL; X03520; CAA27752.1; -. DR

DR EMBL; X03421; CAA27753.1; -. DR

DR EMBL; X03422; CAA27754.1; -. DR

DR PIR; A01611; IGF1B. DR

DR PDB; 1OFL; 15-OCT-94. DR

DR 2OFL; 15-APR-93. DR

DR PDB; 3OFL; 15-APR-93. DR

DR PDB; 1BQT; 1-APR-99. DR

DR Genew; HGNC; 5465; IGFI. DR

DR MIM; 147440; -. DR

DR MTM; 265850; -. DR

DR GO; GO:0005159; P:insulin-like growth factor receptor binding; TAS. DR

DR GO; GO:0005180; P:peptide hormone; TAS. DR

DR GO; GO:0006928; P:cell motility; TAS. DR

DR GO; GO:0005260; P:DNA replication; TAS. DR

DR GO; GO:0005441; P:glycolate metabolism; TAS. DR

DR GO; GO:0007517; P:muscle development; TAS. DR

DR GO; GO:0008284; P:positive regulation of cell proliferation; TAS. DR

DR GO; GO:0007265; P:RAS protein signal transduction; TAS. DR

GO; GO:0007165; P:signal transduction; TAS.

DR GO; GO:0001501; Piskeletal development; TAS.  
 DR InterPro; IPR04815; Ins/IGF/relax.  
 DR Pfam; PF00049; Insulin; 1.  
 DR PRINTS; PR00277; INSULINB.  
 DR SMART; SM00078; IIGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 DR "Insulin family; Growth factor; 3D-structure; Plasma;  
 KW Alternative Splicing; Signal; Polymorphism.  
 FT SIGNAL 1 21  
 FT PROPEP 22 48  
 FT CHAIN 49 118  
 FT DOMAIN 49 77  
 FT DOMAIN 78 89  
 FT DOMAIN 90 110  
 FT DOMAIN 111 118  
 FT DOMAIN 118 195  
 FT PROPEP 119 96  
 FT DISULFID 54 109  
 FT DISULFID 66 100  
 FT DISULFID 95 100  
 FT VARIANT 187 187  
 A -> D (in dbSNP:6213). /FTId=VAR\_013945.

FT STRAND 51 51  
 FT TURN 55 55  
 FT HELIX 56 69  
 FT TURN 87 88  
 FT HELIX 91 95  
 FT TURN 96 97  
 FT STRAND 99 99  
 FT HELIX 106 109  
 SQ SEQUENCE 195 AA; 21841 MW; E8BA8CFBD1CD1873 CRC64;

Query Match 30.2%; Score 26; DB 1; Length 195;  
 Best Local Similarity 100.0%; Pred No. 4.3e-20;  
 Matches 26; Conservative 0; Mismatches 420; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDCCFRSDRRLRJEMYC 36  
 Db 34 RRAPOTGIVDCCFRSDRRLRJEMYC 109

RESULT 16

ID IGFL\_COTJA STANDARD; PRT; 124 AA.  
 AC P51462;  
 DT 01-OCT-1996 (Rel. 34, Created)  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DB Insulin-like growth factor I precursor (IGF-I) (Somatomedin)  
 DE (Fragment).  
 GN IGF1.  
 OS Coturnix coturnix japonica (Japanese quail).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Buteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Coturnix.  
 OX NCBI\_TaxID=90343;  
 RN [1]  
 RP SEQUENCE FROM N\_A.  
 RX MEDLINE=5187821; PubMed=7881819;  
 RA Kida S., Iwaki M., Nakamura A., Murra Y., Takenaka A., Takahashi S.,  
 RA Noguchi T.,  
 RT "Insulin-like growth factor-I messenger RNA content in the oviduct of  
 RT Japanese quail (Coturnix coturnix japonica): changes during growth  
 RT and development or after estrogen administration.";  
 RT Comp. Biochem. Physiol. 199C:191-204(1994).  
 CC -1- FUNCTION: The insulin-like growth factors, isolated from plasma,  
 are structurally and functionally related to insulin but have a  
 CC much higher growth-promoting activity.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- SIMILARITY: Belongs to the insulin family.  
 CC  
 This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 CC

CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to license@isb-sib.ch).-----  
 CC  
 DR EMBL; S75247; ; NOT\_ANNOTATED\_CDS.  
 DR HSSP; P01343; IGF1.  
 DR InterPro; IPR04825; Ins/IGF/relax.  
 DR Pfam; PF00049; Insulin; 1.  
 DR PRINTS; PR00277; INSULINB.  
 DR SMART; SM00078; IIGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 DR "Insulin family; Growth factor; 3D-structure; Plasma;  
 KW Alternative Splicing; Signal; Polymorphism.  
 FT SIGNAL 1 21  
 FT PROPEP 22 48  
 FT CHAIN 49 118  
 FT DOMAIN 49 77  
 FT DOMAIN 78 89  
 FT DOMAIN 90 110  
 FT DOMAIN 111 118  
 FT DOMAIN 118 195  
 FT PROPEP 119 96  
 FT DISULFID 54 109  
 FT DISULFID 66 100  
 FT DISULFID 95 100  
 FT VARIANT 187 187  
 A -> D (in dbSNP:6213). /FTId=VAR\_013945.

FT STRAND 51 51  
 FT TURN 55 55  
 FT HELIX 56 69  
 FT TURN 87 88  
 FT HELIX 91 95  
 FT TURN 96 97  
 FT STRAND 99 99  
 FT HELIX 106 109  
 SQ SEQUENCE 195 AA; 21841 MW; E8BA8CFBD1CD1873 CRC64;

Query Match 30.2%; Score 26; DB 1; Length 195;  
 Best Local Similarity 100.0%; Pred No. 0.00018;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 26 SCDRRLRJEMYC 36  
 Db 70 SCDRRLRJEMYC 80

RESULT 17

ID IGFL\_CHICK STANDARD; PRT; 153 AA.  
 AC P18254;  
 DT 01-NOV-1990 (Rel. 16, Created)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Insulin-like growth factor I precursor (IGF-I) (Somatomedin).  
 GN IGFL.  
 OS Gallus gallus (Chicken).  
 OC Archosauria; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;  
 OC Gallus.  
 OX NCBI\_TaxID=9031;

RN [1]  
 RP SEQUENCE FROM N\_A.  
 RX MEDLINE=90190646; PubMed=2628728;  
 RA Kajimoto Y., Rotwein P.;  
 RT "Structure and expression of a chicken insulin-like growth factor I  
 RT precursor.";  
 RL Mol. Endocrinol. 3:1907-1913 (1989).

RN [2]  
 RP SEQUENCE OF 1-21 FROM N\_A.  
 RX MEDLINE=91236750; PubMed=2033062;  
 RA Rotwein P., Kajimoto Y.;  
 RT "Structure of the chicken insulin-like growth factor I gene reveals  
 RT conserved promoter elements.";  
 RL J. Biol. Chem. 266:9724-9731 (1991).

RN [3]  
 RP SEQUENCE OF 49-118.  
 RX MEDLINE=9106695; PubMed=2272467;  
 RA Ballard F.J., Johnson R.J., Owens P.C., Francis G.L., Upton F.M.,  
 RA McMurry J.P., Wallace J.C.;  
 RT "Chicken insulin-like growth factor-I: amino acid sequence,  
 RT radioimmunoassay, and plasma levels between strains and during  
 RT growth.";  
 RL Gen. Comp. Endocrinol. 78:459-468 (1990).  
 CC -1- FUNCTION: The insulin-like growth factors, isolated from plasma,



DR Pfam; PF00049; Insulin; 1.  
 DR PRINTS; PS00277; INSULINB.  
 DR SMART; SM0078; IIGF; 1.  
 DR PROSITE; PS00242; INSULIN; 1.  
 KW Insulin; family; Mitogen; Growth factor.  
 FT DOMAIN 1 27 B.  
 FT DOMAIN 1 28 C.  
 FT DOMAIN 1 39 C.  
 FT DOMAIN 40 60 C.  
 FT DOMAIN 61 66 D.  
 FT DOMAIN 61 66 D.  
 FT DISULFID 8 46 BY SIMILARITY.  
 FT DISULFID 20 59 BY SIMILARITY.  
 FT DISULFID 45 50 BY SIMILARITY.  
 FT DISULFID 70 75 BY SIMILARITY.  
 FT NON\_TER 128 128 BY SIMILARITY.  
 SQ SEQUENCE 66 AA; 7298 MW; A018CB71DSEBIE2 CRCG4;  
 Query Match 10.5%; Score 9; DB 1; Length 66;  
 Best Local Similarity 100.0%; Prd. No. 0.013; 0; Mismatches 0; Indels 0; Gaps 0;  
 Matches 9; Conservative 0; BY SIMILARITY.  
 Qy 21 ECCFRSCDL 29  
 Db 44 ECCFRSCDL 52

RESULT 20  
 IGF2\_CAVPO STANDARD; PRT; 128 AA.  
 ID IGF2\_CAVPO  
 AC Q08279;  
 DT 01-FEB-1995 (Rel. 31, Created)  
 DT 01-FEB-1995 (Rel. 31, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Insulin-like growth factor II precursor (IGF-II) (Somatomedin A)  
 DE (Fragment).  
 DE IGF2.  
 OS Cavia porcellus (Guinea Pig).  
 OC Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.  
 OC NCBI\_TAXID=10141;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Hartley; TISSUE=Liver;  
 RX MEDLINE=9246007; PubMed=130179;  
 RA Levinovitz A., Norstedt G., van den Berg S., Robinson I.C.A.F.,  
 RA Ekstrom T.J.;  
 RT "Isolation of an insulin-like growth factor II cDNA from guinea pig liver: expression and developmental regulation.";  
 RT Mol. Cell. Endocrinol. 89:105-110(1992).  
 CC -- FUNCTION: The insulin-like growth factors possess growth-promoting activity. In vitro, they are potent mitogens for cultured cells. IGF-II is influenced by placental lactogen and may play a role in fetal development.  
 CC -- SUBCELLULAR LOCATION: Secreted.  
 CC -- DEVELOPMENTAL STAGE: EXPRESSED AT LOWER LEVELS IN ADULT.  
 CC -- SIMILARITY: Belongs to the insulin family.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).  
 CC  
 CC EMBL; S5989; AAB26479.1; -.  
 DR PRINTS; PR00277; INSULINB.  
 DR SMART; SM0078; IIGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 KW Insulin; family; Mitogen; Growth factor; Signal.  
 FT SIGNAL 1 24 BY SIMILARITY.  
 FT CHAIN 25 92 INSULIN-LIKE GROWTH FACTOR II.  
 FT DOMAIN 25 52 C.  
 FT DOMAIN 53 65 C.  
 FT DOMAIN 53 65 C.  
 FT DOMAIN 66 86 A.  
 FT DOMAIN 87 92 D.

RESULT 21  
 IGF2\_MUSVI STANDARD; PRT; 129 AA.  
 ID IGF2\_MUSVI  
 AC P41694;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Insulin-like growth factor II precursor (IGF-II) (Fragment).  
 DE IGF2.  
 OS Mustela vison (American mink).  
 OC Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mustelidae; Mustelinae; Mustela.  
 OC NCBI\_TAXID=9867;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Liver;  
 RX MEDLINE=93307613; PubMed=7685523;  
 RA Ekstrom T.J., Backlin B.M., Lindqvist Y., Engstrom W.;  
 RT "Insulin-like growth factor II in the mink (Mustela vison): determination of a cDNA nucleotide sequence and developmental regulation of its expression.";  
 RT Mol. Comp. Endocrinol. 90:243-250(1993).  
 CC -- FUNCTION: The insulin-like growth factors possess growth-promoting activity. In vitro, they are potent mitogens for cultured cells. IGF-II is influenced by placental lactogen and may play a role in fetal development.  
 CC -- SUBCELLULAR LOCATION: Secreted.  
 CC -- SIMILARITY: Belongs to the insulin family.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).  
 CC  
 CC EMBL; S63459; AAB27392.2; -.  
 DR HSSP; P01344; IGF2.  
 DR InterPro; IP004825; Ins/IGF/relax.  
 DR PRINTS; PF00049; Insulin; 1.  
 DR SMART; SM0078; IIGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 KW Insulin; family; Mitogen; Growth factor; Signal.  
 FT SIGNAL 1 24 BY SIMILARITY.  
 FT CHAIN 25 92 INSULIN-LIKE GROWTH FACTOR II.  
 FT DOMAIN 25 52 B.  
 FT DOMAIN 53 65 C.  
 FT DOMAIN 66 86 A.  
 FT DOMAIN 87 92 D.

FT PROPEP 93 >129 E PEPTIDE (BY SIMILARITY).  
 FT DISULFD 33 72 BY SIMILARITY.  
 FT DISULFD 45 85 BY SIMILARITY.  
 FT DISULFD 71 76 BY SIMILARITY.  
 FT NON-TER 129 129  
 SQ SEQUENCE 129 AA; 14436 MW; FD06661DARBA73D0 CRC64;  
 Query Match 10.5%; Score 9; DB 1; Length 129;  
 Best Local Similarity 100.0%; Pred. No. 0.024; Mismatches 0;  
 Matches 9; Conservative 0; Indels 0; Gaps 0;  
 Qy 21 ECCRSCDL 29  
 Db 70 ECCRSCDL 78

RESULT 22  
 IGF2\_BOVIN STANDARD; PRT; 155 AA.  
 ID IGF2\_BOVIN  
 AC P07156;  
 DT 01-APR-1988 (Rel. 07, Created)  
 DT 01-MAY-1992 (Rel. 22, last sequence update)  
 DT 10-OCT-2003 (Rel. 42, last annotation update)  
 DE Insulin-like growth factor II precursor (IGF-II) (Erythropoietin) (Fragment).  
 DE IGF2.  
 OS Bos taurus (Bovine).  
 OC Bovidae; Bos.  
 OC Bovidae; Bovine; Bos.  
 OC NCBI\_TaxID=9913;  
 RN [1] SEQUENCE OF 6-155 FROM N.A.  
 RC TISSUE=Liver;  
 RX MEDLINE=9035621; PubMed=2388846;  
 RX Brown W.M., Diegilewska K.M., Foreman R.C., Saunders N.R.; "The nucleotide and deduced amino acid sequences of insulin-like growth factor II cDNAs from adult bovine and fetal sheep liver.";  
 RT Nucleic Acids Res. 18:4614-4614 (1990).  
 RN [2]  
 RP SEQUENCE OF 6-62 FROM N.A.  
 RX MEDLINE=31083057; PubMed=1280544;  
 RA Compte L.F., Mazzu L., Pairee R.G.E.; "Nucleotide sequence of the central coding region of bovine erythropoietin/insulin-like growth factor II cDNA from fetal intestine and northern analysis of the major IGF II transcripts at the time of hepatic erythropoiesis"; Comp. Biochem. Physiol. 103B:127-131 (1992).  
 RL [3]  
 RP SEQUENCE OF 1-67.  
 RX MEDLINE=6608581; PubMed=3941093;  
 RA Honsger A., Rumbel R.E.; "Insulin-like growth factors I and II in fetal and adult bovine serum. Purification, primary structures, and immunological cross-reactivities"; J. Biol. Chem. 261:569-575 (1986).  
 RN [4]  
 RP REVISIONS.  
 RX MEDLINE=68268820; PubMed=3390164;  
 RA Francis G.L., Upton F.M., Ballard F.J., McNeil K.A., Wallace J.C.; "Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form"; Biochem. J. 251:95-103 (1988).  
 RN [5]  
 RP SEQUENCE OF 1-31.  
 RX MEDLINE=9147754; PubMed=2302223;  
 RA Li Q., Blacher R., Esch F., Congore L.F.; "A heparin-binding erythroid cell stimulating factor from fetal bovine serum has the N-terminal sequence of insulin-like growth factor II"; Biochem. Biophys. Res. Commun. 166:557-561 (1990).  
 CC -- FUNCTION: The insulin-like growth factors possess growth-promoting activity. In vitro, they are potent mitogens for cultured cells. IGF-II is influenced by placental lactogen and may play a role in fetal development.  
 CC -- SUBCELLULAR LOCATION: secreted.  
 CC -- SIMILARITY: Belongs to the insulin family.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@ibb-sib.ch).  
 CC DR EMBL; X53553; CAA37820.1;  
 CC DR EMBL; X53867; CAA37861.1;  
 CC DR HSSP; P01344; IGF2.  
 CC DR InterPro; IPR00825; Ins/IGF/Relax.  
 CC DR Pfam; PF00049; Insulin; 1.  
 CC DR PRINTS; PRO0277; INSULINB.  
 CC DR SMART; SM0078; IGF\_1.  
 CC DR PROSITE; PS00265; INSULIN\_1.  
 CC DR Insulin; Mitogen; Growth factor.  
 FT NON-TER 1 1  
 FT CHAIN 1 67 E PEPTIDE.  
 FT DOMAIN 1 28 BY SIMILARITY.  
 FT DOMAIN 29 40 C.  
 FT DOMAIN 41 61 BY SIMILARITY.  
 FT DOMAIN 62 67 D.  
 FT PROPEP 68 155  
 FT DISULFD 9 47 BY SIMILARITY.  
 FT DOMAIN 29 60 BY SIMILARITY.  
 FT DISULFD 46 51 BY SIMILARITY.  
 FT DOMAIN 41 61 BY SIMILARITY.  
 FT DISULFD 22 23 GD -> DG (IN REF. 5).  
 FT CONFLICT 22 23 I -> S (IN REF. 3).  
 FT CONFFLICT 35 35  
 SQ SEQUENCE 155 AA; 17261 MW; 5045E3549397E0F CRC64;  
 Query Match 10.5%; Score 9; DB 1; Length 155;  
 Best Local Similarity 100.0%; Pred. No. 0.029; Mismatches 0;  
 Matches 9; Conservative 0; Indels 0; Gaps 0;  
 Qy 21 ECCRSCDL 29  
 Db 45 ECCRSCDL 53

RESULT 23  
 IGF1\_ONCKI STANDARD; PRT; 176 AA.  
 ID IGF1\_ONCKI  
 AC P21705;  
 DT 01-AUG-1990 (Rel. 15, Created)  
 DT 01-AUG-1990 (Rel. 15, last sequence update)  
 DT 10-OCT-2003 (Rel. 42, last annotation update)  
 DE Insulin-like growth factor I precursor (IGF-I) (Somatomedin).  
 DE Oncorhynchus kisutch (Coho salmon).  
 OC Bokaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Butelostei; Salmoniformes; Salmonidae; Oncorhynchus.  
 OC Protactinopterygii; Salmoniformes; Salmonidae; Oncorhynchus.  
 OC NCBII\_TaxID=8019;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=90150659; PubMed=2628735;  
 RA Cao Q.-P., Duguay S.J., Plisetskaya E.M., Steiner D.F., Chan S.J.; "Nucleotide sequence and growth hormone-regulated expression of salmon insulin-like growth factor I mRNA"; Mol. Endocrinol. 3:1005-1010 (1989).  
 RN [2]  
 RP SEQUENCE OF 45-114.  
 RX MEDLINE=94062830; PubMed=8243465;  
 RA Moriyama S., Duguay S.J., Conlon J.M., Duan C., Dickhoff W.W., Plisetskaya E.M.; "Recombinant coho salmon insulin-like growth factor I. Expression in

RT *Escherichia coli*, purification and characterization.;"  
 RL Bur. J. Biochem. 218:205-211(1993).  
 CC FUNCTION: The insulin-like growth factors, isolated from plasma,  
 CC are structurally and functionally related to insulin but have a  
 CC much higher growth-promoting activity.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC  
 CC -!- SIMILARITY: Belongs to the insulin family.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -!  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>).  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 DR EMBL; M32792; AAA49410 1;  
 DR PIR; AA1396; AA1396.  
 DR HSSP; P01343; IGF1.  
 DR InterPro; IPR04925; Ins/IGF/relax.  
 CC Pfam; PF00049; Insulin; 1.  
 DR PRINTS; PRO0277; INSULIN.  
 DR SMART; SM00078; IIGF; 1.  
 DR PROSITE; PS00262; INSULIN; 1.  
 KW insulin family; Growth factor; Plasma; Signal.  
 FT SIGNAL 1 ?  
 FT PROPEP ? 44  
 FT CHAIN 45 114 INSULIN-LIKE GROWTH FACTOR I.  
 FT DOMAIN 45 73 B.  
 FT DOMAIN 74 85 C.  
 FT DOMAIN 86 106 A.  
 FT DOMAIN 107 114 D.  
 FT PROPEP 115 176 E PEPTIDE.  
 FT DISULFID 50 92 BY SIMILARITY.  
 FT DISULFID 52 105 BY SIMILARITY.  
 FT DISULFID 91 96 BY SIMILARITY.  
 SQ SEQUENCE 176 AA; 19517 MN; 4AACFCGDDA88094 CRC64;  
 Query Match 10.5%; Score 9; DB 1; Length 176;  
 Best Local Similarity 100.0%; Prede. No. 0.032; 0; Mismatches 0; Indels 0; Gaps 0; JAligner  
 Matches 9; Conservative 0; Missmatches 0; Indels 0; Gaps 0; JAligner  
 Q9 49 RAQHRTDMP 57  
 Db 118 RAQHRTDMP 126  
 RN 11  
 RESULT 24  
 IGF1\_ONCMMY STANDARD; PRT; 176 AA.  
 ID IGF1\_ONCMMY  
 AC 002815;  
 DT 01-FEB-1995 (Rel. 31, Created)  
 DT 01-FEB-1995 (Rel. 31, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DR Insulin-like growth factor I precursor (IGF-I) (Somatomedin).  
 OS *Oncorhynchus mykiss* (Rainbow trout) (*Salmo gairdneri*).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;  
 OC *protoactanthopterygii*; Salmoniformes; Salmonidae; *Oncorhynchus*.  
 OC NCBI\_TaxID:8022;  
 RN 11  
 RP SOURCE FROM N.A.  
 RC TISSUE=liver;  
 RX MEDLINE=9308377; PubMed=1409585;  
 RA Shambott M.J., Chen T.T.;  
 RT "Identification of a second insulin-like growth factor in a fish  
 RT species,";  
 RL Proc. Natl. Acad. Sci. U.S.A. 89:8913-8917(1992).  
 CC -!- FUNCTION: The insulin-like growth factors, isolated from plasma,  
 CC are structurally and functionally related to insulin but have a  
 CC much higher growth-promoting activity.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC  
 CC -!- SIMILARITY: Belongs to the insulin family.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC EMBL; M95183; ARB49412.1; -

CC DR PIR; A46244; ARB49412.1; -

CC DR HSSP; P01343; IGF1.

CC DR InterPro; IPR0049; Insulin; 1.

CC DR Pfam; PF00049; Insulin; 1.

CC DR PRINTS; PRO0277; INSULINB.

CC DR SMART; SM00078; IIGF; 1.

CC DR PROSITE; PS00262; INSULIN; 1.

CC DR KW Insulin family; Growth factor; Plasma; Signal.

FT SIGNAL; 1 ? BY SIMILARITY.

FT PROPEP; ? 44 BY SIMILARITY.

FT CHAIN; 45 114 INSULIN-LIKE GROWTH FACTOR 1.

FT DOMAIN; 45 73 B.

FT DOMAIN; 74 85 C.

FT DOMAIN; 86 105 A.

FT DOMAIN; 107 114 D.

FT PROPEP; 115 176 E. PEPTIDE.

FT DISULFID; 50 92 BY SIMILARITY.

FT DISULFID; 62 105 BY SIMILARITY.

FT DISULFID; 91 95 BY SIMILARITY.

FT SEQUENCE; 176 AA; 19510 MW; DE8283D80DDAD06 CRC64; SQ

Query Match 10.5%; Score 9; DB 1; Length 176; Best Local Similarity 100.0%; Pred. No. 0.032; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0; CQ 49 RAORHITDMP 57

Db 118 RAORHITDMP 126

RESULT 25

IGF2\_SHEEP STANDARD; PRT; 179 AA.

ID IGF2\_SHEEP

AC 210764; DT 01-JUL-1989 (Rel. 11, Created)

DT 01-OCT-1989 (Rel. 12, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Insulin-like growth factor II precursor (IGF-II).

GN IGF2.

OS *Ovis aries* (Sheep).

OC Bovidae; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Ruthetia; Cetartiodactyla; Ruminantia; Pecora; Bovoidea; Bovidae; Caprinae; Ovis.

OC NCBITaxonID=9940; RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE;Liver;

RX MEDLINE=89345107; PubMed=2762134;

RA O'Mahoney J V., Adams T.E.,

RT "Nucleotide sequence of an ovine insulin-like growth factor-II cDNA.",

RL Nucleic Acids Res. 17:5399-5392(1989).

RN [2]

RP SEQUENCE FROM N.A.

RC TISSUE;Liver;

RX MEDLINE=90356421; PubMed=2388846;

RA Medline W.M., Dzegilowska K.M., Foreman R.C., Saunders N.R.;

RT "The nucleotide and deduced amino acid sequences of insulin-like growth factor-II cDNAs from adult bovine and fetal sheep liver.",

RL Nucleic Acids Res. 18:4614-4614(1990).

[3]

RP SEQUENCE FROM N.A.

RA STRAIN=Coopworth; TISSUE;Liver;

RX MEDLINE=93250051; PubMed=8485157;

RA Dumm J., Hill D.F., Petersen G.B.;  
 RT "Characterization of two sheep insulin-like growth factor II cDNAs  
 RT with different 5'-untranslated regions.";  
 RL Biochim. Biophys. Acta 1173:79-80(1993).  
 RN [4]

RP SEQUENCE FROM N.A.

RC TISSUE=Liver;

RA Onisen S.M., Wong E.A.;  
 RL Submitted (SEP-1990) to the EMBL/GenBank/PDBJ databases.

RN [5]

RP SEQUENCE OF 25-91.

RX MEDLINE:89136887; PubMed=2537174;

RA Francis G.L., McNeil K.A., Wallace J.C., Ballard F.J., Owens P.C.;  
 RT "Sheep insulin-like growth factors I and II: sequences, activities  
 RL and assays.";  
 Endocrinology 124:1173-1183(1989).

RN [6]

RP SEQUENCE OF 25-58.

RX MEDLINE:8932215; PubMed=2752053;

RA Hey A.W., Browne C.A., Simpson R.J., Thorburn G.D.;  
 RT "Simultaneous isolation of insulin-like growth factors I and II from  
 RL adult sheep serum";  
 Biochim. Biophys. Acta 997:27-35(1989).

CC --!- FUNCTION: The insulin-like growth factors possess growth-promoting  
 activity. In vitro, they are potent mitogens for cultured cells.  
 IGF-II is influenced by placental lactogen and may play a role in  
 fetal development.

CC --!- SUBCELLULAR LOCATION: Secreted.

CC --!- SIMILARITY: Belongs to the insulin family.

This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to license@isb-sib.ch).

CC DR EMBL; U00668; AAB0626\_1; -.

CC DR EMBL; U00666; AAB0626\_1; JOINED.

CC DR EMBL; U00667; AAB0626\_1; JOINED.

CC DR EMBL; X15241; CAA23324\_1; -.

CC DR EMBL; X33534; CAA7621\_1; -.

CC DR EMBL; M9788; AAA31548\_1; -.

CC DR EMBL; M9789; AAA31549\_1; -.

CC DR EMBL; X55638; CAA39163\_1; -.

CC DR PIR; S04858; S04858.

CC DR HSSP; P01344; IGF2.

CC DR InterPro; IPR004835; Ins/IGF/relax.

CC DR Pfam; PF00049; insulin; 1.

CC DR PRINTS; PR00277; INSULINB.

CC DR SMART; SMC078; IIGF\_1.

CC DR PROSITE; PS00362; INSULIN\_1.

CC KW Insulin family; Mitogen; Growth factor; Signal.

CC FT SIGNAL\_1 24

CC FT CHAIN 25 91 INSULIN-LIKE GROWTH FACTOR II.

CC FT DOMAIN 25 52 B.

CC FT DOMAIN 53 64 C.

CC FT DOMAIN 65 85 A.

CC FT DOMAIN 86 91 D.

CC FT PROPEP 92 179 E PEPTIDE.

CC FT DISULFID 33 71 BY SIMILARITY.

CC FT DISULFID 45 84 BY SIMILARITY.

CC FT DISULFID 70 75 BY SIMILARITY.

CC FT CONFLICT 46 47 GD -> DG (IN REF. 5)

CC SEQUENCE 179 AA; 19616 MW; TB369AB57F2E4378 CRC64;

CC Query Match 10.5%; Score 9; DB 1; length 179;  
 CC Best Local Similarity 100.0%; Pred. No. 0.033; 0; Mismatches 0; Indels 0; Gaps 0;

CC Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC QY 21 ECCFRSCDL 29

Db 69 ECCFRSCDL 77  
 Search completed: March 3, 2004, 12:01:46  
 Job time : 15 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on:

March 3, 2004, 11:59:30 ; Search time 20 Seconds  
(without alignments)

413.624 Million cell updates/sec

Title: US\_09-852-261-4\_COPY\_26\_111

Perfect score: 86

Sequence: 1 NKPTVYGSSTRRRAPQGIVD.....THKKRKLQRKKGKSTLIEHK 86

Scoring table: OLIGO

Gapop 60.0 , Gapext 60.0

Searched: 283366 seqs, 96191526 residues

Word size : 0

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Listing first 100 summaries

Database : P.R\_7B\_\*

1: pir1\_\*

2: pir2\_\*

3: pir3\_\*

4: pir4\_\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

### SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	81	94.2	I33	2 A40912 insulin-like growth
2	56	65.1	B40912	insulin-like growth
3	47	54.7	A26859	insulin-like growth
4	40	46.5	A27804	insulin-like growth
5	31	36.0	A25540	insulin-like growth
6	31	36.0	B27804	insulin-like growth
7	26	30.2	PN0622	insulin-like growth
8	26	30.2	IGGP1	insulin-like growth
9	26	30.2	A36552	insulin-like growth
10	26	30.2	S22878	insulin-like growth
11	26	30.2	153	1 IGH01 insulin-like growth
12	26	30.2	153	2 S12825 insulin-like growth
13	26	30.2	153	2 IGB01 insulin-like growth
14	26	30.2	154	2 JCC2483 insulin-like growth
15	26	30.2	A33390	insulin-like growth
16	26	30.2	195	1 IGH01B insulin-like growth
17	11	12.8	A41399	insulin-like growth
18	10	11.6	153	2 A36079 insulin-like growth
19	9	10.5	153	2 IGB01 insulin-like growth
20	9	10.5	128	2 157671 insulin-like growth
21	9	10.5	149	2 D54270 insulin-like growth
22	9	10.5	155	1 IGB02 insulin-like growth
23	9	10.5	155	1 C44012 insulin-like growth
24	9	10.5	161	2 C54270 insulin-like growth
25	9	10.5	176	2 A41396 insulin-like growth
26	9	10.5	176	2 A46244 insulin-like growth
27	9	10.5	179	2 S04858 insulin-like growth
28	9	10.5	180	1 IGH02 insulin-like growth
29	9	10.5	1	IGRT2 insulin-like growth

## ALIGNMENTS

A;Residues: 1-159 <SHL>;A;Cross-references: GB:X06107; GB:M32260; GB:Y00429; NID:956424; PID:CAA29480.1; PID:C;Superfamily: insulin C;Keywords: alternative splicing; growth factor

imulin-like growth factor I precursor form 1 - rat  
C;Species: *Rattus norvegicus* (Norway rat)

C;Date: 28-Feb-1992 #sequence\_revision 28-Feb-1992 #text\_change 16-Jul-1999  
C;Accession: A490192  
R;Roberts Jr., C.T.; Lasky, S.R.; Lowe Jr., W.L.; Seaman, W.T.; Leboith, D.  
Mol. Endocrinol. 1, 243-248, 1987  
A;Title: Molecular cloning of rat insulin-like growth factor I complementary d-

C tissues. A;Reference number: A40912; PMID:3453891 A;Accession: A40912

A;Status: preliminary  
A;Molecule type: mRNA  
A;Residues: 1-133 <RKB>  
A;Cross-references: GB:MI5480; NID:9204749; PIDN:AAA41385.1; PID:9204750  
C;Superfamily: insulin

QY  
6 YGSSIRRAFOTGIVDECCFRSCDLRLEMVKYVRCKPRTKSARSTRARQRTDHMDPKTQSQPL 65  
7 YGSSIRRAFOTGIVDECCFRSCDLRLEMVKYVRCKPRTKSARSTRARQRTDHMDPKTQSQPL 112  
8 YGSSIRRAFOTGIVDECCFRSCDLRLEMVKYVRCKPRTKSARSTRARQRTDHMDPKTQSQPL

QY	DB
66	STHKKKLQRRKGSTLEEHK 86 IUGSIKKAPQIGIVDECCFQSCLL

113 STHRKRKLUQRRRKGOSTLLEHK 133

RESULT 2  
B40912  
insulin-like growth factor I precursor form 2 - rat

C;Species: *Rattus norvegicus* (Norway rat)  
Date: 20-Feb-1992 #sequence\_revision 28-Feb-1992 #text\_change 16-Jul-1999  
C;Accession: BA0912

R. Roberts Jr., C. T. Lasky, S. R. Lowe Jr., W. L. Seaman, W. I. Lekoff, D. Mol, Endocrinol., 1987, 101, 243-248.  
ARTICLE: Molecular cloning of rat insulin-like growth factor I complementary deoxyribonu-

C:Issues; Reference number: A40912; MUID:88288198; PMID:3453891  
A:Accession: B40912  
A:Start; A:End; A:Primary; A:Secondary

A;Molecule type: nRNA  
A;Residues: 1-127 <ROB>  
A;Cross-references: GB:MI5481; NID:9204753; PIDN:AAA41387.1; PID:9204754

C;Superfamily: insulin  
Query Match 65.1%; Score 56; DB 2; Length 127;

Best Local Similarity 100.0%; Pred. No. 1.2e-49; Mismatches 0; Indels 0; Gaps 0; Matches 56; Conservative

Db	QY	YSSIRRAPOQVDBCEFRSDQKRLMVLCKPKISAKSIRQWHLNPFIAQGIL
6		YSSIRRAPOQVDBCEFRSDQKRLMVLCKPKISAKSIRQWHLNPFIAQGIL
53		YSSIRRAPOQVDBCEFRSDQKRLMVLCKPKISAKSIRQWHLNPFIAQGIL

RESULT 3

insulin-like growth factor 1B precursor - rat  
C;Species: Rattus norvegicus (Norway rat-)  
C;Date: 19-Nov-1988 #sequence\_revision 19-Nov-1988 #text\_change 16-Jul-1999

C;Accession: A26559  
R;Shimatsu, A.; Rotwein, P.  
Nucleic Acids Res. 15, 7196, 1987

A;Title: Sequence of two rat insulin-like growth factor I mRNAs differing within A;Reference number: A26859; PMID:88015572; PMID:3658684 A;Accession: A26859 A;Molecule type: mRNA

A;Cross-references: GB:M28139; NID:9341835; PIDN:AA74553.1; PID:9550489  
 R;Matthews, L.S.; Norstedt, G.; Palmiter, R.D.;  
 Proc. Natl. Acad. Sci. U.S.A. 83, 9343-9347, 1986  
 A;Title: Regulation of insulin-like growth factor I gene expression by growth hormone.  
 A;Reference number: 159090; MUID:8709249; PMID:3467309  
 A;Accession: 159090  
 A;Molecule type: DNA  
 A;Residues: 49-108 <REB>  
 A;Cross-references: GB:MI4983; NID:9194495; PIDN:AAA37925.1; PID:9194496  
 C;Genetics:  
 A;Gene: Igf1  
 C;Superfamily: insulin  
 C;Keywords: alternative splicing; growth factor  
 F;1-22/Domain: signal sequence #status predicted <SIG> #status predicted <MAT>  
 F;23-127/Domain: insulin-like growth factor I (active) #status predicted <MAT>  
 F;23-51/Domain: insulin chain B-like #status predicted <DOC>  
 F;64-93/Domain: insulin connecting C peptide-like #status predicted <DOC>  
 F;85-92/Domain: D Peptide #status predicted <DOC>  
 F;93-117/Domain: carboxyl-terminal propeptide (E peptide) #status predicted <CTP>  
 Query Match 36.0%; Score 31; DB 2; Length 127;  
 Best Local Similarity 100.0%; Pred. No. 3-48-24; Mismatches 0;  
 Matches 31; Conservative 0; Indels 0; Gaps 0;  
 Qy 6 YGSSIRRAPQTVIDGCCFRSDCDRLREMYC 36  
 Db 53 YGSSIRRAPQTVIDGCCFRSDCDRLREMYC 83

RESULT 6

B27804  
 insulin-like growth factor IA precursor - rat  
 N;Alternative names: IGF-IA; somatomedin C  
 C;Species: Rattus norvegicus (Norway rat)  
 C;Date: 16-Mar-1989 #sequence revision 16-Mar-1989 #text change 21-Jul-2000  
 C;Accession: B27804; A27849; JH0133; A28504; JN0088; A32857; A61096  
 R;Shimatsu, A.; Rotwein, P.  
 J. Biol. Chem. 262, 7894-7900, 1987  
 A;Title: Mosaic evolution of the insulin-like growth factors. Organization, sequence, and  
 A;Reference number: A27804; MUID:8722243; PMID:034969  
 A;Accession: B27804  
 A;Molecule type: DNA  
 A;Residues: 1-153 <H1>  
 A;Cross-references: GB:MI5651; GB:J02743; NID:9204297; PIDN:AAA41215.1; PID:9204300  
 R;Caelli, S.J.; Smith, E.P.; Van Wyk, J.J.; Joseph, D.R.; Hynes, M.A.; Hoyt, E.C.; Lund  
 DNA 6, 325-330, 1987  
 A;Title: Isolation of rat testis cDNAs encoding an insulin-like growth factor I precursor  
 A;Reference number: A27849; MUID:8003970; PMID:362906  
 A;Accession: A27849  
 A;Molecule type: mRNA  
 A;Residues: 27-153 <CAS>  
 A;Cross-references: GB:MI7335; NID:9204751; PIDN:AAA41386.1; PID:9204752  
 R;Kato, H.; Okochi, A.; Miura, Y.; Noguchi, T.  
 Agric. Biol. Chem. 54, 1959-1961, 1990  
 A;Title: A new cDNA clone relating to larger molecular species of rat insulin-like growth  
 A;Reference number: JH0133; MUID:91103966; PMID:1368571  
 A;Accession: JH0133  
 A;Molecule type: mRNA  
 A;Residues: 27-153 <KAT>  
 A;Cross-references: GB:DD0698; NID:9220780; PIDN:BA000604.1; PID:9220781  
 A;Experimental source: liver  
 R;Murphy, L.J.; Bell, G.I.; Duckworth, M.L.; Frieben, H.G.  
 Endocrinology 121, 684-691, 1987  
 A;Title: Identification, characterization, and regulation of a rat complementary deoxyri  
 A;Reference number: A28504; MUID:8724637; PMID:359538  
 A;Accession: A28504  
 A;Molecule type: mRNA  
 A;Residues: 46-153 <NUR>  
 A;Cross-references: GB:MI7714; NID:9204324; PIDN:AAA41227.1; PID:9204325  
 R;Kato, H.; Takenaka, A.; Miura, Y.; Nishiyama, M.; Noguchi, T.  
 Agric. Biol. Chem. 54, 2225-2230, 1990

RESULT 7

PN0622  
 insulin-like growth factor Ia precursor - dog (fragment)  
 C;Species: Canis lupus familiaris (dog)  
 C;Date: 10-Mar-1994 #sequence revision 10-Mar-1994 #text\_change 07-May-1999  
 C;Accession: PN0622  
 R;Delafontaine, P.; Lou, H.; Harrison, D.G.; Bernstein, K.B.  
 Gene 130, 305-306, 1993  
 A;Title: Sequence of a cDNA encoding dog insulin-like growth factor I.  
 A;Reference number: PN0622; MUID:93366192; PMID:0359700  
 A;Accession: PN0622  
 A;Molecule type: mRNA  
 A;Residues: 1-122 <DEL>  
 C;Comment: This protein is a potent inducer of DNA synthesis in multiple cell types, acti  
 C;Genetics:  
 A;Gene: Igf1a  
 C;Superfamily: insulin  
 C;Keywords: growth factor  
 F;20-89/Product: insulin-like growth factor Ia (fragment) #status predicted <MAT>  
 Query Match 30.2%; Score 26; DB 2; Length 122;  
 Best Local Similarity 100.0%; Pred. No. 4-1e-19;  
 Matches 26; Conservative 0; Indels 0; Gaps 0;  
 Qy 11 RRAAPQTVIDGCCFRSDCDRLREMYC 36  
 Db 55 RRAAPQTVIDGCCFRSDCDRLREMYC 80

RESULT 8

IGGP1  
 insulin-like growth factor I precursor - guinea pig  
 C;Species: Cavia porcellus (guinea pig)  
 C;Date: 30-Sep-1991 #sequence\_revision 30-Sep-1991 #text\_change 07-Nov-1997  
 C;Accession: S12719  
 R;Bell, G.I.; Stempert, M.M.; Pong, N.M.; Seino, S.  
 Nucleic Acids Res. 18, 4275, 1990  
 A;Title: Sequence of a cDNA encoding guinea pig IGF-I.  
 A;Reference number: S12719; MUID:903247; PMID:2377480

A;Accession: S12719  
 A;Molecule type: mRNA  
 A;Cross-references: EMBL:X52951  
 A;Note: it is uncertain whether Met-1 or Met-8 is the initiator  
 C;Superfamily: insulin  
 C;Keywords: glycoprotein; growth factor; plasma  
 F;1-32/Domain: signal sequence #status predicted <SGG>  
 F;33-102/Domain: insulin-like growth factor I #status predicted <MAT>  
 F;33-61/Domain: insulin chain B-like #status predicted <CHB>  
 F;62-73/Domain: insulin connecting C peptide-like #status predicted <CHO>  
 F;74-94/Domain: insulin chain A-like #status predicted <CHA>  
 F;95-102/Domain: D peptide #status predicted <CDP>  
 F;103-137/Domain: carboxyl-terminal propeptide (E peptide) #status predicted <CHE>  
 F;124/Binding site: carbohydrate (Asn) (covalent) #status predicted  
 Query Match 30.2%; Score 26; DB 1; Length 137;  
 Best Local Similarity 100.0%; Pred. No. 4.5e-19;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOQTGIVDECCFRSCDLRLLEMVC 36  
 Db 68 RRAPOQTGIVDECCFRSCDLRLLEMVC 93  
 RESULT 9  
 A;5552  
 insulin-like growth factor 1a precursor - human  
 A;Cross-species: Homo sapiens (man)  
 C;Species: Homo sapiens (man)  
 C;Date: 12-Apr-1991 #sequence\_revision 12-Apr-1991 #text\_change 16-Jul-1999  
 C;Accession: A36552  
 R;Robin, G.; Yee, D.; Bruenner, N.; Rotwein, P.  
 R;Mol, Endocrinol, 4, 194-1950, 1990  
 A;Title: A novel human insulin-like growth factor I messenger RNA is expressed in normal  
 A;Reference number: A36552; MUID:91187000; PMID:2082190  
 A;Accession: A36552  
 A;status: preliminary  
 A;Molecule type: mRNA  
 A;Accession: GB:M37484; NID:9184833; PIDN:AAA52789.1; PID:9184834  
 C;Superfamily: insulin  
 C;Accession: 1-137 <TOB>  
 Query Match 30.2%; Score 26; DB 2; Length 137;  
 Best Local Similarity 100.0%; Pred. No. 4.5e-19;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOQTGIVDECCFRSCDLRLLEMVC 36  
 Db 68 RRAPOQTGIVDECCFRSCDLRLLEMVC 93  
 RESULT 10  
 S22878  
 insulin-like growth factor I precursor, splice form 2 - sheep  
 C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)  
 C;Date: 23-Apr-1999 #sequence\_revision 23-Apr-1999 #text\_change 23-Jul-1999  
 C;Accession: S22878; S07198  
 R;Dickson, M.C.; Saunders, J.C.; Gilmour, R.S.  
 J;Mol. Endocrinol, 6, 17-31, 1991  
 A;Title: Sequence of the human genes for insulin-like growth factors I and II.  
 A;Reference number: A91356; MUID:8610862; PMID:3002851  
 A;Accession: A23251  
 A;Molecule type: DNA  
 A;Residues: 24-153 <DEP>  
 A;Cross-references: GB:X03420; GB:X00362; NID:933020; PIDN:CAM27152.1; PID:933021; GB:  
 R;Jansen, M.; van Schaik, F.M.A.; Ricker, A.T.; Bullock, B.; Woods, D.E.; Gabay, K.H.  
 Nature, 306, 609-611, 1983  
 A;Title: Sequence of cDNA encoding human insulin-like growth factor I precursor.  
 A;Reference number: A93321; MUID:84068210; PMID:6358902  
 A;Accession: A93321  
 A;Molecule type: mRNA  
 A;Residues: 1-153 <DPN>  
 A;Cross-references: GB:X00173; NID:933015; PIDN:CAA24998.1; PID:933016  
 A;Note: Met-24 is proposed as a likely initiator  
 R;Steenbeek, P.H.; Koeten-Reemst, A.M.C.B.; Cleutjens, C.B.J.M.; Sussenbach, J.S.  
 Biochem. Biophys. Res. Commun, 175, 507-514, 1991  
 A;Title: Complete nucleotide sequence of the high molecular weight human IGF-I mRNA.  
 A;Reference number: JT0571; MUID:91207342; PMID:2018498  
 A;Accession: JT0571  
 A;Molecule type: mRNA  
 A;Residues: 1-153 <STE>  
 A;Cross-references: EMBL:X57025; NID:933007; PIDN:CAA40342.1; PID:933008  
 R;Le Bouc, Y.; Dreier, D.; Jaeger, F.; Birnou, M.; Sondermeyer, P.  
 P;BS Lett, 196, 108-112, 1985  
 A;Title: Complete characterization of the human IGF-I nucleotide sequence isolated fr  
 A;Reference number: A23622; MUID:86108910; PMID:2935423  
 A;Accession: A23622  
 A;Molecule type: mRNA  
 A;Residues: 1-153 <IIEB>  
 A;Cross-references: GB:M27544; NID:9184829; PIDN:AAA52787.1; PID:9306927  
 R;Ridderkroft, E.; Humbel, R.E.; Sonderegger, P.; Biol. Chem., 253, 2769-2776, 1978  
 A;Residues: 34-103 <FRAS>

A;Title: The amino acid sequence of human insulin-like growth factor I and its structure  
 A;Reference number: A92226; MUID:78130171; PMID:632300  
 A;Accession: A92226  
 A;Molecule type: protein  
 A;Residues: 49-118 <RINS  
 R;Kasey, K.P.; Marquardt, H.; Sirbasku, D.A.  
 Blood 74, 1084-1092, 1969  
 A;Title: Human platelet-derived mitogens. Identification of insulinlike growth factors I  
 A;Reference number: A60483; MUID:89323462; PMID:2752153  
 A;Accession: A60483  
 A;Molecule type: protein  
 A;Residues: 49-53, 'X', 55-65, 'X', 67-75 <KAR>  
 A;Experimental source: platelet lysate  
 R;Nordqvist Sandberg, A.C.; Stahlbom, P.A.; Lake, M.; Sara, V.R.  
 submitted to the EMBL Data Library, November 1990  
 A;Description: Nucleotide sequence of the human fetal brain IGF-1a.  
 A;Reference number: S30519  
 A;Accession: S30519  
 A;Molecule type: mRNA  
 A;Residues: 1-153 <NOR>  
 A;Cross-references: EMBL:X56773; NID:932989; PID:CA140092.1; PID:932990  
 R;Sandberg-Nordqvist, A.C.; Stahlbom, P.A.; Reinecke, M.; Collins, V.P.; von Holst, H.;  
 Cancer Res. 53, 2475-2478, 1993  
 A;Title: Characterization of insulin-like growth factor 1 in human primary brain tumors.  
 A;Reference number: A48960; MUID:93265440; PMID:8495408  
 A;Accession: A48960  
 A;Molecule type: mRNA  
 A;Residues: 1-123, 'E', 125-132, 'E', 134-153 <SAN>  
 A;Experimental source: anaplastic Oligodendroglioma  
 A;Note: sequence extracted from NCBIN:133056, NCBIPI:133057  
 A;Note: sequence inconsistent with the nucleotide translation  
 R;Rail, L.B.; Scott, J.; Bell, G.I.  
 Meth. Enzymol. 146, 239-248, 1987  
 A;Title: Human insulin-like growth factor I and II messenger RNA: isolation of complemen-  
 A;Reference number: 157044; MUID:88065102; PMID:3683205  
 A;Accession: 157044  
 A;Stcatus: preliminary; translated from GB/EMBL/DDJB  
 A;Molecule type: mRNA  
 A;Residues: 24-153 <RAL>  
 A;Cross-references: GB:MG9644; NID:9183119; PID:AAAC2543.1; PID:9183120  
 C;Comment: The insulin-like growth factors, isolated from plasma, are structurally and f-  
 C;Comment: For an alternative splice form, see PIR:IGH1B.  
 C;Genetics:  
 A;Gene: GDF:IGF1  
 A;Cross-references: GDB:120081; OMIM:147440  
 A;Map position: 12q22-12q24.1  
 A;introns: 21/3; 74/1; 134/3  
 C;Superfamily: insulin  
 C;Keywords: alternative splicing; growth factor; plasma  
 F;1-21-/Domain: signal sequence #status predicted <SIG>  
 F;2-21-/Domain: propeptide #status predicted <PRO>  
 F;49-118-/Domain: propeptide #status predicted <PRO>  
 F;49-118-/Domain: insulin chain B-like #status experimental <CHB>  
 F;49-118-/Domain: insulin connecting C peptide-like #status predicted <PRO>  
 F;49-118-/Domain: insulin chain A-like #status experimental <CHA>  
 F;111-118-/Domain: D peptide #status experimental <CHD>  
 F;111-118-/Domain: carboxy-terminal propeptide (E peptide) #status predicted <CPR>  
 F;54-96, 66-109, 95-100/Disulfide bonds: #status predicted  
 Query Match: 30.2%; Score: 26; DB 1; Length: 153;  
 Best Local Similarity: 100.0%; Pred. No. 4.9e-19; Mismatches: 0; Indels: 0; Gaps: 0;  
 Matches: 26; Conservative: 0;  
 CQ 11 RRAPOGTGIVDECFCRSCLDRRLREMYC 36  
 DB 84 RRAPOGTGIVDECFCRSCLDRRLREMYC 109

RESULT 13  
 S12825  
 insulin-like growth factor I precursor - pig  
 N;Alternate names: somatomedin C  
 C;Species: Sus scrofa domesticus (domestic pig)  
 C;Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 16-Jul-1999  
 C;Accession: S12825; S21488; A34938; A60738  
 R;Mueller, M.; Brem, G.  
 Nucleic Acids Res. 18, 364, 1990  
 A;Title: Nucleotide sequence of porcine insulin-like growth factor I: 5' untranslated re-  
 A;Reference number: S12825; MUID:9021822; PMID:2326169  
 A;Accession: S12825  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-153 <MUB>  
 A;Cross-references: EMBL:X52388  
 A;Submitted to the EMBL Data Library, November 1989  
 A;Description: Porcine insulin-like growth factor gene: sequence of exon and 5' non-codir-  
 A;Reference number: S21488  
 A;Accession: S21488  
 A;Molecule type: DNA  
 A;Residues: 1-21 <DIC>

RESULT 12  
 RGAOL  
 insulin-like growth factor I precursor - bovine (fragment)  
 Db 84 RRAPOGTGIVDECFCRSCLDRRLREMYC 109

A;Cross-references: EMBL:XL17638; NID:91995; PIDN:CA35632.1; PID:91996  
 A;Ravakkol, A.; Simmen, F.A.; Simmen, R.C.M.  
 Mol. Endocrinol. 2, 674-681, 1988  
 A;Title: Porcine insulin-like growth factor-I (IGF-I): complementary deoxyribonucleic acids  
 A;Reference number: A34938; MUID:89096956; PMID:3211153  
 A;Accession: A34938  
 A;Molecule type: mRNA  
 A;Residues: Y, 21-153 <TAV>  
 A;Cross-references: GB:M31175  
 A;Molecule type: protein  
 A;Residues: 49-117, 'X' <FRA>  
 A;Genetics: C:Genetics: 49-117, 'X' <FRA>  
 A;Introns: 21/3; 74/1  
 C:Superfamily: insulin  
 C:Keywords: growth factor  
 F;1-2/Domain: signal sequence #status predicted <SIG>  
 F;23-48/Domain: propeptide #status predicted <PRO>  
 F;49-153/Domain: insulin-like growth factor I A #status experimental <MAT>  
 Query Match 30.2%; Score 26; DB 2; Length 153;  
 Best Local Similarity 100.0%; Pred. No. 4.9e-19; Mismatches 0; Indels 0; Gaps 0;  
 Matches 26; Conservative 0; MisMatches 0; Indels 0; Gaps 0;  
 QY 11 RRAPOQTGIVDECCFRSCDLRRLMYC 36  
 DB 84 RRAPOQTGIVDECCFRSCDLRRLMYC 109

RESULT 14  
 JC2483 insulin-like growth factor-I precursor - goat  
 C:Species: Capra aegagrus hircus (domestic goat)  
 C:Date: 16-Mar-1995 #sequence\_revision 26-May-1995 #text\_change 17-Mar-1999  
 C:Accession: JC2483  
 C:Residues: 50-119 <FRA>  
 A;Molecule type: mRNA  
 A;Biosci. Biotechnol. Biochem. 59, 87-92, 1995  
 A;Title: Dynamic aspects in the expression of the goat insulin-like growth factor-I (IGF-I precursor) in the mammary gland  
 A;Reference number: JC2483; MUID:95201385; PMID:7765981  
 A;Accession: JC2483  
 A;Molecule type: mRNA  
 A;Residues: 1-154 <MTK>  
 A;Cross-references: GB:SL1378; DDBJ:D26116; DDBJ:D26117; DDBJ:D26118; DDBJ:D26119  
 C:Genetics: C:Genetics: 21/3; 75/1; 135/3  
 C:Superfamily: insulin  
 F;1-49/Domain: signal sequence #status predicted <SIG>  
 F;50-119/Domain: insulin-like growth factor-I precursor - goat  
 A;Reference number: JC2483; MUID:95201385; PMID:7765981  
 A;Accession: JC2483  
 A;Molecule type: mRNA  
 A;Residues: 1-154 <MTK>  
 A;Cross-references: GB:SL1378; DDBJ:D26116; DDBJ:D26117; DDBJ:D26118; DDBJ:D26119  
 C:Genetics: 21/3; 75/1; 135/3  
 C:Superfamily: insulin  
 F;1-49/Domain: signal sequence #status predicted <SIG>  
 F;120-154/Region: E domain  
 Query Match 30.2%; Score 26; DB 2; Length 154;  
 Best Local Similarity 100.0%; Pred. No. 4.9e-19; Mismatches 0; Indels 0; Gaps 0;  
 Matches 26; Conservative 0; MisMatches 0; Indels 0; Gaps 0;  
 QY 11 RRAPOQTGIVDECCFRSCDLRRLMYC 36  
 DB 85 RRAPOQTGIVDECCFRSCDLRRLMYC 110

RESULT 15  
 A33390 insulin-like growth factor I precursor, splice form 1 - sheep  
 N1:Alternate names: somatomedin C  
 C:Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)  
 C:Date: 09-Mar-1990 #sequence\_revision 27-Feb-1997 #text\_change 23-Jul-1999  
 C:Accession: S22877  
 A;Title: Two insulin-like growth factor I messenger RNAs are expressed in human liver  
 A;Reference number: A26181; MUID:86094355; PMID:3455760  
 A;Accession: A26181

RESULT 16  
 A33390 insulin-like growth factor I precursor, splice form B [validated] - human  
 N1:Alternate names: IGF-IB; somatomedin C  
 N2:Contains: insulin-like growth factor IB-El amide  
 C:Species: Homo sapiens (man)  
 C:Date: 30-Jun-97 #sequence\_revision 30-Jun-1987 #text\_change 31-Dec-2000  
 C:Accession: A01611, A26181; S07965; S07198  
 R;Rotwein, P.; Pollock, K.M.; Didier, D.K.; Keihi, G.G.  
 J. Biol. Chem. 261, 4828-4832, 1986  
 A;Title: Organization and sequence of the human insulin-like growth factor I gene. A 1.5-kilobase DNA  
 A;Reference number: A92581; MUID:86168194; PMID:2937782  
 A;Accession: A01611  
 A;Molecule type: DNA  
 A;Residues: 1-195 <ROM1>  
 A;Cross-references: GB:MI4155; NID:9183106; PIDN:AA52537.1; PID:9183109  
 R;Rotwein, P.;  
 Proc. Natl. Acad. Sci. U.S.A. 83, 77-81, 1986  
 A;Title: Two insulin-like growth factor I messenger RNAs are expressed in human liver  
 A;Reference number: A26181; MUID:86094355; PMID:3455760  
 A;Accession: A26181

A;Molecule type: mRNA  
 A;Residues: 1-195 <ROT2>  
 A;Cross-references: GB:MI1568; NID:918311; PIDN:AAA52539-1; PID:9183112  
 R;Sandberg Nordqvist, A.C.; Stahlbon, P.A.; Lake, M.; Sara, V.R.  
 submitted to the EMBL Data Library, November 1990  
 A;Description: Nucleotide sequence of the human fetal brain IGF-1b.  
 A;Reference number: S30540  
 A;Molecule type: mRNA  
 A;Residues: 1-195 <SAN>  
 A;Cross-references: EMBL:X56774; NID:932991; PIDN:CAA40093-1; PID:932992  
 R;Sandberg Nordqvist, A.C.; Stahlbon, P.A.; Reinecke, M.; Collins, V.P.; von Holst, H.;  
 Cancer Res. 53, 2475-2478, 1993  
 A;Title: Characterization of insulin-like growth factor 1 in human primary brain tumors.  
 A;Reference number: A48960; MUID:93265440; PMID:8495408  
 A;Accession: B48960  
 A;Molecule type: mRNA  
 A;Residues: 1-195 <SH2>  
 A;Cross-references: GB:X16774; GB:X561860; NID:932991; PIDN:CAA40093-1; PID:932992  
 A;Experimental source: anaplastic oligodendroglioma  
 A;Note: sequence modified after extraction from NCBI backbone (NCBIN:133058)  
 A;Title: A mitogenic peptide amide encoded within the B peptide domain of the insulin-like  
 peptide. Natl. Acad. Sci. U.S.A. 89, 8107-8111, 1992  
 A;Note: the authors translated the codon CAG for residues 124 and 133 as Glu  
 A;Title: sequence extracted from NCBI backbone (NCBIN:133058)  
 R;Siegrist, J.M.; Kasprzak, T.G.; Treson, A.M.; Mulshine, J.L.; Quin, K.A.; Cutitta, C.;Genetics: For an alternative splice form, see PIR:IGHU.  
 A;Gene: GDI; IGF1  
 A;Cross-references: GDB:120081; OMIM:147440  
 A;Map position: 12q2-12q24.1  
 A;Introns: 21/3; 74/1; 134/3  
 C;Superfamily: insulin  
 C;Keywords: alternative splicing; amidated carboxyl end; growth factor; plasma  
 F;1-21/Domain: signal sequence #status predicted <SIG>  
 F;22-48/Domain: propeptide #status predicted <PRO>  
 A;Map position: insulin-like growth factor I #status predicted <MAT>  
 F;49-77/Domain: insulin chain B-like #status predicted <CHB>  
 F;78-89/Domain: insulin connecting C peptide-like #status predicted <CHC>  
 F;90-110/Domain: insulin chain A-like #status predicted <CHA>  
 F;111-118/Domain: D peptide #status predicted <CHD>  
 F;119-195/Domain: carboxyl-terminal propeptide (E peptide) #status predicted <CHE>  
 F;172-Product: insulin-like growth factor IB-El amide #status predicted <MA2>  
 F;54-96, 109-109, 95-100/Disulfide bonds: #status predicted  
 F;172/Modified site: amidated carboxyl end (Arg) (amide in mature form from following 91  
 Query Match 30.0%; Score 26; DB 1; Length 195;  
 Best Local Similarity 100.0%; Pred. No. 6e-19; 0; Mismatches 0; Indels 0; Gaps 0;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Query 11 RRAQOTGIVDECCFPRSDCDLRLRLEMVC 36  
 Db 84 RRAQOTGIVDECCFPRSDCDLRLRLEMVC 109  
 Db 84 RRAQOTGIVDECCFPRSDCDLRLRLEMVC 109  
 RESULT 17  
 A41399  
 insulin-like growth factor IA precursor - chicken  
 C;Species: Gallus gallus (chicken)  
 C;Date: 03-Apr-1992 #sequence revision 03-Apr-1992 #text\_change 16-Jul-1999  
 C;Accession: A41399; A61092; A40012; B60853; A37415  
 R;Kajimoto, Y.; Rotwein, P.  
 Mol. Endocrinol. 3, 1907-1913, 1989  
 A;Title: Structure and expression of a chicken insulin-like growth factor I precursor.  
 A;Reference number: A41399; MUID:90190646; PMID:2628729  
 A;Accession: A41399  
 A;Molecule type: mRNA  
 A;Residues: 1-153 <KAJ>  
 A;Cross-references: GB:MI29857; NID:9214287; PIDN:AAA70330-1; PID:9214288  
 R;Shuldtner, A.R.; Nirula, A.; Scott, L.A.; Roth, J.  
 Biochem. Biophys. Res. Commun. 166, 223-230, 1990  
 A;Title: Evidence that Xenopus laevis contains two different nonallelic insulin-like growth factor I genes.  
 A;Reference number: A90158; MUID:90147704; PMID:2302204  
 A;Accession: A36079  
 A;Molecule type: mRNA  
 A;Residues: 1-153 <KAJ>  
 A;Cross-references: GB:MI29857; NID:9214287; PIDN:AAA70330-1; PID:9214288  
 R;Shuldtner, A.R.; Nirula, A.; Scott, L.A.; Roth, J.  
 Biochem. Biophys. Res. Commun. 166, 223-230, 1990  
 A;Title: Evidence that Xenopus laevis contains two different nonallelic insulin-like growth factor I genes.  
 A;Reference number: A90158; MUID:90147704; PMID:2302204  
 A;Accession: A36079  
 A;Molecule type: DNA  
 A;Residues: 82-85, 'A', 87-125 <SH2>  
 C;Genetics:  
 A;Gene: IGF-I  
 C;Superfamily: insulin  
 C;Keywords: growth factor  
 A;Title: Molecular cloning, sequence analysis and expression of putative chicken insulin-like growth factor-I gene reveals conserved pre-mRNA sequences. J. Biol. Chem. 266, 9724-9731, 1991  
 R;Kajimoto, Y.; Rotwein, P.  
 J. Biol. Chem. 266, 9724-9731, 1991  
 A;Title: Structure of the chicken insulin-like growth factor I gene reveals conserved pre-mRNA sequences and properties of chicken insulin-like growth factor-I gene. Gen. Comp. Endocrinol. 79, 459-468, 1990  
 A;Title: Chicken insulin-like growth factor-I: amino acid sequence, radioimmunoassay, and immunological properties. J. Biol. Chem. 265, 106695; PMID:2272467  
 A;Reference number: A37415; MUID:9106695; PMID:2272467  
 A;Accession: A37415  
 A;Status: preliminary  
 A;Molecule type: protein  
 A;Residues: 49-118 <BLU>  
 C;Superfamily: insulin  
 C;Keywords: growth factor  
 C;Species: Xenopus laevis (African clawed frog)  
 C;Date: 30-Nov-1990 #sequence\_revision 30-Nov-1990 #text\_change 16-Jul-1999  
 C;Accession: A36079; B34049  
 R;Kajimoto, Y.; Rotwein, P.  
 Mol. Endocrinol. 4, 217-226, 1990  
 A;Title: Evolution of insulin-like growth factor I (IGF-I): structure and expression of  
 A;Reference number: A36079; MUID:90231335; PMID:2330002  
 A;Accession: A36079  
 A;Molecule type: mRNA  
 A;Residues: 1-153 <KAJ>  
 A;Cross-references: GB:MI29857; NID:9214287; PIDN:AAA70330-1; PID:9214288  
 R;Shuldtner, A.R.; Nirula, A.; Scott, L.A.; Roth, J.  
 Biochem. Biophys. Res. Commun. 166, 223-230, 1990  
 A;Title: Evidence that Xenopus laevis contains two different nonallelic insulin-like growth factor I genes.  
 A;Reference number: A90158; MUID:90147704; PMID:2302204  
 A;Accession: A36079  
 A;Molecule type: DNA  
 A;Residues: 82-85, 'A', 87-125 <SH2>  
 C;Genetics:  
 A;Gene: IGF-I  
 C;Superfamily: insulin  
 C;Keywords: growth factor

Query Match 11.6%; Score 10; DB 2; Length 153;  
 Best Local Similarity 100.0%; Pred. No. 0.0098; Mismatches 0; Indels 0; Gaps 0;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 RAQRTDMPK 58  
 Db 122 RAQRTDMPK 131

RESULT 19  
 153642  
 Insulin-like growth factor II precursor - horse (fragment)  
 C;Species: Equus caballus (domestic horse)  
 C;Accession: 15-Oct-1996 #sequence\_revision 15-Oct-1996 #text\_change 16-Jul-1999

R;Otte, K.; Engstrom, W.  
 Gen. Comp. Endocrinol. 96, 270-275, 1994  
 A;Title: Insulin-like growth factor II in the horse: determination of a cDNA nucleotide  
 A;Reference number: 153642; MUID:95154655; PMID:7851727

A;Status: preliminary; translated from GB/EMBL/DBJ  
 A;Accession: 153642  
 A;Molecule type: mRNA  
 A;Residue: 1-93 <OTR>  
 A;Cross-references: EMBL:U11241; NID:9508703; PIDN:AAA73915.1; PID:9508704  
 A;Genetics:  
 C;Superfamily: insulin

Query Match 10.5%; Score 9; DB 2; Length 149;  
 Best Local Similarity 100.0%; Pred. No. 0.01; Mismatches 0; Indels 0; Gaps 0;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 ECCFRSCD 29  
 Db 45 ECCFRSCD 53

RESULT 20  
 157671  
 Insulin-like growth factor II - guinea pig  
 C;Species: Cavia porcellus (guinea pig)  
 C;Accession: 02-Aug-1996 #sequence\_revision 02-Aug-1996 #text\_change 16-Jul-1999

R;Levinovitz, A.; Norstedt, G.; van den Berg, S.; Robinson, I.C.; Ekstrom, T.J.  
 Mol. Cell. Endocrinol. 89, 105-110, 1992  
 A;Title: Isolation of an insulin-like growth factor II cDNA from guinea pig liver: expression  
 A;Title: Isolation of an insulin-like growth factor II cDNA from guinea pig liver: expression  
 A;Accession: 157671; MUID:93246007; PMID:1301379

A;Status: preliminary; translated from GB/EMBL/DBJ  
 A;Molecule type: mRNA  
 A;Cross-references: GB:S59899; NID:9300070; PIDN:ABA26479.1; PID:9300071  
 C;Superfamily: insulin

Query Match 10.5%; Score 9; DB 2; Length 128;  
 Best Local Similarity 100.0%; Pred. No. 0.088; Mismatches 0; Indels 0; Gaps 0;

QY 21 ECCFRSCD 29  
 Db 69 ECCFRSCD 77

RESULT 21  
 154270  
 Insulin-like growth factor-I precursor (clone OTIGFI-0) - chinook salmon  
 C;Species: Oncorhynchus tshawytscha (chinook salmon)  
 C;Accession: 13-Sep-1994 #sequence\_revision 25-Apr-1997 #text\_change 16-Jul-1999

R;Wallis, A.E.; Devlin, R.H.  
 Mol. Endocrinol. 7, 409-422, 1993  
 A;Title: Duplicate insulin-like growth factor-I genes in salmon display alternative splicing

Query Match 10.5%; Score 9; DB 2; Length 149;  
 Best Local Similarity 100.0%; Pred. No. 0.1; Mismatches 0; Indels 0; Gaps 0;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 RAQRTDMP 57  
 Db 118 RAQRTDMP 126

RESULT 22  
 157671  
 Insulin-like growth factor II precursor - bovine  
 N;Alternate names: IGF-II  
 C;Species: Bos Primigenius taurinus (attle)  
 C;Accession: 31-Mar-1998 #sequence\_revision 22-Apr-1995 #text\_change 23-Mar-2001  
 C;Accession: S10983; S37617; B35623; A34445; S00466; A57470  
 R;Brown, W.M.; Dziegielewska, K.M.; Foreman, R.C.; Saunders, N.R.  
 Nucleic Acids Res. 18, 4614-4619, 1990  
 A;Title: The nucleotide and deduced amino acid sequences of insulin-like growth factor  
 A;Reference number: S10983; MUID:90356421; PMID:238846  
 A;Accession: 157671  
 A;Molecule type: mRNA  
 A;Residue: 6-155 <BR>  
 A;Cross-references: EMBL:X53553; NID:9459; PIDN:CAA37620.1; PID:91364191  
 A;Experimental source: liver  
 R;Congote, L.F.; Mazza, L.; Palfrree, R.G.E.  
 Comp. Biochem. Physiol. B 103, 127-131, 1992  
 A;Title: Nucleotide sequence of the central coding region of bovine erythropoietin/insulin-like growth factor-I  
 A;Reference number: S37617; MUID:93083057; PMID:1280544  
 A;Accession: 157671  
 A;Molecule type: mRNA  
 A;Residues: 6-62 <CON>  
 A;Cross-references: EMBL:X53867; NID:9461; PIDN:CAA37861.1; PID:9300044  
 A;Experimental source: fetal intestine  
 R;Honegger, A.; Humbel, R.E.  
 J. Biol. Chem. 261, 569-575, 1986  
 A;Title: Insulin-like growth factors I and II in fetal and adult bovine serum. Purification and characterization  
 A;Reference number: A92585; MUID:86085881; PMID:3941093  
 A;Accession: B25623  
 A;Molecule type: protein  
 A;Residues: 1-34, S, 36-67 <HON>  
 R;Li, Q.; Blacher, R.; Esch, F.; Congote, L.F.  
 Biochem. Biophys. Res. Commun. 166, 557-561, 1990  
 A;Title: A heparin-binding erythroid cell stimulating factor from fetal bovine serum  
 A;Reference number: A34645; MUID:90147754; PMID:2302223  
 A;Accession: A34645  
 A;Molecule type: protein  
 A;Residues: 1-8, X, 10-20, X, 22-31 <HIO>  
 R;Francis, G.L.; Upton, P.M.; Ballard, P.J.; McNeil, K.A.; Wallace, J.C.  
 Biochem. J. 251, 95-103, 1988  
 A;Title: Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities  
 A;Reference number: S00466; MUID:88268820; PMID:3390164  
 A;Accession: S00466  
 A;Molecule type: protein  
 A;Residues: 1-67 <PR>  
 R;Valenzano, K.J.; Remmler, J.; Lobel, P.  
 J. Biol. Chem. 270, 16411-16448, 1995  
 A;Title: Soluble insulin-like growth factor II/nanomose 6-phosphate receptor carries 1  
 A;Reference number: A57470; MUID:9533360; PMID:7608215  
 A;Accession: A57470  
 A;Status: preliminary  
 A;Molecule type: protein  
 A;Residues: 1-5 <VAL>

C;Superfamily: insulin  
 C;Keywords: colostrom; growth factor; heparin binding; mitogen; plasma  
 F;1-57/Product: insulin-like growth factor II #status experimental <PAT>  
 F;1-27/Domain: insulin B chain-like #status experimental <DB>  
 F;28-41/Domain: insulin A chain-like #status experimental <CBP>  
 F;62-67/Domain: D peptide #status experimental <CBP>  
 F;68-75/Domain: carboxyl-terminal propeptide (E peptide) #status predicted  
 F;9-47,21-60,46-51/disulfide bonds: #status predicted

Query Match 10.5%; Score 9; DB 1; Length 155;  
 Best Local Similarity 100.0%; Pred. No. 0.1; Mismatches 0; Indels 0; Gaps 0;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 21 ECPRSRCDL 29  
 Db 45 ECPRSRCDL 53

RESULT 23  
 C44012  
 insulin-like growth factor I precursor, splice form 3 - coho salmon (fragment)  
 N;Contains: insulin-like growth factor I, splice form 1; insulin-like growth factor I, e  
 C;Species: Ondorhynchus kisutch (coho salmon)  
 C;Date: 27-Apr-1993 #sequence\_revision 27-Apr-1993 #text\_change 16-Jul-1999  
 C;Accession: C44012; A44012; B44012  
 R;Duguay, S.J.; Park, L.K.; Samadpour, M.; Dickhoff, W.W.  
 Mol. Endocrinol. 6, 1202-1210, 1992  
 A;Title: Nucleotide sequence and tissue distribution of three insulin-like growth factor  
 A;Reference number: A44012; MUID:93024477; PMID:1406698  
 A;Accession: C44012  
 A;Status: preliminary; not compared with conceptual translation  
 A;Molecule type: mRNA  
 A;Residues: 1-155 <DUG>  
 A;Cross-references: GB:M81913; NID:g213442; PIDN:AA249413.1; PID:g213443  
 A;Note: sequence extracted from NCBI backbone (NCBIP:115177)  
 C;Genetics:  
 A;Gene: IGF-I  
 C;Superfamily: insulin  
 C;Keywords: growth factor

Query Match 10.5%; Score 9; DB 2; Length 155;  
 Best Local Similarity 100.0%; Pred. No. 0.1; Mismatches 0; Indels 0; Gaps 0;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 49 RAQHDTMP 57  
 Db 92 RAQHDTMP 100

RESULT 24  
 C5270  
 insulin-like growth factor-I precursor (clone OTIGFI-36) - chinook salmon  
 C;Species: Ondorhynchus tshawytscha (chinook salmon)  
 C;Date: 13-Sep-1994 #sequence\_revision 25-Apr-1997 #text\_change 16-Jul-1999  
 C;Accession: C5270  
 R;Willis, A.E.; Devlin, R.H.  
 Mol. Endocrinol. 7, 409-422, 1993  
 A;Title: Duplicate insulin-like growth factor-I genes in salmon display alternative splicing  
 A;Reference number: A5270; MUID:93247592; PMID:7683374  
 A;Accession: C54270  
 A;Status: preliminary  
 A;Molecule type: mRNA  
 A;Residues: 1-161 <WAL>  
 A;Cross-references: GB:M815961; GB:S59514; NID:9559008; PIDN:AA67267.1; PID:g559009  
 A;Note: sequence extracted from NCBI backbone (NCBIP:130893)  
 C;Superfamily: insulin

Query Match 10.5%; Score 9; DB 2; Length 161;  
 Best Local Similarity 100.0%; Pred. No. 0.11; Mismatches 0; Indels 0; Gaps 0;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 49 RAQHDTMP 57  
 Db 18 RAQHDTMP 126

Search completed: March 3, 2004, 12:03:11  
 Job time : 21 secs

GenCore version 5.1.6  
 copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 3, 2004, 12:02:41 ; Search time 33 Seconds  
 Sequence: (without alignments)  
 550.278 Million cell updates/sec

Title: US-09-852-261-4\_COPY\_26\_111  
 Perfect score: 86

Sequence: 1. NKRPTVYVSSIRRAPQPTGIVD. .... THKKRKLQRRRKGSSTLEHK 86

Scoring table: Oligo  
 Gapop 60.0 , Gapext 60.0

Searched: 809742 seqs, 211153259 residues

Word size : 0

Total number of hits satisfying chosen parameters: 809742

Minimum DB seq length: 0  
 Maximum DB seq length: 200000000

Post Processing: Listing first 100 summaries

Database : Published Applications AA:\*

1: /cgn2\_6/ptodata/1/pubpaal/us07\_pubcomb.pep:\*
 2: /cgn2\_6/ptodata/1/pubpaal/pct1\_new\_pub.pep:\*
 3: /cgn2\_6/ptodata/1/pubpaal/us06\_new\_pub.pep:\*
 4: /cgn2\_6/ptodata/1/pubpaal/us05\_pubcomb.pep:\*
 5: /cgn2\_6/ptodata/1/pubpaal/us07\_new\_pub.pep:\*
 6: /cgn2\_6/ptodata/1/pubpaal/pctus\_pubcomb.pep:\*
 7: /cgn2\_6/ptodata/1/pubpaal/us08\_pubcomb.pep:\*
 8: /cgn2\_6/ptodata/1/pubpaal/us09\_pubcomb.pep:\*
 9: /cgn2\_6/ptodata/1/pubpaal/us06\_pubcomb.pep:\*
 10: /cgn2\_6/ptodata/1/pubpaal/us05\_pubcomb.pep:\*
 11: /cgn2\_6/ptodata/1/pubpaal/us09\_pubcomb.pep:\*
 12: /cgn2\_6/ptodata/1/pubpaal/us09\_new\_pub.pep:\*
 13: /cgn2\_6/ptodata/1/pubpaal/us10\_pubcomb.pep:\*
 14: /cgn2\_6/ptodata/1/pubpaal/us10b\_pubcomb.pep:\*
 15: /cgn2\_6/ptodata/1/pubpaal/us10c\_pubcomb.pep:\*
 16: /cgn2\_6/ptodata/1/pubpaal/us10\_new\_pub.pep:\*
 17: /cgn2\_6/ptodata/1/pubpaal/us60\_new\_pub.pep:\*
 18: /cgn2\_6/ptodata/1/pubpaal/us60\_pubcomb.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	86	100.0	111 9	US-09-852-261-4
2	61	70.9	105 9	US-09-852-261-12
3	31	36.0	133 14	US-10-161-882
4	26	30.2	70 9	US-09-848-664-29
5	26	30.2	70 9	US-09-848-664-30
6	26	30.2	70 10	US-09-858-35B-3
7	26	30.2	70 13	US-10-028-110-1
8	26	30.2	70 13	US-10-066-89A-1
9	26	30.2	70 14	US-10-136-639-1
10	26	30.2	70 14	US-10-136-639-1
11	26	30.2	70 14	US-10-44-626-1
12	26	30.2	70 15	US-10-272-531A-7
13	26	30.2	70 15	US-10-272-531A-7
14	26	30.2	70 15	US-10-44-626-1
15	26	30.2	70 15	US-10-44-626-1
16	26	30.2	70 15	US-10-44-626-1
17	26	30.2	70 15	US-10-44-626-1
18	26	30.2	70 15	US-10-44-626-1
19	26	30.2	70 15	US-10-44-626-1
20	26	30.2	70 15	US-10-44-626-1
21	26	30.2	70 15	US-10-44-626-1
22	26	30.2	70 15	US-10-44-626-1
23	26	30.2	70 15	US-10-44-626-1
24	26	30.2	70 15	US-10-44-626-1
25	26	30.2	70 15	US-10-44-626-1
26	30.2	70 15	US-10-44-626-1	
27	26	30.2	70 15	US-10-44-626-1
28	26	30.2	70 15	US-10-44-626-1
29	26	30.2	70 15	US-10-44-626-1
30	26	30.2	70 15	US-10-44-626-1
31	26	30.2	70 15	US-10-44-626-1
32	26	30.2	70 15	US-10-44-626-1
33	26	30.2	70 15	US-10-44-626-1
34	26	30.2	70 15	US-10-44-626-1
35	26	30.2	70 15	US-10-44-626-1
36	26	30.2	70 15	US-10-44-626-1
37	26	30.2	70 15	US-10-44-626-1
38	26	30.2	70 15	US-10-44-626-1
39	22	68	14	US-10-339-40-218
40	26	30.2	70 15	US-10-66-009A-5
41	11	12.8	29	US-10-241-556-14
42	11	12.8	14	US-10-279-001-72
43	11	12.8	103	US-10-279-051-82
44	11	12.8	14	US-10-279-081-88
45	11	12.8	131	US-10-336-841-8
46	9	10.5	67	US-09-055-140
47	9	10.5	46	US-09-055-658-141
48	9	10.5	46	US-09-963-693-140
49	9	10.5	67	US-10-066-009A-2
50	9	10.5	67	US-10-272-531A-4
51	9	10.5	67	US-10-336-841-8
52	9	10.5	67	US-10-272-531A-8
53	9	10.5	67	US-10-272-483A-8
54	9	10.5	70	US-10-336-841-4
55	9	10.5	70	US-10-272-531A-4
56	9	10.5	70	US-10-272-841-4
57	9	10.5	156	US-09-970-809-7
58	9	10.5	58	US-10-081-119-38
59	9	10.5	67	US-10-272-483A-8
60	9	10.5	60	US-10-097-310-145
61	9	10.5	61	US-10-272-531A-4
62	9	10.5	62	US-10-295-027-199
63	9	10.5	180	US-10-272-531A-2
64	9	10.5	180	US-10-173-939-99
65	9	10.5	180	US-10-258-666-2
66	9	10.5	180	US-10-272-483A-2
67	9	10.5	180	US-10-443-466A-21
68	9	10.5	180	US-10-116-881-6
69	9	10.5	722	US-10-272-531A-6
70	9	10.5	15	US-10-272-483A-5
71	8	9.3	1785	US-10-369-433-7019
72	7	8.1	13	US-09-746-170-3
73	7	8.1	13	US-09-746-170-12
74	7	8.1	13	US-09-746-170-22
75	7	8.1	13	US-09-746-170-37
76	7	8.1	20	US-10-339-749-70-225
77	7	8.1	46	US-09-205-658-144
78	7	8.1	46	US-09-205-658-145
79	7	8.1	46	US-09-963-693-144
80	7	8.1	10	US-09-963-693-145
81	7	8.1	236	US-10-369-433-20167
82	7	8.1	15	US-10-369-433-20167
83	7	8.1	429	US-10-389-556-117
84	7	8.1	15	US-10-669-433-21077
85	7	8.1	537	US-10-037-667-1
86	7	8.1	720	US-10-161-933-118
87	7	8.1	1070	US-09-961-403-3
88	7	8.1	1070	US-10-161-215-155

Result No.	Score	Query Match Length	DB ID	Description
1	86	100.0	111 9	US-09-852-261-4
2	61	70.9	105 9	US-09-852-261-12
3	31	36.0	133 14	US-10-161-882
4	26	30.2	70 9	US-09-848-664-29
5	26	30.2	70 9	US-09-848-664-30
6	26	30.2	70 10	US-09-858-35B-3
7	26	30.2	70 13	US-10-028-110-1
8	26	30.2	70 13	US-10-066-89A-1
9	26	30.2	70 14	US-10-136-639-1
10	26	30.2	70 14	US-10-136-639-1
11	26	30.2	70 14	US-10-44-626-1
12	26	30.2	70 14	US-10-44-626-1
13	26	30.2	70 15	US-10-272-531A-7
14	26	30.2	70 15	US-10-44-626-1
15	26	30.2	70 15	US-10-44-626-1
16	26	30.2	70 15	US-10-44-626-1
17	26	30.2	70 15	US-10-44-626-1
18	26	30.2	70 15	US-10-44-626-1
19	26	30.2	70 15	US-10-44-626-1
20	26	30.2	70 15	US-10-44-626-1
21	26	30.2	70 15	US-10-44-626-1
22	26	30.2	70 15	US-10-44-626-1
23	26	30.2	70 15	US-10-44-626-1
24	26	30.2	70 15	US-10-44-626-1
25	26	30.2	70 15	US-10-44-626-1
26	30.2	70 15	US-10-44-626-1	
27	7	8.1	13	Sequence 42, Appli
28	7	8.1	13	Sequence 10, Appli
29	7	8.1	13	Sequence 14, Appli
30	7	8.1	13	Sequence 3, Appli
31	7	8.1	13	Sequence 2, Appli
32	7	8.1	13	Sequence 6, Appli
33	7	8.1	13	Sequence 14, Appli
34	7	8.1	13	Sequence 8, Appli
35	7	8.1	13	Sequence 74, Appli
36	7	8.1	13	Sequence 3, Appli
37	7	8.1	13	Sequence 2, Appli
38	7	8.1	13	Sequence 55, Appli
39	7	8.1	13	Sequence 39, Appli
40	7	8.1	13	Sequence 39, Appli
41	7	8.1	13	Sequence 41, Appli
42	7	8.1	13	Sequence 41, Appli
43	7	8.1	13	Sequence 20, Appli
44	7	8.1	13	Sequence 12, Appli
45	7	8.1	13	Sequence 5, Appli
46	7	8.1	13	Sequence 14, Appli
47	7	8.1	13	Sequence 14, Appli
48	7	8.1	13	Sequence 14, Appli
49	7	8.1	13	Sequence 14, Appli
50	7	8.1	13	Sequence 14, Appli
51	9	10.5	67	Sequence 141, Appli
52	9	10.5	67	Sequence 140, Appli
53	9	10.5	67	Sequence 140, Appli
54	9	10.5	70	Sequence 140, Appli
55	9	10.5	70	Sequence 140, Appli
56	9	10.5	70	Sequence 140, Appli
57	9	10.5	156	Sequence 140, Appli
58	9	10.5	58	Sequence 8, Appli
59	9	10.5	67	Sequence 8, Appli
60	9	10.5	60	Sequence 8, Appli
61	9	10.5	61	Sequence 8, Appli
62	9	10.5	180	Sequence 8, Appli
63	9	10.5	180	Sequence 8, Appli
64	9	10.5	180	Sequence 8, Appli
65	9	10.5	180	Sequence 8, Appli
66	9	10.5	180	Sequence 8, Appli
67	9	10.5	180	Sequence 8, Appli
68	9	10.5	180	Sequence 8, Appli
69	9	10.5	722	Sequence 8, Appli
70	9	10.5	15	Sequence 6, Appli
71	8	9.3	1785	Sequence 7019, Appli
72	7	8.1	13	Sequence 3, Appli
73	7	8.1	13	Sequence 12, Appli
74	7	8.1	13	Sequence 22, Appli
75	7	8.1	13	Sequence 37, Appli
76	7	8.1	13	Sequence 37, Appli
77	7	8.1	20	Sequence 37, Appli
78	7	8.1	20	Sequence 37, Appli
79	7	8.1	20	Sequence 37, Appli
80	7	8.1	20	Sequence 37, Appli
81	7	8.1	20	Sequence 37, Appli
82	7	8.1	20	Sequence 37, Appli
83	7	8.1	20	Sequence 37, Appli
84	7	8.1	20	Sequence 37, Appli
85	7	8.1	20	Sequence 37, Appli
86	7	8.1	20	Sequence 37, Appli
87	7	8.1	20	Sequence 37, Appli
88	7	8.1	20	Sequence 37, Appli
89	7	8.1	20	Sequence 37, Appli
90	7	8.1	20	Sequence 37, Appli
91	7	8.1	20	Sequence 37, Appli
92	7	8.1	20	Sequence 37, Appli
93	7	8.1	20	Sequence 37, Appli
94	7	8.1	20	Sequence 37, Appli
95	7	8.1	20	Sequence 37, Appli
96	7	8.1	20	Sequence 37, Appli
97	7	8.1	20	Sequence 37, Appli
98	7	8.1	20	Sequence 37, Appli
99	7	8.1	20	Sequence 37, Appli
100	7	8.1	20	Sequence 37, Appli
101	7	8.1	20	Sequence 37, Appli
102	7	8.1	20	Sequence 37, Appli
103	7	8.1	20	Sequence 37, Appli
104	7	8.1	20	Sequence 37, Appli
105	9	10.5	105	Sequence 10, Appli
106	9	10.5	105	Sequence 14, Appli
107	9	10.5	105	Sequence 14, Appli
108	9	10.5	105	Sequence 14, Appli
109	9			

100	89	7	8.1	1070	15	US-10-291-027-534	Sequence 534, APP
6	8.1	7	8.1	1070	15	US-10-291-027-534	Sequence 534, APP
91	7	7	8.1	1070	15	US-10-173-999-60	Sequence 60, APP
91	7	7	8.1	1130	14	US-10-171-889-1	Sequence 1, APP
92	7	7	8.1	1130	14	US-10-263-480-2	Sequence 2, APP
93	7	7	8.1	1130	14	US-10-204-041-4	Sequence 4, APP
94	7	8.1	1130	14	US-10-451-546-5	Sequence 6, APP	
95	7	8.1	1149	15	US-10-211-088-236	Sequence 236, APP	
96	7	7.0	9	15	US-10-107-532-1696	Sequence 1696, APP	
97	6	7.0	9	15	US-10-107-532-2791	Sequence 2791, APP	
98	6	7.0	9	15	US-10-107-532-4027	Sequence 4027, APP	
99	6	7.0	9	15	US-10-107-532-4041	Sequence 4041, APP	
100	7.0	9	15	US-10-107-532-4041	Sequence 4041, APP		

Matches	Best Local Similarity	Locality	Recd. No.	Line No.	Indels	Gaps
61;	Conservative	100.0%	REC'D.	2.000-32	0;	0
QY	1	NKPTTYGSIRRAPQTGIVDECCRSCDIRLEMVCYRKPTKSARSIRAQRTDMPKTQ	60			
Db	26	NKPTTYGSIRRAPQTGIVDECCRSCDIRLEMVCYRKPTKSARSIRAQRTDMPKTQ	85			
QY	61	K 61				
Db	86	K 86				

US-09-852-261-4  
; Sequence 4, Application US/09852261  
; Patent No. US20020083477A1  
; GENERAL INFORMATION:  
; APPLICANT: GOLDSINK, GEOFFREY  
; TITLE OF INVENTION: REPAIR OF NERVE DAMAGE  
; FILE REFERENCE: 117-351  
; CURRENT APPLICATION NUMBER: US/09-852,261  
; CURRENT FILING DATE: 2001-05-10  
; PRIORITY APPLICATION NUMBER: GB 0011279,9  
; PRIORITY FILING DATE: 2000-05-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 111  
; TYPE: PRT  
; ORGANISM: Rattus sp.  
; US-09-852-261-4  
; Query Match 100 %; Score 86; DB 9; Length 111;  
; Best Local Similarity 100 %; Pred. No. 8.6e-7;  
; Matches 86; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
; QY |||||||KRPPTVYGGSSIRRAQPTGIVDECCFRSCDLRRLLEMVYCRCKPTKSARSIRAQRTIDMPKTQ 60  
; Db 26 NKPTVYGGSSIRRAQPTGIVDECCFRSCDLRRLLEMVYCRCKPTKSARSIRAQRTIDMPKTQ 85  
; QY 61 KSQPASTTHKKKLQRERKGSTBLEHK 86  
; Db 86 KSQPASTTHKKKLQRERKGSTBLEHK 111

RESULT 2  
; Sequence 12, Application US/09852261  
; Patent No. US20020083477A1  
; GENERAL INFORMATION:  
; APPLICANT: GOLDSINK, GEOFFREY  
; APPLICANT: TERENGH, GIORGIO  
; TITLE OF INVENTION: REPAIR OF NERVE DAMAGE  
; FILE REFERENCE: 117-351  
; CURRENT APPLICATION NUMBER: US/09-852,261  
; CURRENT FILING DATE: 2001-05-10  
; PRIORITY APPLICATION NUMBER: GB 0011278,9  
; PRIORITY FILING DATE: 2000-05-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 12  
; LENGTH: 105  
; TYPE: PRT  
; ORGANISM: Rattus sp.  
; US-09-852-261-12

RESULT 4  
; Sequence 4, Application US/09852261  
; Patent No. US20020083477A1  
; GENERAL INFORMATION:  
; APPLICANT: SAKIYAMA-ELBERT, Shelly E.  
; APPLICANT: Hubbard, Jeffrey A.  
; TITLE OF INVENTION: Controlled Release of No. US20020146414A1-Heparin Binding Growth Factor  
; TITLE OF INVENTION: Factors from Heparin Containing Matrices  
; FILE REFERENCE: ETH 108  
; CURRENT APPLICATION NUMBER: US/09-848,664  
; CURRENT FILING DATE: 2001-05-03  
; PRIORITY APPLICATION NUMBER: 09/298,084  
; PRIORITY FILING DATE: 1999-04-22  
; NUMBER OF SEQ ID NOS: 31  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 29  
; LENGTH: 70  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-09-848-664-29

Query Match 30.2%; Score 26; DB 9; Length 70;  
; Best Local Similarity 100.0%; Pred. No. 4.7e-18;  
; Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
; QY 11 RRAQPTGIVDECCFRSCDLRRLLEMVYCRCKPTKSARSIRAQRTIDMPKTQ 36  
; Db 36 RRAQPTGIVDECCFRSCDLRRLLEMVYCRCKPTKSARSIRAQRTIDMPKTQ 61

RESULT 5  
 US-09-848-664-30  
 ; Sequence 30, Application US/09848664  
 ; Patent No. US20020146414A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Hubbell, Jeffrey A.  
 ; APPLICANT: Hubbell, Shelly E.  
 ; TITLE OF INVENTION: Controlled Release of Factors from Heparin Containing Matrices  
 ; FILE REFERENCE: EPH 108  
 ; CURRENT APPLICATION NUMBER: US/09-848-664  
 ; CURRENT FILING DATE: 2001-05-03  
 ; PRIORITY APPLICATION NUMBER: 09/298,084  
 ; PRIORITY FILING DATE: 1999-04-22  
 ; NUMBER OF SEQ ID NOS: 31  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 30  
 ; LENGTH: 70  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-09-848-664-30

Query Match 30.2%; Score 26; DB 9; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 4.7e-18;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 RRAPQTGIVDECCFRSCDLRLRLEMVC 36  
 Db 36 RRAPQTGIVDECCFRSCDLRLRLEMVC 61

RESULT 6  
 US-09-903-327A-8  
 ; Sequence 8, Application US/09903327A  
 ; Patent No. US20020164333A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Nemerow, Glen R.  
 ; APPLICANT: Li, Erguang  
 ; TITLE OF INVENTION: BIFUNCTIONAL MOLECULES AND VECTORS COMPLEXED THEREWITH FOR TARGET  
 ; TITLE OF INVENTION: GENE  
 ; TITLE OF INVENTION: DELIVERY  
 ; FILE REFERENCE: 22908-1-228  
 ; CURRENT APPLICATION NUMBER: US/09/903,327A  
 ; CURRENT FILING DATE: 2001-07-10  
 ; PRIORITY APPLICATION NUMBER: 09/613,017  
 ; PRIORITY FILING DATE: 2000-07-10  
 ; NUMBER OF SEQ ID NOS: 33  
 ; SOFTWARE: FastSEQ for Windows Version 4.0  
 ; LENGTH: 70  
 ; TYPE: PRT  
 ; ORGANISM: Human  
 ; FEATURE:  
 ; NAME/KEY: PEPTIDE  
 ; LOCATION: (0)..(0)  
 ; OTHER INFORMATION: Human Insulin-like Growth Factor 1 sequence  
 US-09-903-327A-8

Query Match 30.2%; Score 26; DB 9; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 4.7e-18;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 RRAPQTGIVDECCFRSCDLRLRLEMVC 36  
 Db 36 RRAPQTGIVDECCFRSCDLRLRLEMVC 61

RESULT 7  
 US-09-858-935B-3  
 ; Sequence 3, Application US/09958935B  
 ; Publication No. US20030059177A1  
 ; GENERAL INFORMATION:

RESULT 8  
 US-10-028-410-1  
 ; Sequence 1, Application US/10028410  
 ; Publication No. US2002160955A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Dubaque, Yves  
 ; APPLICANT: Lowman, Henry  
 ; TITLE OF INVENTION: PROTEIN VARIANTS  
 ; FILE REFERENCE: P112R1-1  
 ; CURRENT APPLICATION NUMBER: US/10/028 410  
 ; CURRENT FILING DATE: 2001-12-19  
 ; PRIORITY APPLICATION NUMBER: US/09/477,924  
 ; PRIORITY FILING DATE: 2000-01-05  
 ; NUMBER OF SEQ ID NOS: 6  
 ; SEQ ID NO 1  
 ; LENGTH: 70  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-10-028-410-1

Query Match 30.2%; Score 26; DB 10; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 4.7e-18;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 RRAPQTGIVDECCFRSCDLRLRLEMVC 36  
 Db 36 RRAPQTGIVDECCFRSCDLRLRLEMVC 61

RESULT 9  
 US-10-066-009A-1  
 ; Sequence 1, Application US/10066009A  
 ; Publication No. US20020165155A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Schaffter, Michelle  
 ; APPLICANT: Utsch, Mark  
 ; APPLICANT: Vajdos, Felix  
 ; TITLE OF INVENTION: CRYSTALLIZATION OF IGF-1  
 ; FILE REFERENCE: P106R1  
 ; CURRENT APPLICATION NUMBER: US/10/066,009A  
 ; CURRENT FILING DATE: 2002-06-24  
 ; PRIORITY APPLICATION NUMBER: US 60/287,072  
 ; PRIORITY FILING DATE: 2001-04-27  
 ; PRIORITY APPLICATION NUMBER: US 60/267,977  
 ; PRIORITY FILING DATE: 2001-02-09  
 ; NUMBER OF SEQ ID NOS: 5

SEQ ID NO	LENGTH:	TYPE:	ORGANISM:	Best local Similarity	Score	DB	Length	Indels	Gaps
1	70	PRT	Homo sapiens	100.0%	Score 26;	DB 13;	Length 70;	0;	0;
US-10-066-009A-1				Best Local Similarity 100.0%; Pred. No. 4.7e-18;					
Qy	11	RRAPQTGIVDECCFRSDQRLRLEMVC	36	Matches 26;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
Db	36	RRAPQTGIVDECCFRSDQRLRLEMVC	61						
RESULT 10									
US-10-136-639-1				Sequence 1, Application US/10136639					
				Publication No. US20030072761A1					
				GENERAL INFORMATION:					
				APPLICANT: Lebowitz, Jonathan					
				TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TARGETING PROTEINS ACROSS THE BLOOD					
				TITLE OF INVENTION: BARRIER					
				FILE REFERENCE: SYM-008					
				CURRENT APPLICATION NUMBER: US/10/136,639					
				CURRENT FILING DATE: 2002-09-05					
				PRIOR APPLICATION NUMBER: US 60/329,650					
				PRIOR FILING DATE: 2001-10-16					
				NUMBER OF SEQ ID NOS: 4					
				SOFTWARE: PatentIn version 3.0					
SEQ ID NO 1									
LENGTH: 70									
TYPE: PRT									
ORGANISM: Homo sapiens									
US-10-136-639-1									
Query Match				30.2%; Score 26;	DB 14;	Length 70;			
Best Local Similarity				100.0%; Pred. No. 4.7e-18;					
Matches 26;				Matches 0;					
Qy	11	RRAPQTGIVDECCFRSDQRLRLEMVC	36	Qy	11	RRAPQTGIVDECCFRSDQRLRLEMVC	36	Qy	11
Db	36	RRAPQTGIVDECCFRSDQRLRLEMVC	61	Db	36	RRAPQTGIVDECCFRSDQRLRLEMVC	61	Db	36
RESULT 12									
US-10-444-326-1				Sequence 1, Application US/10444326					
				Publication No. US2003019065A1					
				GENERAL INFORMATION:					
				APPLICANT: Dubaigue, Yves					
				APPLICANT: Lowman, Henry					
				TITLE OF INVENTION: PROTEIN VARIANTS					
				FILE REFERENCE: P1712R1					
				CURRENT APPLICATION NUMBER: US/10/444,326					
				CURRENT FILING DATE: 2003-05-22					
				PRIOR APPLICATION NUMBER: US/09/723,866					
				PRIOR FILING DATE: 2000-11-28					
				PRIOR APPLICATION NUMBER: US/09/477,923					
				PRIOR FILING DATE: 2000-01-05					
				NUMBER OF SEQ ID NOS: 6					
				SEQ ID NO 1					
				LENGTH: 70					
				TYPE: PRT					
				ORGANISM: Homo sapiens					
US-10-444-326-1									
Query Match				30.2%; Score 26;	DB 14;	Length 70;			
Best Local Similarity				100.0%; Pred. No. 4.7e-18;					
Matches 26;				Matches 0;					
Qy	11	RRAPQTGIVDECCFRSDQRLRLEMVC	36	Qy	11	RRAPQTGIVDECCFRSDQRLRLEMVC	36	Qy	11
Db	36	RRAPQTGIVDECCFRSDQRLRLEMVC	61	Db	36	RRAPQTGIVDECCFRSDQRLRLEMVC	61	Db	36
RESULT 13									
US-10-272-531A-7				Sequence 1, Application US/10272531A					
				Publication No. US20040005309A1					
				GENERAL INFORMATION:					
				APPLICANT: Lebowitz, Jonathan H					
				APPLICANT: Beverly, Stephen					
				APPLICANT: Sly, William S.					
				TITLE OF INVENTION: TARGETED THERAPEUTIC PROTEINS					
				FILE REFERENCE: SYM-009					
				CURRENT APPLICATION NUMBER: US/10/272,531A					
				CURRENT FILING DATE: 2003-10-16					
				PRIOR APPLICATION NUMBER: US 60/384,452					
				PRIOR FILING DATE: 2002-05-29					
				PRIOR APPLICATION NUMBER: US 60/386,019					
				PRIOR FILING DATE: 2002-06-05					
				PRIOR APPLICATION NUMBER: US 60/408,816					
				PRIOR FILING DATE: 2002-09-06					
				NUMBER OF SEQ ID NOS: 22					
				SOFTWARE: PatentIn version 3.1					
				SEQ ID NO 7					
				LENGTH: 70					
				TYPE: PRT					
				ORGANISM: Homo sapiens					
US-10-272-531A-7									
Query Match				30.2%; Score 26;	DB 15;	Length 70;			
Best Local Similarity				100.0%; Pred. No. 4.7e-18;					
Matches 26;				Matches 0;					
Qy	11	RRAPQTGIVDECCFRSDQRLRLEMVC	36	Qy	11	RRAPQTGIVDECCFRSDQRLRLEMVC	36	Qy	11
Db	36	RRAPQTGIVDECCFRSDQRLRLEMVC	61	Db	36	RRAPQTGIVDECCFRSDQRLRLEMVC	61	Db	36

```

RESULT 14
US-10-272-483A-7
; Sequence 7, Application US/10272483A
; Publication No. US20040006008A1
; GENERAL INFORMATION:
; APPLICANT: Beasley, Stephen H
; TITLE OF INVENTION: TARGETED THERAPEUTIC PROTEINS
; FILE REFERENCE: SYM-007CP
; CURRENT APPLICATION NUMBER: US/10/272,483A
; CURRENT FILING DATE: 2002-10-16
; PRIOR APPLICATION NUMBER: US 60/287,531
; PRIOR FILING DATE: 2001-04-30
; PRIOR APPLICATION NUMBER: US 10/136,841
; PRIOR FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/384,452
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/386,019
; PRIOR FILING DATE: 2002-06-05
; PRIOR APPLICATION NUMBER: US 60/408,816
; PRIOR FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 60/304,609
; PRIOR FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US 60/329,461
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: US 60/351,276
; NUMBER OF SEQ ID NOS: 22
; SEQ ID NO 7
; LENGTH: 70
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-272-483A-7

RESULT 15
Query Match 30.2%; Score 26; DB 15; Length 70;
Best Local Similarity 100.0%; Pred. No. 4.7e-18;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 11 RRAAPQTGIVDECCFRSCDLRRLEMYC 36
Db 36 RRAAPQTGIVDECCFRSCDLRRLEMYC 61

RESULT 15
; Sequence 1, Application US/10444262
; Publication No. US20040023883A1
; GENERAL INFORMATION:
; APPLICANT: Dubaquel, Yves
; APPLICANT: Lowman, Henry
; TITLE OF INVENTION: PROTEIN VARIANTS
; FILE REFERENCE: P712R1
; CURRENT APPLICATION NUMBER: US/10/444,262
; CURRENT FILING DATE: 2003-05-22
; PRIOR APPLICATION NUMBER: US/09/724,478
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/477,923
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 5
; SEQ ID NO 1
; LENGTH: 70
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-444-262-1

RESULT 16
US-10-323-046-42
; Sequence 42, Application US/10323046
; Publication No. US20030187232A1
; GENERAL INFORMATION:
; APPLICANT: Hubbell, Jeffrey A
; APPLICANT: Schense, Jason C
; TITLE OF INVENTION: Growth Factor Modified Protein Matrices for Tissue
; FILE REFERENCE: E7H 107 CIP (2)
; CURRENT APPLICATION NUMBER: US/10/323,046
; CURRENT FILING DATE: 2002-12-17
; PRIOR APPLICATION NUMBER: 09/141,153
; PRIOR FILING DATE: 1999-08-27
; NUMBER OF SEQ ID NOS: 43
; SEQ ID NO 42
; LENGTH: 91
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Modified IGF 1 from Homo sapiens
US-10-323-046-42

RESULT 17
US-09-852-261-10
; Sequence 10, Application US/09852261
; Patent No. US2002003477A1
; GENERAL INFORMATION:
; APPLICANT: GOLDSPIK, GIORGIO
; APPLICANT: TERENGHI, GIORGIO
; TITLE OF INVENTION: REPAIR OF NERVE DAMAGE
; FILE REFERENCE: 11-351
; CURRENT APPLICATION NUMBER: US/09/852,261
; PRIOR APPLICATION NUMBER: GB 001278.9
; CURRENT FILING DATE: 2001-05-10
; PRIOR FILING DATE: 2000-05-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-852-261-10

RESULT 18
US-09-852-261-14
; Sequence 14, Application US/09852261
; Patent No. US2002008477A1
; GENERAL INFORMATION:
; APPLICANT: GOLDSPIK, GEOFFREY
; APPLICANT: GOLDSPIK, GIORGIO
; TITLE OF INVENTION: Growth Factor Modified Protein Matrices for Tissue
; FILE REFERENCE: E7H 107 CIP (2)
; CURRENT APPLICATION NUMBER: US/10/323,046
; CURRENT FILING DATE: 2002-12-17
; PRIOR APPLICATION NUMBER: 09/141,153
; PRIOR FILING DATE: 1999-08-27
; NUMBER OF SEQ ID NOS: 43
; SEQ ID NO 42
; LENGTH: 91
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Modified IGF 1 from Homo sapiens
US-09-852-261-14

Query Match 30.2%; Score 26; DB 9; Length 105;
Best Local Similarity 100.0%; Pred. No. 6.5e-18;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 11 RRAAPQTGIVDECCFRSCDLRRLEMYC 36
Db 36 RRAAPQTGIVDECCFRSCDLRRLEMYC 61

```

APPLICANT: TERENGH, GIORGIO  
 TITLE OF INVENTION: REPAIR OF NERVE DAMAGE  
 FILE REFERENCE: 11v-351  
 CURRENT APPLICATION NUMBER: US/09/852,261  
 CURRENT FILING DATE: 2001-05-10  
 PRIOR APPLICATION NUMBER: GB 0011278.9  
 PRIOR FILING DATE: 2000-05-10  
 NUMBER OF SEQ ID NOS: 14  
 SOFTWARE: PatentIn Ver. 2.1  
 SEQ ID NO: 14  
 LENGTH: 105  
 TYPE: PRT  
 ORGANISM: Oryctolagus cuniculus  
 US-09/852-261-14

Query Match 30.2%; Score 26; DB 9; Length 105;  
 Best Local Similarity 100.0%; Pred. No. 6.8e-18;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Publication No. US/10238114

GENERAL INFORMATION:  
 APPLICANT: Merial  
 TITLE OF INVENTION: IGF-1 LAS FELINE VACCINE ADJUVANT, IN PARTICULAR AGAINST FELINE RECURRENT FILING DATE: 2000-09-10  
 CURRENT APPLICATION NUMBER: US/10/238,114  
 CURRENT FILING DATE: 2000-09-10  
 PRIOR APPLICATION NUMBER: FR 01 11736  
 PRIOR FILING DATE: 2001-09-11  
 PRIOR APPLICATION NUMBER: US 60/318,666  
 PRIOR FILING DATE: 2001-09-12  
 NUMBER OF SEQ ID NOS: 20  
 SOFTWARE: PatentIn version 3.1  
 SEQ ID NO: 3  
 LENGTH: 105  
 TYPE: PRT  
 ORGANISM: Felis catus  
 US-10-238-114-3

Query Match 30.2%; Score 26; DB 14; Length 105;  
 Best Local Similarity 100.0%; Pred. No. 6.5e-18;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Publication No. US20030100673A1

GENERAL INFORMATION:  
 APPLICANT: ANDRONI, Christine Michelle  
 TITLE OF INVENTION: 454313-3165.1  
 FILE REFERENCE: 454313-3165.1  
 CURRENT FILING DATE: 2000-09-10  
 CURRENT APPLICATION NUMBER: US/09/852,261  
 CURRENT FILING DATE: 2001-05-10  
 PRIOR APPLICATION NUMBER: GB 0011278.9  
 PRIOR FILING DATE: 2000-05-10  
 NUMBER OF SEQ ID NOS: 14  
 SOFTWARE: PatentIn Ver. 2.1  
 SEQ ID NO: 6  
 LENGTH: 111  
 TYPE: PRT  
 ORGANISM: Oryctolagus cuniculus  
 US-09-852-261-6

Query Match 30.2%; Score 26; DB 9; Length 111;  
 Best Local Similarity 100.0%; Pred. No. 6.8e-18;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Publication No. US/09/852,261-6

GENERAL INFORMATION:  
 APPLICANT: GOLDSTEIN, GEOFFREY  
 TITLE OF INVENTION: REPAIR OF NERVE DAMAGE  
 FILE REFERENCE: 11-351  
 CURRENT APPLICATION NUMBER: US/09/852,261  
 CURRENT FILING DATE: 2001-05-10  
 PRIOR APPLICATION NUMBER: GB 0011278.9  
 PRIOR FILING DATE: 2000-05-10  
 NUMBER OF SEQ ID NOS: 14  
 SOFTWARE: PatentIn Ver. 2.1  
 SEQ ID NO: 2  
 LENGTH: 110

RESULT 20  
 US-09-852-261-2  
 ; Sequence 2, Application US/09852261  
 ; GENERAL INFORMATION:  
 ; Patent No. US20030083477A1  
 ; APPLICANT: GOLDSTEIN, GEOFFREY  
 ; TITLE OF INVENTION: REPAIR OF NERVE DAMAGE  
 ; FILE REFERENCE: 11-351  
 ; CURRENT APPLICATION NUMBER: US/09/852,261  
 ; CURRENT FILING DATE: 2001-05-10  
 ; PRIOR APPLICATION NUMBER: GB 0011278.9  
 ; PRIOR FILING DATE: 2000-05-10  
 ; NUMBER OF SEQ ID NOS: 14  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO: 2  
 ; LENGTH: 110

Query Match 30.2%; Score 26; DB 9; Length 111;  
 Best Local Similarity 100.0%; Pred. No. 6.8e-18;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Publication No. US/10179046

GENERAL INFORMATION:  
 APPLICANT: ZAROR, ISABEL  
 INNIS, MICHAEL  
 TITLE OF INVENTION: Picina Secretary Leader for Protein  
 NUMBER OF SEQUENCES: 40  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Chiron Corporation  
 STREET: 4500 Horton Street  
 CITY: Emeryville  
 STATE: California  
 COUNTRY: United States  
 ZIP: 94608

COMPUTER READABLE FORM:  
 COMPUTER: Floppy disk  
 MEDIUM: TYPE: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/10/179,046  
 FILING DATE: 25-Jun-2002  
 CLASSIFICATION: <Unknown>  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US/09/029,267  
 FILING DATE: <Unknown>

```

; ATTORNEY/AGENT INFORMATION:
;   NAME: Chung, Ling-ong
;   REGISTRATION NUMBER: 36,482
;   REFERENCE/DOCKET NUMBER: 1165-100
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (510) 601-2704
;     TELEFAX: (510) 655-3142
;     INQUIRY FOR SEQ ID NO: 14:
;       SEQUENCE CHARACTERISTICS:
;         LENGTH: 118 amino acids
;         TYPE: amino acid
;         STRANDEDNESS: single
;         TOPOLOGY: linear
;         MOLECULE TYPE: protein
;         SEQUENCE DESCRIPTION: SEQ ID NO: 14:
;           US-09-179-046-14

; Query Match      30.2%; Score 26; DB 14; Length 118;
; Best Local Similarity 100.0%; Pred. No. 7.1e-18;
; Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
; Qy   11 RRAPQTGIVDECCFRSCDLRRLEMYC 36
; Db   84 RRAPQTGIVDECCFRSCDLRRLEMYC 109

RESULT 23
US-10-251-661-8
; Sequence 8; Application US/10251661
; Publication No. US20030166515A1
; GENERAL INFORMATION:
;   APPLICANT: Bear, Mark F.
;   APPLICANT: Bear, Mark M.
;   TITLE OF INVENTION: Methods and Compositions for Regulating
;   TITLE OF INVENTION: Memory Consolidation
;   TITLE OF INVENTION: 3499..001-003
;   CURRENT APPLICATION NUMBER: US/10/251,661
;   CURRENT FILING DATE: 2002-09-20
;   PRIORITY APPLICATION NUMBER: 60/193,614
;   PRIORITY FILING DATE: 2000-03-31
;   PRIORITY APPLICATION NUMBER: PCT/US01/10661
;   PRIORITY FILING DATE: 2001-04-02
;   NUMBER OF SEQ ID NOS: 12
;   SOFTWARE: FASTSEQ for Windows Version 4.0
;   SEQ ID NO: 8
;   LENGTH: 137
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;     US-10-251-661-8

; Query Match      30.2%; Score 26; DB 14; Length 137;
; Best Local Similarity 100.0%; Pred. No. 8.1e-18;
; Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
; Qy   11 RRAPQTGIVDECCFRSCDLRRLEMYC 36
; Db   68 RRAPQTGIVDECCFRSCDLRRLEMYC 93

RESULT 24
US-09-919-497-74
; Sequence 74; Application US/09919497
; Patent No. US2002010662A1
; GENERAL INFORMATION:
;   APPLICANT: Mitter, George L.
;   TITLE OF INVENTION: PROGNOSTIC CLASSIFICATION OF ENDOMETRIAL CANCER
;   FILE REFERENCE: B080117225
;   CURRENT APPLICATION NUMBER: US/09/919,497
;   CURRENT FILING DATE: 2001-07-31
;   PRIORITY FILING DATE: 2000-07-31
;   NUMBER OF SEQ ID NOS: 100
;   SOFTWARE: Patentin version 3.0

; Query Match      30.2%; Score 26; DB 9; Length 153;
; Best Local Similarity 100.0%; Pred. No. 8.8e-18;
; Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
; Qy   11 RRAPQTGIVDECCFRSCDLRRLEMYC 36
; Db   84 RRAPQTGIVDECCFRSCDLRRLEMYC 109

; Query Match      30.2%; Score 26; DB 9; Length 153;
; Best Local Similarity 100.0%; Pred. No. 8.8e-18;
; Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
; Qy   11 RRAPQTGIVDECCFRSCDLRRLEMYC 36
; Db   84 RRAPQTGIVDECCFRSCDLRRLEMYC 109
;   US-09-919-497-74

; Query Match      30.2%; Score 26; DB 9; Length 153;
; Best Local Similarity 100.0%; Pred. No. 8.8e-18;
; Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
; Qy   11 RRAPQTGIVDECCFRSCDLRRLEMYC 36
; Db   84 RRAPQTGIVDECCFRSCDLRRLEMYC 109
;   US-09-919-497-74

```

Run on: March 3, 2004, 12:00:16 ; Search time 22 Seconds (Without alignments) 201.811 Million cell updates/sec									
Copyright (c) 1993 - 2004 Compugen Ltd.									
Title: US-09-852-261_4_COPY_26_111									
Perfect score: 86									
Sequence: 1 NKPVIVGSSIRRQRPQGIVD. .... THKKRKLUQRRRKKGSTLEHK 86									
Scoring table: OLIB30 Gappop 60.0 , Gapext 60.0									
Searched: 389414 seqs, 51625971 residues									
Minimum DB seq length: 0									
Maximum DB seq length: 2000000000									
Word size : 0									
Total number of hits satisfying chosen parameters: 389414									
Post-processing: Listing first 100 summaries									
Database : Issued Patents AA:*									
1:	/cgnz_6/prodata/2/1aa/5A_COMB.pep:*	Patent No. 5489517							
2:	/cgnz_6/prodata/2/1aa/5B_COMB.pep:*	Patent No. 540721							
3:	/cgnz_6/prodata/2/1aa/6A_COMB.pep:*								
4:	/cgnz_6/prodata/2/1aa/6B_COMB.pep:*								
5:	/cgnz_6/prodata/2/1aa/PCITUS_COMB.pep:*								
6:	/cgnz_6/prodata/2/1aa/backfile1.pep:*								
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.									
SUMMARIES									
Result No.	Score	Query	Match Length	DB ID	Description				
1	26	30.2	36	6	5489517-4				
2	26	30.2	38	6	US-07-023-229A-2				
3	26	30.2	67	4	US-07-063-4-2				
4	26	30.2	67	5	PCIT-US92-0943A-2				
5	26	30.2	70	1	US-07-054-611-2				
6	26	30.2	70	1	US-07-047-035-1				
7	26	30.2	70	1	US-07-776-272-17				
8	26	30.2	70	1	US-07-558-913A-17				
9	26	30.2	70	1	US-08-62-018-17				
10	26	30.2	70	1	US-08-023-245-17				
11	26	30.2	70	1	US-08-082-271-1				
12	26	30.2	70	3	US-09-080-120A-1				
13	26	30.2	70	3	US-08-032-517-1				
14	26	30.2	70	4	US-07-963-329A-1				
15	26	30.2	70	4	US-09-177-924-1				
16	26	30.2	70	4	US-09-123-981-1				
17	26	30.2	70	4	US-09-723-886-1				
18	26	30.2	70	5	PCIT-US92-09443A-1				
19	26	30.2	70	5	PCIT-US93-11458-1				
20	26	30.2	70	5	PCIT-US93-08925-1				
21	26	30.2	70	6	5470828-1				
22	26	30.2	78	2	US-08-160-830A-47				
23	26	30.2	78	3	US-08-167-614-47				
24	26	30.2	78	3	US-08-160-971A-47				
25	26	30.2	78	3	US-08-162-040-47				
26	26	30.2	83	1	US-07-147-035-18				
27	26	30.2	83	1	US-08-311-585A-12				

## ALIGNMENTS

RESULT 1  
 549517-4  
 ;Patent No. 5489517  
 ;APPLICANT: WONG, EDITH; BITTNER, MICHAEL J.;  
 ;TITLE OF INVENTION: SECRETION OF INSULIN-LIKE GROWTH  
 ;FACTOR-I IN E. COLI  
 ;NUMBER OF SEQUENCES: 7  
 ;CURRENT APPLICATION DATA:  
 ;APPLICATION NUMBER: US/07/704,486  
 ;SEQ ID NO:4:  
 ;LENGTH: 36  
 ;549517-4

Query Match 30.2%; Score 26; DB 6; Length 36;  
 Best Local Similarity 100.0%; Prcd. No. 2.9e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36  
 Db 2 RRAPOTGIVDECCFRSCLLRLLEMIC 27

## RESULT 2

5470721-4  
 ;Patent No. 5470721  
 ;APPLICANT: BOULLI, GARY N.; MOVA, NAGESWARAO  
 ;TITLE OF INVENTION: PRODUCTION OF HUMAN SOMATOMEDIN C  
 ;NUMBER OF SEQUENCES: 7  
 ;CURRENT APPLICATION DATA:  
 ;APPLICATION NUMBER: US/08/81,979  
 ;FILING DATE: 23-JUN-1993  
 ;PRIOR APPLICATION DATA:  
 ;APPLICATION NUMBER: 965,047  
 ;FILING DATE: 21-OCT-1992  
 ;APPLICATION NUMBER: 496,086  
 ;FILING DATE: 15-MAR-1990  
 ;APPLICATION NUMBER: 938,170  
 ;FILING DATE: 19-NOV-1986  
 ;SEQ ID NO:4:  
 ;LENGTH: 38

Query Match 30.2%; Score 26; DB 6; Length 36;  
 Best Local Similarity 100.0%; Prcd. No. 5e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36  
 Db 33 RRAPOTGIVDECCFRSCLLRLLEMIC 58

## RESULT 4

PCT-US92-09443A-2  
 ; Sequence 2, Application PC/TUS9209443A  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Boyczko-Coyne, Donna  
 ; APPLICANT: Neff, Nicola  
 ; APPLICANT: Lewis, Michael E.  
 ; APPLICANT: Iqbal, Mohamed

Query Match 30.2%; Score 26; DB 6; Length 38;  
 Best Local Similarity 100.0%; Prcd. No. 3e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36  
 Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

## RESULT 3

US-07-963-329A-2  
 ; Sequence 2, Application US/07963329A  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Boyczko-Coyne, Donna  
 ; APPLICANT: Neff, Nicola  
 ; APPLICANT: Lewis, Michael E.  
 ; APPLICANT: Iqbal, Mohamed

Query Match 30.2%; Score 26; DB 6; Length 38;  
 Best Local Similarity 100.0%; Prcd. No. 3e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36  
 Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

RESULT 3  
 US-07-963-329A-2  
 ; Sequence 2, Application US/07963329A  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Boyczko-Coyne, Donna  
 ; APPLICANT: Neff, Nicola  
 ; APPLICANT: Lewis, Michael E.  
 ; APPLICANT: Iqbal, Mohamed

Query Match 30.2%; Score 26; DB 6; Length 38;  
 Best Local Similarity 100.0%; Prcd. No. 3e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36  
 Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: U.S.A.  
 ZIP: 02110-2804  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 COMPUTER: IBM PS/2 Model 50Z or 55SX  
 OPERATING SYSTEM: MS-DOS (Version 5.0)  
 SOFTWARE: WordPerfect (Version 5.1)  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/07/963,329A  
 FILING DATE: 19921015  
 CLASSIFICATION: 514  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 07/790,690  
 FILING DATE: NO 631004ember 8, 1991  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Clark, Paul T.  
 REGISTRATION NUMBER: 30,162  
 REFERENCE/DOCKET NUMBER: 02655/012002  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617) 542-5070  
 TELEFAX: (617) 542-8906  
 INQUIRY FOR SEQ ID NO: 2:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 67  
 TYPE: amino acid  
 STRANDEDNESS:  
 TOPOLOGY: linear  
 ; US-07-963-329A-2

Query Match 30.2%; Score 26; DB 4; Length 67;  
 Best Local Similarity 100.0%; Prcd. No. 5e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36  
 Db 33 RRAPOTGIVDECCFRSCLLRLLEMIC 58

RESULT 4  
 PCT-US92-09443A-2

; Sequence 2, Application PC/TUS9209443A

; GENERAL INFORMATION:

; APPLICANT: Boyczko-Coyne, Donna

; APPLICANT: Neff, Nicola

; APPLICANT: Lewis, Michael E.

; APPLICANT: Iqbal, Mohamed

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPOTGIVDECCFRSCLLRLLEMIC 36

Db 4 RRAPOTGIVDECCFRSCLLRLLEMIC 29

Query Match 30.2%; Score 26; DB 6; Length 38;

Best Local Similarity 100.0%; Prcd. No. 3e-20;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

APPLICATION NUMBER: 07/963,329  
 FILING DATE: October 15, 1992  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Clark, Paul T.  
 REGISTRATION NUMBER: 30,162  
 REFERENCE/DOCKET NUMBER: 30,162  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617) 542-5070  
 TELEFAX: (617) 542-8906  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 2:  
 LENGTH: 67  
 TYPE: AMINO ACID  
 STRANDEDNESS: N/A  
 TOPOLOGY: N/A  
 PCT-US92-09443A-2

Query Match 30.2%; Score 26; DB 5; Length 67;  
 Best Local Similarity 100.0%; Pred. No. 5e-20; Mismatches 0; Indels 0; Gaps 0;  
 Matches 26; Conservative 0; Name/KEY: RRAPOQTGIVDECCFPRSCDILRLEMVYC 36  
 Db 33 RRAPOQTGIVDECCFPRSCDILRLEMVYC 59

RESULT 5 US-07-654-611-2  
 Sequence 2, Application US/07654611  
 Patent No. 5273966  
 GENERAL INFORMATION:  
 APPLICANT: Skottner-Lundin, Anna  
 APPLICANT: Fryklund, Linda  
 APPLICANT: Gällfors, Par  
 TITLE OF INVENTION: O-Glycosylated IGF-1  
 NUMBER OF SEQUENCES: 2  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Pollock, Vande Sande and Priddy  
 STREET: 1990 M Street, NW Suite 800  
 CITY: Washington  
 STATE: DC  
 ZIP: 20036  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.25  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/07/654,611  
 FILING DATE: 1993-04-22  
 CLASSIFICATION: 435  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: GB 8819826,2  
 FILING DATE: 20-AUG-1988  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: PCT/EP89/00972  
 FILING DATE: 17-AUG-1989  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Amick, Burton A.  
 REGISTRATION NUMBER: 24,832  
 REFERENCE/DOCKET NUMBER: 151/031  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (202)331-7111  
 TELEFAX: (202)223-2596  
 TELEX: 248587 RING 2596  
 INFORMATION FOR SEQ ID NO: 2:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 70 amino acids  
 TYPE: AMINO ACID  
 TOPOLOGY: linear  
 MOLECULE TYPE: protein

FEATURE: Protein  
 NAME/KEY: Protein  
 LOCATION: 1..70  
 OTHER INFORMATION: /label= IGF-1  
 FEATURE: Binding-site  
 NAME/KEY: Binding-site  
 LOCATION: 4  
 OTHER INFORMATION: /note= "potential glycosylation  
 OTHER INFORMATION: site"  
 FEATURE: Binding-site  
 NAME/KEY: Binding-site  
 LOCATION: 29  
 OTHER INFORMATION: /note= "potential glycosylation  
 OTHER INFORMATION: site"  
 FEATURE: Binding-site  
 NAME/KEY: Binding-site  
 LOCATION: one-of(33, 34, 35)  
 OTHER INFORMATION: /note= "potential glycosylation  
 OTHER INFORMATION: site"  
 FEATURE: Binding-site  
 NAME/KEY: Binding-site  
 LOCATION: 41  
 OTHER INFORMATION: /note= "potential glycosylation  
 OTHER INFORMATION: site"  
 FEATURE: Binding-site  
 NAME/KEY: Binding-site  
 LOCATION: 51  
 OTHER INFORMATION: /note= "potential glycosylation  
 OTHER INFORMATION: site"  
 FEATURE: Binding-site  
 NAME/KEY: Binding-site  
 LOCATION: 69  
 OTHER INFORMATION: /note= "potential glycosylation  
 OTHER INFORMATION: site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (21^22)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (24^25)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (21^22)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (29^30)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (31^32)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (36^37)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (31^32)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (37^38)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (41^42)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (55^56)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE: Cleavage-site  
 NAME/KEY: Cleavage-site  
 LOCATION: (56^57)  
 OTHER INFORMATION: /note= "trypsin cleavage site"

OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE:  
 NAME/KEY: Cleavage-site  
 LOCATION: (60^61)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE:  
 NAME/KEY: Cleavage-site  
 LOCATION: (68^69)  
 OTHER INFORMATION: /note= "trypsin cleavage site"  
 FEATURE:  
 NAME/KEY: Cross-links  
 LOCATION: 6..48  
 FEATURE:  
 NAME/KEY: Cross-links  
 LOCATION: 18..61  
 FEATURE:  
 NAME/KEY: Cross-links  
 LOCATION: 47..52  
 US-07-654-611-2

Query Match 30.2%; Score 26; DB 1; length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20; Indels 0; Gaps 0;  
 Matches 26; Conservative 0; Mismatches 0; Gaps 0;

Qy 11 RRAPQGIVDCCFRSCDLRLLEMVC 36  
 Db 36 RRAPQGIVDCCFRSCDLRLLEMVC 61

RESULT 6  
 US-07-947-035-1  
 Sequence 1, Application US/07947035  
 Patent No. 544045  
 GENERAL INFORMATION:  
 APPLICANT: Francis, Geoffrey L.  
 APPLICANT: Walton, Paul E.  
 APPLICANT: Ballard, Francis J.  
 APPLICANT: McMurti, John P.  
 APPLICANT: Phelps, Patricia V.  
 TITLE OF INVENTION: Method of Administering IGF-1, IGF-2, TITLE OF INVENTION: and Analogs Thereof to Birds  
 NUMBER OF SEQUENCES: 18  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Kenneth D. Sibley  
 STREET: P.O. Drawer 34009  
 CITY: Charlotte  
 STATE: No. 544045th Carolina  
 COUNTRY: United States of America  
 ZIP: 28234

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/07/776,272  
 FILING DATE: 1991129  
 CLASSIFICATION: 530  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Player, William E.  
 REGISTRATION NUMBER: 31,409  
 REFERENCE/DOCKET NUMBER: P-450-23167  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 202-887-0600  
 TELEFAX: 202-887-0605  
 TELEX: 440706

INFORMATION FOR SEQ ID NO: 17:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 70 amino acids  
 TYPE: AMINO ACID  
 TOPOLOGY: linear  
 MOLECULE TYPE: Peptide  
 HYPOOTICAL: YES

US-07-776-272-17

Query Match 30.2%; Score 26; DB 1; length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20; Indels 0; Gaps 0;  
 Matches 26; Conservative 0; Mismatches 0; Gaps 0;

Qy 11 RRAPQGIVDCCFRSCDLRLLEMVC 36  
 Db 36 RRAPQGIVDCCFRSCDLRLLEMVC 61

RESULT 7  
 US-07-776-272-17  
 Sequence 17, Application US/07776272  
 Patent No. 5612454  
 GENERAL INFORMATION:  
 APPLICANT: Kaninuma, Toshihiko  
 APPLICANT: Iida, Toshihi  
 APPLICANT: Tajima, Masahiro  
 TITLE OF INVENTION: Process for Purification of Polypeptide  
 NUMBER OF SEQUENCES: 31  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Wegner, Cantor, Mueller & Player  
 STREET: 1233 20th St. N.W. P.O. Box 18218  
 CITY: Washington  
 STATE: District of Columbia  
 COUNTRY: United States of America  
 ZIP: 20036-8118

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/07/776,272  
 FILING DATE: 1991129  
 CLASSIFICATION: 530  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Player, William E.  
 REGISTRATION NUMBER: 31,409  
 REFERENCE/DOCKET NUMBER: P-450-23167  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 202-887-0600  
 TELEFAX: 202-887-0605  
 TELEX: 440706

INFORMATION FOR SEQ ID NO: 17:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 70 amino acids  
 TYPE: AMINO ACID  
 TOPOLOGY: linear  
 MOLECULE TYPE: Peptide  
 HYPOOTICAL: YES

US-07-776-272-17

Query Match 30.2%; Score 26; DB 1; length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20; Indels 0; Gaps 0;  
 Matches 26; Conservative 0; Mismatches 0; Gaps 0;

Qy 11 RRAPQGIVDCCFRSCDLRLLEMVC 36  
 Db 36 RRAPQGIVDCCFRSCDLRLLEMVC 61

RESULT 8  
 US-07-958-903A-17  
 Sequence 17, Application US/07958903A  
 Patent No. 562214  
 GENERAL INFORMATION:  
 APPLICANT: Lewis, Michael E.  
 APPLICANT: Kauer, James C.  
 APPLICANT: Smith, Kevin R.  
 APPLICANT: Callison, Kathleen V.

APPLICANT: Baldino, Frank  
 APPLICANT: Neff, Nicola  
 APPLICANT: Igbal, Mohamed  
 TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND NUMBER OF SEQUENCES: 56  
 CORRESPONDENCE ADDRESS:  
 ADDRESSE: Fish & Richardson  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: U.S.A.  
 STATE: Massachusetts  
 COUNTRY: U.S.A.  
 ZIP: 02110-2804

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 COMPUTER: IBM PS/2 Model 502 or 55SX  
 OPERATING SYSTEM: MS-DOS (Version 5.0)  
 SOFTWARE: WordPerfect (Version 5.1)  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US07/958,903A  
 FILING DATE: October 7, 1992  
 CLASSIFICATION: 514  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 07/361,595  
 FILING DATE: June 5, 1989  
 APPLICATION NUMBER: 07/534,139  
 FILING DATE: June 5, 1990  
 APPLICATION NUMBER: 07/869,913  
 FILING DATE: April 15, 1992  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Clark, Paul T.  
 REGISTRATION NUMBER: 30,162  
 REFERENCE/DOCKET NUMBER: 02655/003004  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617) 542-5070  
 TELEFAX: (617) 542-8906  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 17:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 70  
 TYPE: amino acid  
 STRANDEDNESS:  
 TOPOLOGY: linear  
 US-07-958-903A-17

Query Match 30.2%; Score 26; DB 1; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOQTGIVDECCFRSDCLRLRLEMYC 36  
 Db 36 RRAPQTGIVDECCFRSDCLRLRLEMYC 61

RESULT 9  
 US-08-462-018-17  
 Sequence 17 Application US/08823245  
 Patent No. 5776897  
 GENERAL INFORMATION:  
 APPLICANT: Lewis, Michael E.  
 APPLICANT: Lewis, Michael E.  
 APPLICANT: Kauer, James C.  
 APPLICANT: Kauer, James C.  
 APPLICANT: Smith, Kevin R.  
 APPLICANT: Callison, Kathleen V.  
 APPLICANT: Baldino, Frank  
 APPLICANT: Neff, Nicola  
 APPLICANT: Igbal, Mohamed  
 TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND NUMBER OF SEQUENCES: 56  
 CORRESPONDENCE ADDRESS:  
 ADDRESSE: Fish & Richardson  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: U.S.A.  
 ZIP: 02110-2804

Query Match 30.2%; Score 26; DB 1; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOQTGIVDECCFRSDCLRLRLEMYC 36  
 Db 36 RRAPQTGIVDECCFRSDCLRLRLEMYC 61

RESULT 10  
 US-08-823-245-17  
 Sequence 17 Application US/08823245  
 Patent No. 5776897  
 GENERAL INFORMATION:  
 APPLICANT: Lewis, Michael E.  
 APPLICANT: Lewis, Michael E.  
 APPLICANT: Kauer, James C.  
 APPLICANT: Kauer, James C.  
 APPLICANT: Smith, Kevin R.  
 APPLICANT: Callison, Kathleen V.  
 APPLICANT: Baldino, Frank  
 APPLICANT: Neff, Nicola  
 APPLICANT: Igbal, Mohamed  
 TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND NUMBER OF SEQUENCES: 56  
 CORRESPONDENCE ADDRESS:  
 ADDRESSE: Fish & Richardson  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: U.S.A.  
 ZIP: 02110-2804

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 COMPUTER: IBM PS/2 Model 50Z or  
 COMPUTER: 55SX  
 OPERATING SYSTEM: MS-DOS (Version 5.0)  
 SOFTWARE: WordPerfect (Version 5.1)  
 SOFTWARE: 5.1)  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/823,245  
 FILING DATE: March 24, 1997  
 CLASSIFICATION: 514  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 07/361,595  
 FILING DATE: June 6, 1989  
 APPLICATION NUMBER: 07/534,139  
 FILING DATE: June 5, 1990  
 APPLICATION NUMBER: 07/869,913  
 FILING DATE: April 15, 1992  
 APPLICATION NUMBER: 07/958,903  
 FILING DATE: October 7, 1992  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Creenon, Gary L.  
 REGISTRATION NUMBER: 34,310  
 REFERENCE/DOCKET NUMBER: 02655/003008  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617) 542-5070  
 TELEFAX: (617) 542-8906  
 TELEX: 200154  
 INFORMATION FOR SEQ ID NO: 17:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 70  
 TYPE: amino acid  
 STRANDEDNESS: N/A  
 TOPOLOGY: N/A  
 US-08-823-245-17

Query Match 30.2%; Score 26; DB 1; length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPQGIVDCCFRSODRLEMIC 36  
 Db 36 RRAPQGIVDCCFRSODRLEMIC 61

RESULT 12  
 US-09-080-120A-1  
 Sequence 1, Application US/09080120A  
 ; Patent No. 607885  
 ; GENERAL INFORMATION:  
 ; APPLICANT: BAGI, CEDO M.  
 ; APPLICANT: BROMMAGE, ROBERT  
 ; APPLICANT: ROSEN, DAVID M.  
 ; APPLICANT: ADAMS, STEVEN W.  
 ; TITLE OF INVENTION: IGF/IGFBP COMPLEX FOR PROMOTING BONE  
 ; NUMBER OF SEQUENCES: 7  
 ; TITLE OF INVENTION: FORMATION AND FOR REGULATING BONE REMODELING  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: MORRISON & FOERSTER  
 ; STREET: 755 Page Mill Road  
 ; CITY: Palo Alto  
 ; STATE: California  
 ; COUNTRY: USA  
 ; ZIP: 94304-1018

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 COMPUTER: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/080,120A  
 FILING DATE: 14-MAY-1998  
 CLASSIFICATION: 514  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 08/450,258  
 FILING DATE: 25-MAY-1995  
 CLASSIFICATION: 514  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 08/278,456  
 FILING DATE: 20-JUL-1994  
 CLASSIFICATION: 514  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Bulteiner, Nicholas  
 REGISTRATION NUMBER: 39,124  
 REFERENCE/DOCKET NUMBER: 220952027203  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (650) 813-5600  
 TELEX: 706141MRSN FORS SFO  
 INFORMATION FOR SEQ ID NO: 1:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 70 amino acids  
 TYPE: amino acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear

Query Match 30.2%; Score 26; DB 1; length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPQGIVDCCFRSODRLEMIC 36  
 Db 36 RRAPQGIVDCCFRSODRLEMIC 61

RESULT 11  
 US-08-482-271-1  
 Sequence 1, Application US/08482271  
 ; Patent No. 5789547  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Sommer, Andreas  
 ; APPLICANT: Osawa, Yasushi  
 ; APPLICANT: Tac, Peggy  
 ; TITLE OF INVENTION: METHOD OF PRODUCING IGF-1 AND IGFBP-3  
 ; TITLE OF INVENTION: WITH CORRECT FOLDING AND DISULFIDE BONDING  
 ; NUMBER OF SEQUENCES: 8  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: MORRISON & FOERSTER  
 ; STREET: 755 Page Mill Road  
 ; CITY: Palo Alto  
 ; STATE: California  
 ; COUNTRY: USA  
 ; ZIP: 94304-1018

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 COMPUTER: PC-DOS/MS-DOS  
 SOFTWARE: PatentIn Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/080,120A  
 FILING DATE: 14-MAY-1998  
 CLASSIFICATION: 514  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 08/450,258  
 FILING DATE: 25-MAY-1995  
 CLASSIFICATION: 514  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 08/278,456  
 FILING DATE: 20-JUL-1994  
 CLASSIFICATION: 514  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Bulteiner, Nicholas  
 REGISTRATION NUMBER: 39,124  
 REFERENCE/DOCKET NUMBER: 220952027203  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (650) 813-5600  
 TELEX: 706141MRSN FORS SFO  
 INFORMATION FOR SEQ ID NO: 1:  
 INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:  
 LENGTH: 70 amino acids  
 TYPE: amino acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear

RESULT 13  
 Query Match 30.2%; Score 26; DB 3; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
 Matches 26; Conservative 0; Mismatches 0;  
 Indels 0; Gaps 0;  
 Db 36 RRAPQGIVDCCFRSCDLRLEMVC 61  
 US-09-080-120A-1

RESULT 13  
 Sequence 1, Application US/08432517  
 Patent No. 6083912

GENERAL INFORMATION:  
 APPLICANT: KHOURI, ROGER K.  
 TITLE OF INVENTION: METHOD FOR SOFT TISSUE AUGMENTATION  
 NUMBER OF SEQUENCES: 2

CORRESPONDENCE ADDRESS:  
 ADDRESSEE: ROGERS, HOWELL & HAERKAMP, L.C.  
 STREET: 7733 FORSYTH BOULEVARD, SUITE 1400  
 CITY: ST. LOUIS  
 STATE: MISSOURI  
 COUNTRY: USA  
 ZIP: 63110-1817

COMPUTER READABLE FORM:  
 MEDIUM TYPE: FLOPPY disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patient Release #1.0, Version #1.25

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/432,517  
 FILING DATE: 01-MAY-1995  
 CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:  
 NAME: HOLLAND, DONALD R.  
 REGISTRATION NUMBER: 35,197  
 REFERENCE/DOCKET NUMBER: 952584

TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (314) 727-5188  
 TELEFAX: (314) 727-6092

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:  
 LENGTH: 70 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: protein  
 HYPOTHETICAL: NO

FEATURE:  
 NAME/KEY: Disulfide-bond  
 LOCATION: 6..48  
 OTHER INFORMATION: /note= "Disulfide bond between two  
 OTHER INFORMATION: cysteines."

FEATURE:  
 NAME/KEY: Disulfide-bond  
 LOCATION: 18..61  
 OTHER INFORMATION: /note= "Disulfide bond between two  
 OTHER INFORMATION: cysteines."

FEATURE:  
 NAME/KEY: Disulfide-bond  
 LOCATION: 47..52  
 OTHER INFORMATION: /note= "Disulfide bond between two  
 OTHER INFORMATION: cysteines."

Query Match 30.2%; Score 26; DB 3; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
 Matches 26; Conservative 0; Mismatches 0;  
 Indels 0; Gaps 0;  
 Db 36 RRAPQGIVDCCFRSCDLRLEMVC 61  
 US-08-432-517-1

RESULT 14  
 Query Match 30.2%; Score 26; DB 4; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
 Matches 26; Conservative 0; Mismatches 0;  
 Indels 0; Gaps 0;  
 Db 36 RRAPQGIVDCCFRSCDLRLEMVC 61  
 US-07-963-329A-1

GENERAL INFORMATION:  
 APPLICANT: Boryczko-Coyne, Donna  
 APPLICANT: Neff, Nicola  
 APPLICANT: Lewis, Michael E.  
 APPLICANT: Idbai, Mohamed

TITLE OF INVENTION: TREATING RETINAL NEURONAL DISORDERS  
 TITLE OF INVENTION: BY THE APPLICATION OF INSULIN-LIKE  
 NUMBER OF SEQUENCES: 79

CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Fish & Richardson  
 STREET: 225 Franklin Street  
 CITY: Boston  
 STATE: Massachusetts  
 COUNTRY: U.S.A.  
 ZIP: 02110-2804

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 COMPUTER: IBM PS/2 Model 502 or 550x  
 OPERATING SYSTEM: MS-DOS (Version 5.0)  
 SOFTWARE: WordPerfect (Version 5.1)

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/07/963,329A  
 FILING DATE: 19921015  
 CLASSIFICATION: 514

PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 07/790,690  
 FILING DATE: NO. 6310040ember 8, 1991

ATTORNEY/AGENT INFORMATION:  
 NAME: Clark, Paul T.  
 REGISTRATION NUMBER: 30,162  
 REFERENCE/DOCKET NUMBER: 02655/012002

TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617) 542-5070  
 TELEFAX: (617) 542-8906  
 TELEX: 200154

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:  
 LENGTH: 70  
 TYPE: amino acid  
 STRANDEDNESS:  
 TOPOLOGY: linear

Query Match 30.2%; Score 26; DB 4; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
 Matches 26; Conservative 0; Mismatches 0;  
 Indels 0; Gaps 0;  
 Db 36 RRAPQGIVDCCFRSCDLRLEMVC 61  
 US-07-963-329A-1

RESULT 15  
 Query Match 30.2%; Score 26; DB 4; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
 Matches 26; Conservative 0; Mismatches 0;  
 Indels 0; Gaps 0;  
 Db 36 RRAPQGIVDCCFRSCDLRLEMVC 61  
 US-09-477-924-1

GENERAL INFORMATION:  
 APPLICANT: Dubaque, Yves  
 APPLICANT: Lowman, Henry  
 TITLE OF INVENTION: PROTEIN VARIANTS  
 FILE REFERENCE: P712R1-1

Db 36 RRAPQGIVDBCCFRSCDLRLEMVC 61

RESULT 18  
PCT-US92-09443A-1  
; Sequence 1, Application PC/TUS9209443A  
; GENERAL INFORMATION:  
; APPLICANT: Boyczko-Coyne, Donna  
; APPLICANT: Neff, Nicola  
; APPLICANT: Lewis, Michael E.  
; APPLICANT: Ihab, Mohamed  
; TITLE OF INVENTION: TREATING RETINAL NEURONAL  
; DISORDERS BY THE APPLICATION OF  
; TITLE OF INVENTION: INSULIN-LIKE GROWTH FACTORS AND  
; TITLE OF INVENTION: ANALOGS  
; NUMBER OF SEQUENCES: 79

RESULT 16  
US-09-723-981-1  
; Sequence 1, Application US/09723981  
; Patent No. 6506874  
; GENERAL INFORMATION:  
; APPLICANT: Dubague, Yves  
; APPLICANT: Lowman, Henry  
; TITLE OF INVENTION: PROTEIN VARIANTS  
; FILE REFERENCE: P1712R1  
; CURRENT APPLICATION NUMBER: US/09/723, 981  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: 09/477, 923  
; PRIOR FILING DATE: 2000-01-05  
; NUMBER OF SEQ ID NOS: 6  
; SEQ ID NO: 1  
; LENGTH: 70  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-09-723-981-1

RESULT 17  
US-09-723-896-1  
; Sequence 1, Application US/0923896  
; Patent No. 6509443  
; GENERAL INFORMATION:  
; APPLICANT: Dubague, Yves  
; APPLICANT: Lowman, Henry  
; TITLE OF INVENTION: PROTEIN VARIANTS  
; FILE REFERENCE: P1712R1  
; CURRENT APPLICATION NUMBER: US/09/723, 896  
; CURRENT FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: US/09/477, 923  
; PRIOR FILING DATE: 2000-01-05  
; NUMBER OF SEQ ID NOS: 6  
; SEQ ID NO: 1  
; LENGTH: 70  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-09-723-896-1

RESULT 19  
PCT-US93-11458-1  
; Sequence 1, Application PC/TUS9311458  
; GENERAL INFORMATION:  
; APPLICANT:  
; TITLE OF INVENTION: MODIFIED INSULIN-LIKE GROWTH FACTOR  
; NUMBER OF SEQUENCES: 20  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS

Qy 11 RRAPQGIVDBCCFRSCDLRLEMVC 35  
Db 36 RRAPQGIVDBCCFRSCDLRLEMVC 61

Query Match 30.2%; Score 26; DB 4; Length 70;  
Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPQGIVDBCCFRSCDLRLEMVC 35  
Db 36 RRAPQGIVDBCCFRSCDLRLEMVC 61

Query Match 30.2%; Score 26; DB 5; Length 70;  
Best Local Similarity 100.0%; Pred. No. 5.2e-20;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SOFTWARE: Patent Release #1.0, Version #1.25 (EPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US93/11458

FILING DATE: 24-NOV-1993

CLASSIFICATION:

SEQUENCE CHARACTERISTICS:

LENGTH: 70 amino acids

TYPE: amino acid

STRANDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

PCT-US93-11458-1

Query Match 30.2%; Score 26; DB 5; Length 70;

Best Local Similarity 100.0%; Pred. No. 5.2e-20; Mismatches 0; Indels 0; Gaps 0;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 RRAPOQTGIVDCCFRSCDRLRLEMVC 36

Db 36 RRAPOQTGIVDCCFRSCDRLRLEMVC 61

RESULT 20

PCT/US95/08925-1

Sequence 1, Application PC/TUS95/08925

GENERAL INFORMATION:

APPLICANT: CELTRIX PHARMACEUTICALS, INC.

TITLE OF INVENTION: IGF/IGFB COMPLEX FOR PROMOTING BONE REMODELING

NUMBER OF SEQUENCES: 7

CORRESPONDENCE ADDRESS:

ADDRESSEE: MORRISON & FOERSTER

STREET: 755 Page Mill Road

CITY: Palo Alto

STATE: California

COUNTRY: USA

ZIP: 94304-1018

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/08925

CLASSIFICATION: NEW

ATTORNEY/AGENT INFORMATION:

NAME: PARK, PREDIE K.

REGISTRATION NUMBER: 35,636

REFERENCE/DOCKET NUMBER: 220952027240

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 813-5600

TELEFAX: (415) 494-0792

TELEX: 706141

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:

LENGTH: 70 amino acids

TYPE: amino acid

STRANDNESS: single

TOPOLOGY: linear

PCT-US95-08925-1

Query Match 30.2%; Score 26; DB 5; Length 70;

Best Local Similarity 100.0%; Pred. No. 5.2e-20; Mismatches 0; Indels 0; Gaps 0;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 RRAPOQTGIVDCCFRSCDRLRLEMVC 36

Db 36 RRAPOQTGIVDCCFRSCDRLRLEMVC 61

RESULT 21

5470828-1

Patent No. 5470828

APPLICANT: BALLARD, FRANCIS J.;WALLACE, JOHN C.;

TITLE OF INVENTION: PEPTIDE ANALOGS OF INSULIN-LIKE GROWTH

FACTOR II

NUMBER OF SEQUENCES: 2

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/947,514

FILING DATE: 17-SEP-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 408,518

FILING DATE: 24-AUG-1989

SEQ ID NO:1:

LENGTH: 70

5470828-1

Query Match 30.2%; Score 26; DB 6; Length 70;

Best Local Similarity 100.0%; Pred. No. 5.2e-20; Mismatches 0; Indels 0; Gaps 0;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 RRAPOQTGIVDCCFRSCDRLRLEMVC 36

Db 36 RRAPOQTGIVDCCFRSCDRLRLEMVC 61

SEQUENCE CHARACTERISTICS:

INFORMATION FOR SEQ ID NO: 47:

LENGTH: 78 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide

RESULT 23  
US-08-167-641C-47

Query Match 30.2%; Score 26; DB 2; length 78;  
Best Local Similarity 100.0%; Pred. No. 5.7e-20;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 11 RRAPQTCIVDECCFRSCDLRLLEMVC 36  
Db 34 RRAPQTCIVDECCFRSCDLRLLEMVC 59

||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||  
34 RRAPQTCIVDECCFRSCDLRLLEMVC 59

RESULT 24  
US-08-460-971A-47

Query Match 30.2%; Score 26; DB 3; length 78;  
Best Local Similarity 100.0%; Pred. No. 5.7e-20;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 11 RRAPQTCIVDECCFRSCDLRLLEMVC 36  
Db 34 RRAPQTCIVDECCFRSCDLRLLEMVC 59

||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||  
34 RRAPQTCIVDECCFRSCDLRLLEMVC 59

RESULT 23  
US-08-167-641C-47

Sequence 47, Application US/08167641C  
Patent No. 6033884  
GENERAL INFORMATION:  
APPLICANT: Woo, Savio L.C.  
APPLICANT: Woo, Savio L.C.  
APPLICANT: Smith, Louis C.  
APPLICANT: Cristiano, Richard J.  
APPLICANT: Gottchalk, Stephen  
TITLE OF INVENTION: NUCLEAR ACID TRANSPORTER SYSTEMS AND  
METHODS OF USE  
NUMBER OF SEQUENCES: 65  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FASTSEQ for Windows 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/167 641C  
FILING DATE: December 14, 1993  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/1855 389  
FILING DATE: March 20, 1992  
APPLICATION NUMBER: PCT/US93/02725  
FILING DATE: December 19, 1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 212/063  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 47:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 78 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide

US-08-460-971A-47

Query Match 30.2%; Score 26; DB 3; length 78;  
Best Local Similarity 100.0%; Pred. No. 5.7e-20;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPQTCIVDECCFRSCDLRLLEMVC 36  
Db 34 RRAPQTCIVDECCFRSCDLRLLEMVC 59

RESULT 23  
US-08-167-641C-47

Sequence 47, Application US/08460971A  
Patent No. 6150168  
GENERAL INFORMATION:  
APPLICANT: Smith, Louis C.  
APPLICANT: Cristiano, Richard J.  
APPLICANT: Gottchalk, Stephen  
TITLE OF INVENTION: NUCLEAR ACID TRANSPORTER SYSTEMS AND  
METHODS OF USE  
NUMBER OF SEQUENCES: 65  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FASTSEQ for Windows 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/460,971A  
FILING DATE: June 5, 1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/167,641  
FILING DATE: December 14, 1993  
APPLICATION NUMBER: 07/1855 389  
FILING DATE: March 20, 1992  
APPLICATION NUMBER: PCT/US93/02725  
FILING DATE: December 19, 1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 212/063  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 47:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 78 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide

US-08-460-971A-47

Query Match 30.2%; Score 26; DB 3; length 78;  
Best Local Similarity 100.0%; Pred. No. 5.7e-20;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 RRAPQTCIVDECCFRSCDLRLLEMVC 36  
Db 34 RRAPQTCIVDECCFRSCDLRLLEMVC 59

RESULT 23  
US-08-167-641C-47

Sequence 47, Application US/08460971A  
Patent No. 6177554  
GENERAL INFORMATION:  
APPLICANT: Woo, Savio L.C.

Query Match 30.2%; Score 26; DB 3; length 78;  
Best Local Similarity 100.0%; Pred. No. 5.7e-20;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 11 RRAPQTCIVDECCFRSCDLRLLEMVC 36  
Db 34 RRAPQTCIVDECCFRSCDLRLLEMVC 59

RESULT 25  
US-08-462-040-47

Sequence 47, Application US/08462040  
Patent No. 6177554  
GENERAL INFORMATION:  
APPLICANT: Woo, Savio L.C.

APPLICANT: Smith, Louis C.  
 APPLICANT: Cristiano, Richard J.  
 APPLICANT: Gottschalk, Stephen  
 TITLE OF INVENTION: NUCLEIC ACID TRANSPORTER SYSTEMS AND  
 METHODS OF USE  
 NUMBER OF SEQUENCES: 65  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Lyon & Lyon  
 STREET: 633 West Fifth Street  
 CITY: Los Angeles  
 STATE: California  
 COUNTRY: U.S.A.  
 ZIP: 90071-2066  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: IBM P.C. DOS 5.0  
 SOFTWARE: FastSEQ for Windows 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/462,040  
 FILING DATE: June 5, 1995  
 CLASSIFICATION: 536  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 08/167,641  
 FILING DATE: December 14, 1993  
 APPLICATION NUMBER: 07/855,389  
 FILING DATE: March 20, 1992  
 APPLICATION NUMBER: PCT/US93/02725  
 FILING DATE: March 19, 1993  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Warburg, Richard J.  
 REGISTRATION NUMBER: 32,327  
 REFERENCE/DOCKET NUMBER: 212/078  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (213) 489-1600  
 TELEFAX: (213) 955-0440  
 TELEX: 67-3510  
 INFORMATION FOR SEQ ID NO: 47:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 78 amino acids  
 TYPE: amino acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: peptide  
 US-08-462-040-47

Query Match 30.2%; Score 26; DB 3; Length 78;  
 Best Local Similarity 100.0%; Pred No. 5.7e-20;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOQIVDCCFESCDLRLLEMVYC 36  
 Db 34 RRAPOQIVDCCFESCDLRLLEMVYC 59

Search completed: March 3, 2004, 12:03:46  
 Job time : 23 secs

OM protein - protein search, using sw model	GenCore version 5.1.6			
Copyright (c) 1993 - 2004 Compugen Ltd.				
Run on: March 3, 2004, 11:55:20 ; Search time 54 Seconds				
Sequence: US-09-852-261-4_COPY_26_111 (without alignments)	49.983 Million cell updates/sec			
Scoring table: Gapop 60.0 , Gapext 60.0				
Searched: 1586107 seqs, 282547505 residues				
Word size : 0				
Total number of hits satisfying chosen parameters: 1586107				
Minimum DB seq length: 0				
Maximum DB seq length: 2000000000				
Post-processing: Listing first 100 summaries				
Database : A_Geneseq_29Jan04 *				
1: geneseqp1980s:*	56			
2: geneseqp1990s:*	57			
3: geneseqp0008:*	58			
4: geneseqp2001s:*	59			
5: geneseqp2002s:*	60			
6: geneseqp003as:*	61			
7: geneseqp2004s:*	62			
8: geneseqp2004s:*	63			
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.				
SUMMARIES				
Result No.	Score	Query Match Length	DB ID	Description
1	86	100.0	111 4	AAE02448
2	86	100.0	111 5	AAU10560
3	86	100.0	111 7	ABR63168
4	61	70.9	105 4	AAE02531
5	61	70.9	105 4	AAE02451
6	61	70.9	105 5	AAU10563
7	61	70.9	105 7	ABR63171
8	46.5	46.5	181 7	AAE05466
9	36.0	36.0	127 7	ADP23373
10	31	36.0	133 6	ABP58085
11	31	36.0	133 7	ADA23174
12	31	36.0	153 7	ADD4795
13	26	30.2	1 1	APR8033
14	26	30.2	38 1	APR60718
15	26	30.2	62 1	APR90515
16	26	30.2	67 1	ABR36847
17	26	30.2	69 3	AAV5168
18	26	30.2	70 1	APR40034
19	26	30.2	70 1	APR71539
20	26	30.2	70 1	APR70114
21	26	30.2	70 1	APR93366
22	26	30.2	70 1	APR94660
23	26	30.2	70 1	APR94661
24	26	30.2	70 1	APR1502
25	26	30.2	70 1	APR10586
26	26	30.2	70 1	APR50927
27	26	30.2	70 2	AAR10587
28	26	30.2	70 2	AAR36846
29	26	30.2	70 2	AAR41774
30	26	30.2	70 2	AAR43606
31	26	30.2	70 2	AAR55275
32	26	30.2	70 2	AAR48590
33	26	30.2	70 2	AAR87557
34	26	30.2	70 2	AAR89949
35	26	30.2	70 2	AAR86874
36	26	30.2	70 2	AAR87744
37	26	30.2	70 2	AAR33907
38	26	30.2	70 3	AAB12342
39	26	30.2	70 3	AAB35949
40	26	30.2	70 3	AAY8577
41	26	30.2	70 3	AAY84871
42	26	30.2	70 3	AAB12769
43	26	30.2	70 4	AAB12772
44	26	30.2	70 5	AAB35948
45	26	30.2	70 5	AAB35949
46	26	30.2	70 5	AAB18374
47	26	30.2	70 5	AAM48217
48	26	30.2	70 5	AAP50872
49	26	30.2	70 5	AAB28004
50	26	30.2	70 5	AAB71497
51	26	30.2	70 5	AAB76349
52	26	30.2	70 6	AAU90781
53	26	30.2	71 1	AAP81790
54	26	30.2	71 1	AAP81212
55	26	30.2	71 1	AAB81203
56	26	30.2	71 1	AAP94729
57	26	30.2	71 2	AAR05281
58	26	30.2	71 2	AAB21709
59	26	30.2	71 4	AAG62611
60	26	30.2	71 4	AAB63194
61	26	30.2	72 2	AAR13759
62	26	30.2	75 2	AAR41776
63	26	30.2	76 1	AAR13758
64	26	30.2	78 1	AAP81213
65	26	30.2	78 3	AAY98482
66	26	30.2	78 3	AAX159027
67	26	30.2	78 4	AAB45835
68	26	30.2	78 4	AAB40272
69	26	30.2	79 3	AAY43744
70	26	30.2	80 3	AAY43746
71	26	30.2	83 2	AAR51454
72	26	30.2	84 3	AAY43745
73	26	30.2	89 1	AAP40026
74	26	30.2	90 1	AAP40024
75	26	30.2	94 2	AAR3782
76	26	30.2	94 2	AARS1474
77	26	30.2	95 2	AAR37549
78	26	30.2	95 2	AAR367492
79	26	30.2	95 4	AAG63726
80	26	30.2	95 7	AUD84794
81	26	30.2	101 1	AAP82123
82	26	30.2	105 4	AAB0452
83	26	30.2	105 4	AAB02450
84	26	30.2	105 4	AAB2456
85	26	30.2	105 5	AAU10562
86	26	30.2	105 5	AAU10564
87	26	30.2	105 7	AAB63172
88	26	30.2	105 7	AAB63170
89	26	30.2	110 4	AAB0245
90	26	30.2	110 5	AAU10559
91	26	30.2	110 7	AER63167
92	26	30.2	111 4	AAB2449
93	26	30.2	111 5	AAU10561
94	26	30.2	111 7	AER63169
95	26	30.2	118 2	Aaw09772
96	26	30.2	121 2	AAR2301
97	26	30.2	131 1	AAR63193
98	26	30.2	133 1	Aap50927

99 AAP50926 Human ins  
100 AAP70101 Sequence

## ALIGNMENTS

RESULT 1

AAE02448 standard; protein; 111 AA.

XX

AC

XX

AAE02448;

XX

DT

10-AUG-2001 (first entry)

XX

DE

Rat IGF-I isoform mechano-growth factor (Mgf) protein.

XX

Rat; IGF-I isoform; Insulin-like Growth Factor-I; Mgf;

XX

mechano-growth factor; neurological disorder; neurodegenerative disorder; amyotrophic lateral sclerosis; spinal muscular atrophy;

XX

poliomyelitis; post-polio syndrome; toxin; motoneurone disorder;

XX

nerve damage; autonomic muscular dystrophy; diabetic neuropathy;

XX

sex-linked muscular dystrophy; peripheral neuropathy;

XX

Alzheimer's disease; Parkinson's disease.

XX

OS

Rattus sp.

XX

PN

WO200136483-A1.

XX

PD

25-MAY-2001.

XX

PF

15-NOV-2000; 2000WO-GB004354.

XX

PR

15-NOV-1999; 99GB-00026968.

1 NKPTVYGSISRRAPOTGIVDECCFRSCDLRLEMVKVRCPTKSARSIRAQRHTDMPKIQ 60  
26 NRPTVYGSISRRAPOTGIVDECCFRSCDLRLEMVKVRCPTKSARSIRAQRHTDMPKIQ 85  
61 KSQPLSTHKERKLQRRKGSTLEHK 86  
86 KSQPLSTHKERKLQRRKGSTLEHK 111

Oy

Db

Oy

Db</

QY 61 KSQLPLSTHKKQLQRRRKGSQLEHK 86  
 Db 86 KSQLPLSTHKKQLQRRRKGSQLEHK 111

RESULT 3  
 ABR6168  
 ID ABR63168 standard; protein; 111 AA.  
 AC ABR6168;  
 XX DT 18-DBC-2003 (first entry)  
 XX Rat mechano growth factor (C-terminal end).  
 DE Rat mechano growth factor (C-terminal end).  
 XX KW Mechano growth factor; MGF; insulin-like growth factor 1; rat;  
 KW splice variant; cardiac; vasoconstrictive; gene therapy;  
 KW XX Rattus sp.  
 OS XX Rattus sp.  
 PN WO2003066082-A1.  
 XX PD 14-AUG-2003.  
 XX PP 06-FEB-2003; 2003WO-GB000537.  
 XX PR 07-FEB-2002; 2002GB-00002906.  
 XX PA (UNLO ) UNIV COLLEGE LONDON.  
 XX PA (UNLO ) UNIV ILLINOIS FOUND.  
 PI Goldspink G, Goldspink P;  
 XX PT Goldspink G, Johnson I;  
 DR WPI; 2003-636936/60.  
 DR N-PSDB; ACR79636.  
 XX PT Use of Mechano Growth Factor polypeptide or Polynucleotide for preventing or limiting myocardial damage in response to ischemia or mechanical overload of the heart.  
 PT XX PS Claim 5; FIG 8; 74pp; English.  
 CC The present sequence is that of the C-terminal end of novel rat mechano growth factor (MGF), encoded by exons 3-6 of the IGF-I gene. MGF is a splice variant and non-liver type isoform of insulin-like growth factor (IGF-I) that is activated in response to cardiac tissue damage and which has a repair function in the ischaemic and/or over-loaded heart. The rat MGF transcript has a 52 base insert in the E domain that alters the reading frame and hence the C-terminal end of MGF protein in comparison with other IGF-I splice variants. The invention provides use of a MGF polypeptide or polynucleotide for the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischaemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium. The MGF polypeptide or medicament is also useful for administration in response to a heart attack.  
 CC XX SQ Sequence 111 AA:  
 Query Match 100.0%; Score 86; DB 7; Length 111;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-82; Indels 0; Gaps 0;  
 Matches 86; Conservative 0; Mismatches 0;  
 QY 1 NKPTVYGSIRRAPQTGIVDECCFRSCDLRRLMEYCURCKPTKSARSIRAOHTDMPTQ 60  
 Db 26 NKPTVYGSIRRAPQTGIVDECCFRSCDLRRLMEYCURCKPTKSARSIRAOHTDMPTQ 85  
 QY 61 KSQLPLSTHKKQLQRRRKGSQLEHK 86  
 Db 86 KSQLPLSTHKKQLQRRRKGSQLEHK 111

RESULT 4  
 AAE02531  
 ID AAE02531 standard; protein; 105 AA.  
 AC AAE02531;  
 XX DT 10-AUG-2001 (first entry)  
 XX Rat liver-type IGF-I isoform (L.IGF-I) protein, alternative version.  
 XX DE Rat: IGF-I isoform; Insulin-like Growth Factor-I; MGF;  
 KW mechano-growth factor; neurological disorder; neurodegenerative disorder;  
 KW amyotrophic lateral sclerosis; spinal muscular atrophy; muscular atrophy;  
 KW poliomyelitis; post-polio syndrome; toxin; motoneurone disorder;  
 KW nerve damage; autosomal muscular dystrophy; diabetic neuropathy;  
 KW sex-linked muscular dystrophy; peripheral neuropathy;  
 KW Alzheimer's disease; Parkinson's disease; liver; L.IGF-I.  
 XX OS Rattus sp.  
 XX FH Key Location/Qualifiers  
 FT Msc-difference 102  
 FT /note= "Encoded by ACC"  
 XX PN WO200136483-A1.  
 XX PD 25-MAY-2001.  
 XX PR 15-NOV-2000; 2000WO-GB004354.  
 XX PA (UNLO ) UNIV COLLEGE LONDON.  
 XX PT Goldspink G, Johnson I;  
 XX DR WPI; 2001-555620/37.  
 DR N-PSDB; AAD66404.  
 XX PT Use of mechano-growth factor, an isoform of insulin-like Growth Factor-I, capable of reducing motoneurone loss, in the manufacture of a medicament for the treatment of neurological disorder.  
 XX PS Disclosure; FIG 9; 65pp; English.  
 CC The present invention relates to use of mechano-growth factor (MGF), an insulin-like Growth Factor-I (IGF-I) isoform in the manufacture of a medicament for the treatment of neurological disorder. The MGF is capable of reducing motoneurone loss by 20% or greater in response to nerve avulsion, and effects motoneurone rescue, preferably adult motoneurone rescue. The MGF polynucleotide and polypeptide are useful in the manufacture of a medicament for the treatment of a neurological disorder, including a disorder of motoneurones and/or neurodegenerative disorder, e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, progressive spinal muscular atrophy, infantile or juvenile muscular atrophy, progressive poliomyelitis or post-polio syndrome, a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage, an injury that affects motoneurones, motoneurone loss associated with aging, autosomal or sex-linked muscular dystrophy, diabetic neuropathy, peripheral neuropathies, Alzheimer's disease and Parkinson's disease. The present sequence is alternative version of rat liver-type IGF-I isoform (L.IGF-I). The L.IGF-I protein comprises amino acid sequences encoded by nucleic acid sequence of IGF-I exons 4 and 6. Note: The present sequence is stated as being the same as SEQ ID NO: 12 shown in sequence listing (AAE02451) of the specification. However it differs at a single position XX SQ Sequence 105 AA:  
 Query Match 70.9%; Score 61; DB 4; Length 105;  
 Best Local Similarity 100.0%; Pred. No. 3.6e-56; Indels 0; Gaps 0;  
 Matches 61; Conservative 0; Mismatches 0;  
 CC QY 1 NKPTVYGSIRRAPQTGIVDECCFRSCDLRRLMEYCURCKPTKSARSIRAOHTDMPTQ 60  
 Db 86 KSQLPLSTHKKQLQRRRKGSQLEHK 111

Best Local Similarity 100.0%; Pred. No. 3:6e-56; Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Query 1 NKPTVYGSIRRQPTGIVDECCFRSCDLRRLMVCRKPKTSARSIRAQRTDMPKTQ 85  
 Db 61 K 61  
 Qy 61 K 61  
 Db 86 K 86

RESULT 5  
 AAB02451  
 ID AAB02451 standard; protein; 105 AA.  
 XX  
 AC AAB02451;  
 XX  
 DE Rat liver-type IGF-I isoform (L.IGF-I) protein.  
 XX  
 10-AUG-2001 (first entry)  
 XX  
 Rat liver-type IGF-I isoform (L.IGF-I) protein.  
 XX  
 Rat; IGF-I isoform; Insulin-like Growth Factor-I; MGF; mechano-growth factor; neurological disorder; neurodegenerative disorder; muscular atrophy; spinal muscular atrophy; amyotrophic lateral sclerosis; spinal muscular atrophy; muscular atrophy; poliomyelitis; post-polio syndrome; toxin; motoneurone disorder; nerve damage; autosomal muscular dystrophy; diabetic neuropathy; sex-linked muscular dystrophy; peripheral neuropathy; Alzheimer's disease; Parkinson's disease; liver; L.IGF-I.  
 XX  
 OS Rattus sp.  
 XX  
 PN WO200136483-A1.  
 XX  
 PD 25-MAY-2001.  
 XX  
 15-NOV-2000; 2000WO-GB004354.  
 XX  
 PR 15-NOV-1999; 999B-00026968.  
 XX  
 PA (UNILO ) UNIV COLLEGE LONDON.  
 XX  
 PT Goldspink G, Johnson I;  
 XX  
 DR WPI; 2001-355620/37.  
 XX  
 DR N-PSDB; AAD06404.  
 XX  
 PT Use of mechano-growth factor, an isoform of insulin-like Growth Factor-I, capable of reducing motoneurone loss, in the manufacture of a medicament for the treatment of neurological disorder.  
 XX  
 PS Disclosure; Page 58-59; 65pp; English.  
 XX  
 The present invention relates to use of mechano-growth factor (MGF), an insulin-like Growth Factor-I (IGF-I) isoform in the manufacture of a medicament for the treatment of neurological disorder. The MGF is capable of reducing motoneurone loss by 20% or greater in response to nerve avulsion and effects motoneurone rescue, preferably adult motoneurone rescue. The MGF polynucleotide and polypeptide are useful in the manufacture of a medicament for the treatment of a neurological disorder, including a disorder of motoneurones and/or neurodegenerative disorder, e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, progressive spinal muscular atrophy, infantile or juvenile muscular atrophy, poliomyelitis or post-polio syndrome, a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage, an injury that affects motoneurones, motoneurone loss associated with aging, autosomal or sex-linked muscular dystrophy, diabetic neuropathy, peripheral neuropathies, Alzheimer's disease and Parkinson's disease. The present sequence is rat liver-type IGF-I isoform (L.IGF-I). The L.IGF-I protein comprises amino acid sequences encoded by nucleic acid sequence (SEQ ID NO: 12) is stated as being the same as that shown in figure 9 (AAB02531) of the specification. However it differs at a single position

XX  
 Sequence 105 AA;

Query Match 70.9%; Score 61; DB 5; Length 105;  
 Best Local Similarity 100.0%; Pred. No. 3.6e-56;  
 Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Query Match 70.9%; Score 61; DB 4; Length 105;  
 Sequence 105 AA;

Db	86	K	86
<b>RESULT 7</b>			
ABR63171			
ID	ABR63171 standard; protein; 105 AA..		
XX			
AC	ABR63171;		
XX			
DR	18-DEC-2003 (first entry)		
XX			
DE	Rat liver-type insulin-like growth factor 1 (C-terminal end).		
XX			
KW	Insulin-like growth factor 1; IGF-I; rat; mechano growth factor; cardiant; vasotropic; gene therapy.		
KW			
XX			
OS	Rattus sp.		
XX			
PN	WO200306082-A1.		
XX			
PD	14-AUG-2003.		
XX			
PF	06-FEB-2003; 2003WO-GB000537.		
XX			
PR	07-FEB-2002; 2002GB-00002905.		
XX			
PA	(UNIV ) UNIV COLLEGE LONDON.		
XX			
PA	(UNIV ) UNIV ILLINOIS FOUND.		
XX			
PI	Goldspink G, Goldspink P;		
XX			
WPI:	2003-63693650.		
DR	N-PSDB; AC79639.		
XX			
PT	Use of Mechano Growth Factor polypeptide or polynucleotide for preventing or limiting apoptosis in the myocardium, particularly for preventing or limiting myocardial damage in response to ischemia or mechanical overload of the heart.		
XX			
PS	Disclosure; Fig 11; 74pp; English.		
XX			
CC	The present sequence is the protein sequence of rat liver-specific insulin-like growth factor 1 (IGF-1) C-terminal region. It is encoded by exons 3, 4 and 6 of the IGF-1 gene. The invention relates to a novel IGF-I splice variant, denoted mechano growth factor, a non-liver type isoform of IGF-I that is activated in response to cardiac tissue damage and which has a repair function in the ischaemic and/or overloaded heart. The rat MGF transcript has a 52 base insert in the E domain that alters the reading frame and hence the C-terminal end of MGF protein in comparison with other IGF-I splice variants. The invention provides use of a MGF polypeptide or polynucleotide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart, preventing or limiting apoptosis in the myocardium. The MGF polypeptide, polynucleotide or medicament is also useful for administration in response to a heart attack		
CC	Sequence 105 AA;		
CC	Sequence 105 AA;		
<b>RESULT 8</b>			
ABE57466			
ID	ABE57466 standard; protein; 181 AA..		
XX			
AC	ABE57466;		
XX			
DT	29-JAN-2004 (first entry)		
XX			
DE	Rat Protein P08024, SEQ ID NO 3327.		
XX			
KW	Rat; pain; neuronal tissue; gene therapy; spinal segmental nerve injury; chronic constriction injury; CCI; spared nerve injury; SNI; Chung.		
KW			
OS	Rattus norvegicus.		
PN	WO2003016475-A2.		
XX			
PD	27-FEB-2003.		
XX			
PF	14-AUG-2002; 2002WO-US025765.		
XX			
PR	14-AUG-2001; 2001US-0312147P.		
PR	01-NOV-2001; 2001US-0346389P.		
PR	26-NOV-2001; 2001US-0333347P.		
XX			
PA	(EBHO ) GEN HOSPITAL CORP.		
PA	(FARB ) BAYER AG.		
XX			
PI	Wolf C, Durso D, Befort K, Costigan M;		
XX			
DR	WPI; 2003-268312/26.		
XX			
DR	GENBANK; P08024.		
XX			
PT	New composition comprising two or more isolated polypeptides, useful for preparing a medicament for treating pain in an animal.		
XX			
PS	Claim 1; Page: 1017pp; English.		
XX			
CC	The invention discloses a composition comprising two or more isolated rat or human polynucleotides or a polynucleotide which represents a fragment, derivative or allelic variation of the nucleic acid sequence. Also claimed are a vector comprising the novel Polynucleotide, a host cell comprising the vector, a method for identifying a nucleic acid sequence that increases or decreases the expression of the polynucleotide sequence that is differentially expressed in neuronal tissue of a first animal subjected to pain, a method for identifying a nucleic acid sequence which is differentially expressed in an animal subjected to pain and a kit to perform the method, an array, a method for identifying an agent that increases or decreases the expression of the polynucleotide sequence that is differentially expressed in neuronal tissue of a first animal subjected to pain, a method for identifying a compound which regulates the expression of a polynucleotide sequence which is differentially expressed in an animal subjected to pain, a method for identifying a compound that regulates the activity of one or more of the polynucleotides, a method for producing a pharmaceutical composition, a method for identifying a compound or small molecule that regulates the activity in an animal of one or more of the polypeptides given in the specification, a method for identifying a compound useful in treating pain and a pharmaceutical composition comprising the one or more polypeptides or their antibodies. The polynucleotide or the compound that modulates its activity is useful for preparing a medicament for treating pain (e.g. spinal segmental nerve injury (Chung), chronic constriction		
CC	Sequence 105 AA;		
CC	Sequence 105 AA;		

Query Match: 70.9%; Score: 61; DB: 7; Length: 105;  
 Best Local Similarity: 100.0%; Pred. No.: 3.6e-56;  
 Matches: 61; Conservative: 0; Mismatches: 0; Indexes: 0; Gaps: 0

CC  
CC  
XX  
SQ  
Sequence 181 AA:

Best Local Similarity 100.0%; Pred. No. 7.6e-34; Indels 0; Gaps 0; Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0; QY 40 KPTKSARSRRAQRHDMPKRQKSPLSTIKRKQRRRG 79  
 ID ADA23373 standard; protein; 127 AA.  
 XX  
 AC ADA23373;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DB Mouse insulin growth factor 1 amino acid sequence.  
 XX  
 KW ligand; antibody; mechano-growth factor; MGF; inotropic; cardiant; cell signaling; muscle damage; muscular dystrophy; cardiac muscle damage; muscle fatigue; heart attack.  
 XX  
 OS Mus sp.  
 XX  
 WO2003068949-A1.  
 XX  
 PD 21-AUG-2003.  
 XX  
 PR 14-FEB-2003; 2003WO-GB000657.  
 XX  
 FR 14-FEB-2002; 2002GB-00003552.  
 XX  
 PA (BEAU/) BEAUMONT N.  
 XX  
 PI Beaumont N;  
 XX  
 DR WPI; 2003-679637/64.  
 XX  
 PT New peptides corresponding to the C terminus of creatine kinase have a similar function to mechano-growth factor and are useful to treat muscle damage such as exercise injury, muscular dystrophy and heart attack damage.  
 PT  
 Disclosure; Fig 1; 21PP; English.  
 XX  
 CC The present invention describes an isolated peptide capable of acting as a ligand for an antibody with affinity for the C-terminus of mechano-growth factor (MGF), for use in therapy, where the peptide is not MGF. Also described is an isolated peptide for use in therapy comprising the sequence (I) (X1)m(X2)n(X3)G(X4)(X5)(X6)(X7)2(X8)P, where X1 = a basic residue, X2 and X3 = any amino acid, X3 and X4 = Lys or Gln, X5 = Ser, Thr, Ala or Pro, X6 = Ile, Phe or Leu, X7 = Asp or Gln, m = 2 or 3, n = 0 -2, and p = 2-6. (I) has inotropic and cardiant activities, and can be used in cell signaling. (I) can be used for the manufacture of a composition for the treatment of muscle damage, deterioration or injury, particularly damage to skeletal muscle, especially muscular dystrophy or damage to cardiac muscle, and to manufacture a composition for the repair of damage or loss of nerve cells. The peptide can be used in cell culture media to promote growth of muscle or nerve cell lines. The peptides are used to treat conditions associated with muscle fatigue and/or injury for example during exercise, and to treat muscle deterioration or damage for example after a heart attack. They may be useful to identify agents that potentiate or inhibit muscle or nerve cell growth, as a treatment to promote growth or repair of muscle or nerve cells in vivo and to inhibit apoptosis of precursor cells. The present sequence represents a mouse insulin growth factor 1 (IGF1) amino acid sequence, which is given in comparison with mouse MGF in the exemplification of the present invention.  
 XX  
 Sequence 127 AA;

Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0; QY 6 YGSISRRAQRHDMPKRQKSPLSTIKRKQRRRG 36  
 ID ABP58085 standard; protein; 133 AA.  
 XX  
 AC ABP58085;  
 XX  
 DT 07-MAR-2003 (first entry)  
 XX  
 DE Mouse insulin-like growth factor IB.  
 XX  
 KW Insulin-like growth factor IB; IGF-IB; mouse; mRNA; assay; nucleic acid detection.  
 XX  
 OS Mus musculus.  
 XX  
 PN WO200297390-A2.  
 XX  
 PD 05-DEC-2002.  
 XX  
 PR 31-MAY-2002; 2002WO-SE001056.  
 XX  
 PR 01-JUN-2001; 2001SE-0001934.  
 XX  
 PA (BIOV-) BIOVITRUM AB.  
 XX  
 PA Parrow V, Rosengren L;  
 XX  
 PI DR WPI; 2003-129526/12.  
 XX  
 DR N-FSDB; ABV76185.  
 XX  
 PT Quantitating a target nucleic acid in a sample comprises immobilizing, on a solid support, a sample comprising a target nucleic acid, and detecting and quantitating signals generated from the antisense and sense probes.  
 PT  
 PS Example 1; Page 17; 18pp; English.  
 XX  
 CC The present sequence is the protein sequence of murine insulin-like growth factor IB (IGF-IB). IGF-IB cDNA was used in an example of the method of the invention to generate probes for determination of IGF-IB RNA. The method comprises a quantitative hybridisation assay for quantitating the signals generated from the hybridised probes, and (iv) determining the value represented by the antisense probe signal minus the sense probe signal, the value being proportional to the amount of mRNA in the RNA sample. In an example of the method, a cDNA clone containing 60 nucleotides from exon 2 and 119 nucleotides from exon 3 of the mouse IGF-IB gene was cloned into PGEM-4Z vector. Linearisation of the plasmid with BCR1 allowed transcription of a 250-nucleotide antisense probe using T7 polymerase. Linearisation with HindIII allowed transcription of a sense probe of similar length using SP6 polymerase (see ABV76186). The probes were purified and used to determine IGF-1 RNA in mouse hepatocytes and also in rat hepatocytes  
 CC Sequence 133 AA;

Query Match 36.0%; Score 31; DB 6; Length 133;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-24;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0; QY 6 YGSISRRAQRHDMPKRQKSPLSTIKRKQRRRG 36  
 ID 53 YGSISRRAQRHDMPKRQKSPLSTIKRKQRRRG 83  
 XX  
 SQ Query Match 36.0%; Score 31; DB 7; Length 127;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-24;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 11  
 ADA23374  
 ID ADA23374 standard; protein; 133 AA.  
 XX  
 AC ADA23374;  
 XX DT 20-NOV-2003 (first entry)  
 DE Mouse MGF amino acid sequence.  
 XX KW ligand; antibody; mechano-growth factor; MGF; inotropic; cardiot; cardiac muscle damage;  
 KW muscle fatigue; heart attack.  
 OS Mus sp.  
 XX PN WO2003068949-A1.  
 XX PD 21-AUG-2003.  
 XX PF 14-FEB-2003; 2003WO-GB000657.  
 XX PR 14-FEB-2002; 2002GB-00003552.  
 XX PA (BEAU/) BEAUMONT N.  
 XX PI Beaumont N;  
 XX DR WPI; 2003-679637/64.  
 XX PT New peptides corresponding to the C terminus of creatine kinase have a  
 PT similar function to mechano-growth factor and are useful to treat muscle  
 PT damage such as exercise injury, muscular dystrophy and heart attack  
 PT damage.

PS Disclosure; Fig 1; 21pp; English.

XX The present invention describes an isolated peptide capable of acting as  
 CC a ligand for an antibody with affinity for the C-terminus of mechano-  
 CC growth factor (MGF), for use in therapy, where the peptide is not MGF.  
 CC Also described is an isolated peptide for use in therapy comprising the  
 CC sequence (X1)  $(X1)m(X2)n(X3)G(X4)(X5)(X6)(X7)2(X8)p$ , where X1 = a basic  
 CC residue, X2 and X3 = any amino acid, X3 and X4 = Lys or Gln, X5 = Ser, X6 =  
 CC Thr, Ala or Pro, X7 = Ile, Phe or Leu, X8 = Asp or Glu, m = 2 or 3, n = 0  
 CC -2, and p = 2-6. (1) has inotropic and cardiot activities, and can be  
 CC used in cell signaling. (1) can be used for the manufacture of a  
 CC composition for the treatment of muscle damage, deterioration or injury,  
 CC particularly damage to skeletal muscle, especially muscular dystrophy or  
 CC damage to cardiac muscle, and to manufacture a composition for the repair  
 CC of damage or loss of nerve cells. The peptide can be used in cell culture  
 CC media to promote growth of muscle or nerve cell lines. The peptides are  
 CC used to treat conditions associated with muscle fatigue and/or injury for  
 CC example during exercise, and to treat muscle deterioration or damage for  
 CC example after a heart attack. They may be useful to identify agents that  
 CC potentiate or inhibit muscle or nerve cell growth, as a treatment to  
 CC promote growth or repair of muscle or nerve cells in vivo and to inhibit  
 CC apoptosis of precursor cells. The present sequence represents a mouse MGF  
 CC amino acid sequence, which is given in comparison with mouse insulin.  
 CC growth factor 1 (IGF1) in the exemplification of the present invention.  
 XX Sequence 133 AA;  
 SQ

Query Match 36.0%; Score 31; DB 7; Length 133;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-24; Mismatches 0; Indels 0; Gaps 0;

Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 YGSSIRRAPQGIVDECCFRSCDLRLLEMVC 36  
 Db 53 YGSSIRRAPQGIVDECCFRSCDLRLLEMVC 83

RESULT 12

ADD47095  
 ID ADD47095 standard; protein; 153 AA.  
 XX  
 AC ADD47095;  
 XX DT 29-JAN-2004 (first entry)  
 DE Rat Protein AAA41387, SEQ ID NO 12783.  
 XX Rat Protein AAA41387, SEQ ID NO 12783.  
 XX Rattus norvegicus.  
 OS WO2003016475-A2.  
 XX PD 27-FEB-2003.  
 XX PF 14-AUG-2002; 2002WO-US025765.  
 XX PR 14-AUG-2001; 2001US-0312147P.  
 PR 01-NOV-2001; 2001US-0346322P.  
 PR 26-NOV-2001; 2001US-0333347P.  
 XX PA (GEHO ) GEN HOSPITAL CORP.  
 PA (FARB ) BAYER AG.  
 XX PI Woolf C, Durso D, Befort K, Costigan M;  
 XX DR WPI; 2003-268312/26.  
 XX GENBANK; AA441387.  
 XX New composition comprising two or more isolated polypeptides, useful for  
 PT preparing a medicament for treating pain in an animal.  
 XX PS Claim 1; Page; 1017pp; English.

XX The invention discloses a composition comprising two or more isolated rat  
 CC or human polynucleotides or a polynucleotide which represents a fragment,  
 CC derivative or allelic variation of the nucleic acid sequence. Also  
 CC claimed are a vector comprising the novel polynucleotide, a host cell  
 CC comprising the vector, a method for identifying a nucleotide sequence  
 CC which is differentially regulated in an animal subjected to pain and a  
 CC kit to perform the method, an array, a method for identifying an agent  
 CC that increases or decreases the expression of the polynucleotide sequence  
 CC that is differentially expressed in neuronal tissue of a first animal  
 CC subjected to pain, a method for identifying a compound which regulates  
 CC the expression of a polynucleotide sequence which is differentially  
 CC expressed in an animal subjected to pain, a method for identifying a  
 CC compound that regulates the activity of one or more of the  
 CC polynucleotides, a method for producing a pharmaceutical composition, a  
 CC method for identifying a compound or small molecule that regulates the  
 CC activity in an animal of one or more of the polypeptides given in the  
 CC specification, a method for identifying a compound useful in treating  
 CC pain and a pharmaceutical composition comprising the one or more  
 CC polypeptides or their antibodies. The polynucleotide or the compound that  
 CC modulates its activity is useful for preparing medicament for treating  
 CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction  
 CC injury (CCI), and spared nerve injury (SNI)) in an animal (e.g. gene  
 CC therapy). The sequence presented is a rat protein (shown in Table 2 of  
 CC the specification), which is differentially expressed during pain. Note:  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic form directly from WIPO at  
 CC [http://wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences).  
 XX Sequence 153 AA;

Query Match 36.0%; Score 31; DB 7; Length 153;  
 Best Local Similarity 100.0%; Pred. No. 2e-24; Mismatches 0; Indels 0; Gaps 0;

Db 79 YGSSIRRAPQTGIVDECCFRSCDRLRLMYC 109  
 RESULT 13  
 AAP80433  
 ID AAP80433 standard; protein; 36 AA.  
 XX  
 AC AAP80433;  
 XX  
 DT 09-JAN-2003 (revised)  
 14-SEP-1990 (first entry)  
 XX  
 Sequence of C-terminal portion of mature insulin-like growth factor-I  
 (IGF-I).  
 XX  
 Insulin-like growth factor-I (IGF-I); high level accumulation of protein.  
 XX  
 Unidentified.  
 XX  
 EP288451-A.  
 PN  
 XX  
 PD 26-OCT-1988.  
 XX  
 22-APR-1988; 888BP-00870067.  
 XX  
 23-APR-1987; 87US-00041896.  
 XX  
 PA (MONS ) MONSANTO CO.  
 XX  
 Wong E, Bittner ML;  
 DR  
 XX  
 WPI; 1988-301453/43.  
 XX  
 N-PSDB; AAN80985.  
 XX  
 Producing insulin-like growth factor-I in Gram-negative bacteria - using  
 PT a gene comprising DNA encoding a lamB or ompF signal sequence linked to  
 PT the coding sequence.  
 XX  
 Example 1; Fig 1; 16pp; English.  
 XX  
 The synthetic dsDNA encoding this portion of IGF-I was ligated to  
 CC synthetic dsDNA encoding the N-terminal portion. A synthetic DNA sequence  
 CC encoding the lamB or ompF signal sequence can be operatively joined,  
 using, e.g. ligase to a DNA sequence encoding IGF-I. Expression vectors  
 CC contg. the synthetic gene are then used to transform Gram negative host  
 CC cells such as E. coli. The lamB and ompF signal sequences provide for  
 CC site-specific release of the signal sequence from the IGF-I protein so  
 that the IGF-I protein can be released into and accumulate at relatively  
 CC high levels in the periplasmic space of selected bacteria. (Updated on 09  
 -JAN-2003 to add missing OS field.)  
 XX  
 Sequence 36 AA;  
 Query Match 30.2%; Score 26; DB 1; Length 36;  
 Best Local Similarity 100.0%; Prd. No. 1.2e-19;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OS  
 Ov 11 RRAPOQTGIVDECCFRSCDRLRLMYC 36  
 AC AAP90515;  
 DB 4 RRAPQQTGIVDECCFRSCDRLRLMYC 29  
 SQ Sequence 38 AA;  
 Query Match 30.2%; Score 26; DB 1; Length 38;  
 Best Local Similarity 100.0%; Prd. No. 1.2e-19;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OS  
 Ov 11 RRAPOQTGIVDECCFRSCDRLRLMYC 36  
 AC AAP90515;  
 DB 4 RRAPQQTGIVDECCFRSCDRLRLMYC 29  
 RESULT 15  
 AAP90515  
 ID AAP90515 standard; peptide; 62 AA.  
 XX  
 AC AAP90515;  
 DT 25-MAR-2003 (revised)  
 06-JUN-1990 (first entry)  
 XX  
 DE Derivative of insulin-like growth factor-I (IGF-1).  
 DE  
 KW Insulin-like growth factor-1; IGF-1; growth promoter; tissue restoration;  
 KW disulphide bond.  
 XX  
 OS Unidentified.  
 XX  
 Qy 11 RRAPOQTGIVDECCFRSCDRLRLMYC 36  
 DB 2 RRAPQQTGIVDECCFRSCDRLRLMYC 27  
 RESULT 14  
 AAP50718  
 ID AAP50718 standard; protein; 38 AA.  
 XX  
 AC AAP50718;  
 XX  
 DT 22-JUL-1991 (first entry)  
 XX  
 DE Synthetic sequence of C-terminal end (fragment B) of human f-met-  
 DE somatomedin C (SMC) on pLc24mSMC\_ori.  
 XX

Db 79 YGSSIRRAPQTGIVDECCFRSCDRLRLMYC 109  
 KW Hormone; growth stimulator; expression vector.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO8605810-A.  
 XX  
 PD 09-OCT-1986.  
 XX  
 PP 25-MAR-1986; 86WO-US000579.  
 XX  
 PR 26-MAR-1985; 85GB-00007833.  
 XX  
 PA (BIOJ ) BIOGEN NV.  
 PA (BUELL ) BUELL G N.  
 XX  
 PI Buell G, Movva N;  
 XX  
 DR WPI; 1986-278823/42.  
 DR N-PSDB; AAN60877.  
 XX  
 PT Optical prodn. of polypeptide esp. somatomedin C - replacing portion of N  
 PT -terminal end of DNA Sequence encoding easily assayable polypeptide.  
 XX  
 PR Example; Fig 2; 38pp; English.  
 XX  
 CC The easily assayable polypeptide is e.g. beta-galactosidase,  
 CC galactokinase or drug resistance markers. In a pref. system the DNA  
 CC sequence codes for an SMC-like polypeptide and is selected from the DNA  
 CC inserts of pLc24mSMC1 through pLc24mSMC10  
 XX  
 SQ Sequence 38 AA;  
 Query Match 30.2%; Score 26; DB 1; Length 38;  
 Best Local Similarity 100.0%; Prd. No. 1.2e-19;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OS  
 Ov 11 RRAPOQTGIVDECCFRSCDRLRLMYC 36  
 AC AAP90515;  
 DB 4 RRAPQQTGIVDECCFRSCDRLRLMYC 29  
 RESULT 15  
 AAP90515  
 ID AAP90515 standard; peptide; 62 AA.  
 XX  
 AC AAP90515;  
 DT 25-MAR-2003 (revised)  
 06-JUN-1990 (first entry)  
 XX  
 DE Derivative of insulin-like growth factor-I (IGF-1).  
 DE  
 KW Insulin-like growth factor-1; IGF-1; growth promoter; tissue restoration;  
 KW disulphide bond.  
 XX  
 OS Unidentified.  
 XX  
 Qy 11 RRAPOQTGIVDECCFRSCDRLRLMYC 36  
 DB 2 RRAPQQTGIVDECCFRSCDRLRLMYC 27  
 RESULT 14  
 AAP50718  
 ID AAP50718 standard; protein; 38 AA.  
 XX  
 AC AAP50718;  
 XX  
 DT 22-JUL-1991 (first entry)  
 XX  
 DE Synthetic sequence of C-terminal end (fragment B) of human f-met-  
 DE somatomedin C (SMC) on pLc24mSMC\_ori.  
 XX

Db 79 YGSSIRRAPQTGIVDECCFRSCDRLRLMYC 109  
 KW Hormone; growth stimulator; expression vector.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO8605810-A.  
 XX  
 PD 09-OCT-1986.  
 XX  
 PP 25-MAR-1986; 86WO-US000579.  
 XX  
 PR 26-MAR-1985; 85GB-00007833.  
 XX  
 PA (BIOJ ) BIOGEN NV.  
 PA (BUELL ) BUELL G N.  
 XX  
 PI Buell G, Movva N;  
 XX  
 DR WPI; 1986-278823/42.  
 DR N-PSDB; AAN60877.  
 XX  
 PT Optical prodn. of polypeptide esp. somatomedin C - replacing portion of N  
 PT -terminal end of DNA Sequence encoding easily assayable polypeptide.  
 XX  
 PR Example; Fig 2; 38pp; English.  
 XX  
 CC The easily assayable polypeptide is e.g. beta-galactosidase,  
 CC galactokinase or drug resistance markers. In a pref. system the DNA  
 CC sequence codes for an SMC-like polypeptide and is selected from the DNA  
 CC inserts of pLc24mSMC1 through pLc24mSMC10  
 XX  
 SQ Sequence 38 AA;  
 Query Match 30.2%; Score 26; DB 1; Length 38;  
 Best Local Similarity 100.0%; Prd. No. 1.2e-19;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OS  
 Ov 11 RRAPOQTGIVDECCFRSCDRLRLMYC 36  
 AC AAP90515;  
 DB 4 RRAPQQTGIVDECCFRSCDRLRLMYC 29  
 RESULT 15  
 AAP90515  
 ID AAP90515 standard; peptide; 62 AA.  
 XX  
 AC AAP90515;  
 DT 25-MAR-2003 (revised)  
 06-JUN-1990 (first entry)  
 XX  
 DE Derivative of insulin-like growth factor-I (IGF-1).  
 DE  
 KW Insulin-like growth factor-1; IGF-1; growth promoter; tissue restoration;  
 KW disulphide bond.  
 XX  
 OS Unidentified.  
 XX  
 Qy 11 RRAPOQTGIVDECCFRSCDRLRLMYC 36  
 DB 2 RRAPQQTGIVDECCFRSCDRLRLMYC 27  
 RESULT 14  
 AAP50718  
 ID AAP50718 standard; protein; 38 AA.  
 XX  
 AC AAP50718;  
 XX  
 DT 22-JUL-1991 (first entry)  
 XX  
 DE Synthetic sequence of C-terminal end (fragment B) of human f-met-  
 DE somatomedin C (SMC) on pLc24mSMC\_ori.  
 XX

XX  
 PN JP01063597-A.  
 XX  
 PD 09-MAR-1989.  
 XX  
 PR 03-SEP-1987; 87JP-00221607.  
 XX  
 PR 03-SEP-1987; 87JP-00221607.  
 XX  
 PA (SUMU ) SUMITOMO SEIYAKU KK.  
 DR XX  
 DR WPI; 1989-118308/16.  
 XX  
 PT New insulin-like growth factor-1 derivs. - obtd. by condensn. of  
 PT aminoacid units.  
 XX  
 PS Disclosure; Page 1; 11pp; Japanese.  
 XX  
 CC It is synthesised by amino acid condensation. Its functional groups not  
 concerned in the reaction are protected, and each protecting gp. is  
 removed after the reaction. Disulphide bridging is made between CYS  
 residues by oxidation. It is useful as a growth promoter and tissue  
 restoration agent. It does not have insulin-like activity. (Updated on 25  
 MAR-2003 to correct PA field.)  
 CC  
 XX  
 SQ Sequence 62 AA;  
 Query March 30.2%; Score 26; DB 1; Length 62;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-19;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOQTGIVDECCFRSCLDRRLRLEMYC 36  
 Db 36 RRAPOQTGIVDECCFRSCLDRRLRLEMYC 61  
 RESULT 16  
 AAR36947  
 ID AAR36947 standard; peptide; 67 AA.  
 XX  
 AC AAR36947;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 02-SEP-1993 (first entry)  
 DE INSULIN-like growth factor-I functional derivative.  
 XX  
 KW IGF-I; disorder; treatment; survival; retinal neuronal cells; promotion;  
 KW injury; ageing; disease; photodegeneration; trauma; axotomy;  
 KW neurotoxic-excitatory degeneration; diabetic retinopathy;  
 KW ischemic neuronal degeneration; inherited retinal dystrophy;  
 KW Alzheimer's disease; infantile malignant osteopetrosis; cholestasis;  
 KW ceroid-lipofuscosis.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO9308826-A1.  
 XX  
 PD 13-MAY-1993.  
 XX  
 PR 03-NOV-1992; 92WO-US009443.  
 XX  
 PR 08-NOV-1991; 91US-00790590.  
 XX  
 PR 15-OCT-1992; 92US-00963329.  
 XX  
 PA (CEPH-) CEPHALON INC.  
 XX  
 PT Bozyczko-Coyne D, Neff N, Lewis ME, Iqbal M;  
 DR XX  
 DR WPI; 1993-167389/20.  
 PT Use of IGF-I or IGF-II or their functional derivs. - for treating  
 PT disorders characterised by death and/or dysfunction of retinal cells.  
 XX  
 SQ Sequence 67 AA;  
 Query Match 30.2%; Score 26; DB 2; Length 67;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-19;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 11 RRAPOQTGIVDECCFRSCLDRRLRLEMYC 36  
 Db 33 RRAPOQTGIVDECCFRSCLDRRLRLEMYC 58  
 RESULT 17  
 AAY51168  
 ID AAY51168 standard; protein; 69 AA.  
 XX  
 AC AAY51168;  
 XX  
 DT 31-MAR-2000 (first entry)  
 DE Seq ID 2 used in the isolation of insulin-like growth factor.  
 XX  
 KW Insulin-like growth factor-1; yeast; human; alpha-factor;  
 KW ethanol dehydrogenase.  
 XX  
 OS Unidentified.  
 XX  
 PN CN1229133-A.  
 XX  
 PR 22-SEP-1999.  
 XX  
 PF 18-MAR-1998; 98CN-00106111.  
 XX  
 PA (SHEN-) SHENGAIQI BIOTECHNOLOGY INST BEIJING.  
 XX  
 PT Huang L, zhu Y;  
 XX  
 DR WPI; 2000-087760/08.  
 DR N-PSDB; AAZ44266.  
 XX  
 PT Insulin-like growth factor-1 bacterial expression system and method for  
 PT preparation of insulin-like growth factor-1.  
 XX  
 PS Claim 3; Page 2; 23pp; Chinese.  
 XX  
 This invention describes a novel engineered fungal strain of human  
 insulin-like growth factor-1 and a process for preparing human insulin-  
 like growth factor-1 with the fungus. The engineered fungus is a beer  
 yeast cell, which contains the gene sequence of human insulin-like growth  
 factor-1, which is able to encode 69 amino acids. The 5' end of the gene  
 sequence is connected with an alpha-factor leading peptide sequence,  
 before which a Kozak order is fused. It is then cloned to a position  
 downstream of an ethanol dehydrogenase promoter to form the expression  
 carrier. Finally beer yeast cells are transformed to obtain the genetic  
 engineered fungus strain B-IGF-1, which can secrete human insulin-like  
 growth factor-1. This sequence represents a protein used to illustrate  
 the method of the invention.  
 XX  
 SQ Sequence 69 AA;



PT Human insulin like growth factor I prodn. - by oxidising reductive human  
 PT insulin-like growth factor.  
 XX  
 PS Claim 2; Page 935; Gpp; Japanese.  
 XX  
 CC The production of IGF-I by oxidising reductive human insulin-like  
 CC growth factor in a buffer soln. and separating I-A from the reaction  
 CC soln. is improved by the presence of an organic solvent which can  
 CC dissolve in the buffer soln. in the reaction system. (Updated on 25-MAR-  
 CC 2003 to correct PA field.)  
 XX  
 SQ Sequence 70 AA;

RESULT 21  
 AAP93366  
 ID AAP93366 standard; protein; 70 AA.  
 XX  
 AC AAP93366;  
 XX  
 DT 17-JUL-1990 (first entry)  
 XX  
 DE Analogue IGF122 of human insulin-like growth factor-I (hIGF-I).  
 KW Synthetic gene; human insulin-like growth factor I; IGF122; Analogue B;  
 KW lactation enhancer; growth promoter; wound healing; erythropoiesis.  
 OS Homo sapiens.  
 XX  
 PN EP309050-A.  
 XX  
 PD 29-MAR-1989.  
 XX  
 PR 16-SEP-1988; 88EP-00202032.  
 XX  
 PA (MERK ) MERCK & CO INC.  
 XX  
 PI Applebaum JD, Bayne ML, Cascieri MA;  
 XX  
 DR WPI; 1989-095235/13.  
 DR N-PSDB; AAN90691.  
 XX  
 PT Human insulin-like growth factor analogues - have higher activity due to  
 PT reduced affinity for serum components while retaining affinity to type I  
 PT receptor.  
 XX  
 PS Disclosure; Page; 27pp; English.  
 XX  
 CC It is a synthetic polypeptide analogue of hIGF-I called IGF252 or  
 CC Analogue D. Analogue D retains nearly full activity at the type I IGF  
 CC receptor but does not bind to serum components. It is considerably more  
 active than wild-type hIGF-I. It is highly active as an agent to increase  
 CC the yield and efficiency of milk protein. esp. in cows. It is also used as  
 CC a growth promoter to promote wound healing and to stimulate  
 CC erythropoiesis. It is produced by chemical synthesis or recombinant DNA  
 CC techniques using IGF-I DNA sequences prepd. synthetically, chromosomally  
 CC or by recombinant DNA techniques, to transform bacterial, yeast or tissue  
 CC culture cell lines. A synthetic gene for Analogue D is claimed in Claim  
 CC 16.  
 XX  
 SQ Sequence 70 AA;

Query Match 30.2%; Score 26; DB 1; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 1.9e-19;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 11 RRAPOTGIVDECCFRSCDLRLLEMYC 36  
 DB 36 RRAPOTGIVDECCFRSCDLRLLEMYC 61

RESULT 22  
 AAP94660  
 ID AAP94660 standard; protein; 70 AA.  
 XX  
 AC AAP94660;  
 XX  
 DT 17-JUL-1990 (first entry)  
 XX  
 DE Analogue IGF252 of human insulin-like growth factor-I (hIGF-I).  
 KW Synthetic gene; human insulin-like growth factor I; IGF252; Analogue D;  
 KW lactation enhancer; growth promoter; wound healing; erythropoiesis.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EP309050-A.  
 XX  
 PD 29-MAR-1989.  
 XX  
 PR 16-SEP-1988; 88EP-00202032.  
 XX  
 PA (MERK ) MERCK & CO INC.  
 XX  
 PI Applebaum JD, Bayne ML, Cascieri MA;  
 XX  
 DR WPI; 1989-095235/13.  
 DR N-PSDB; AAN90691.  
 XX  
 PT Human insulin-like growth factor analogues - have higher activity due to  
 PT reduced affinity for serum components while retaining affinity to type I  
 PT receptor.  
 XX  
 PS Disclosure; Page; 27pp; English.  
 XX  
 CC It is a synthetic polypeptide analogue of hIGF-I called IGF252 or  
 CC Analogue D. Analogue D retains nearly full activity at the type I IGF  
 CC receptor but does not bind to serum components. It is considerably more  
 active than wild-type hIGF-I. It is highly active as an agent to increase  
 CC the yield and efficiency of milk protein. esp. in cows. It is also used as  
 CC a growth promoter to promote wound healing and to stimulate  
 CC erythropoiesis. It is produced by chemical synthesis or recombinant DNA  
 CC techniques using IGF-I DNA sequences prepd. synthetically, chromosomally  
 CC or by recombinant DNA techniques, to transform bacterial, yeast or tissue  
 CC culture cell lines. A synthetic gene for Analogue D is claimed in Claim  
 CC 16.  
 XX  
 SQ Sequence 70 AA;

Query Match 30.2%; Score 26; DB 1; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 1.9e-19;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 11 RRAPOTGIVDECCFRSCDLRLLEMYC 36  
 DB 36 RRAPOTGIVDECCFRSCDLRLLEMYC 61

RESULT 23  
 AAP94661  
 ID AAP94661 standard; protein; 70 AA.  
 XX  
 AC AAP94661;

Query Match 30.2%; Score 26; DB 1; Length 70;

SQ Sequence 70 AA;

17-JUL-1990 (first entry)  
 XX Analogue IGF130 of human insulin-like growth factor-I (hIGF-I).  
 XX DE Synthetic gene; human insulin-like growth factor I; IGF130; Analogue C;  
 XX KW lactation enhancer; growth promoter; wound healing; erythropoiesis.  
 XX OS Homo sapiens.  
 XX PN EP309050-A.  
 XX RD 29-MAR-1989.  
 XX PF 16-SEP-1988; 88BP-00202032.  
 XX PR 21-SEP-1987; 87US-00099367.  
 XX PA (MERCK ) MERCK & CO INC.  
 XX PT Applebaum JD, Bayne ML, Cascieri MA;  
 XX DR WPI; 1989-095235/13.  
 XX DR N-PSPDB; RAN90690.  
 XX PT Human insulin-like growth factor analogues - have higher activity due to reduced affinity for serum components while retaining affinity to type I receptor.  
 XX PS Disclosure; Page ?; 27pp; English.  
 XX CC It is a synthetic polypeptide analogue of hIGF-I called IGF130 or Analogue C. Analogue C retains nearly full activity at the type I IGF receptor but does not bind to serum components. It is considerably more active than wild-type hIGF-I. It is highly active as an agent to increase the yield and efficiency of milk prod. esp. in cows. It is also used as a growth promoter, to promote wound healing and to stimulate erythropoiesis. It is produced by chemical synthesis or recombinant DNA techniques using IGF-I DNA sequences to transform bacterial, yeast or tissue culture cell lines. A synthetic gene for Analogue C is claimed in Claim 14  
 XX SQ Sequence 70 AA:  
 Query Match 30.2%; Score 26; DB 1; Length 70;  
 Best Local Similarity 100.0%; Pred. No. 1.9e-19;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 11 RRAAPQGIVDECCPRRSQCDIRRLMEYC 36  
 Db 36 RRAAPQGIVDECCPRRSQCDIRRLMEYC 61  
 RESULT 24  
 ID AAP91502 standard; Peptide; 70 AA.  
 AC AAP91502;  
 XX DT 25-MAR-2003 (revised)  
 DT 06-JUN-1990 (first entry)  
 OS Unidentified.  
 XX New insulin-like growth factor-1 (IGF-I) deriv.  
 XX KW Insulin-like growth factor-I; IGF-I; derivative; disulphide bond; growth promoter; tissue repair.  
 XX OS  
 XX Key Location/Qualifiers  
 XX PH Misc-difference 8  
 XX FT /label= Mutated Ala to His  
 XX KW Bovine somatotropin C; milk production; dairy cows.  
 XX OS Bos taurus.  
 XX Key Location/Qualifiers  
 XX DE Modified mammalian somatomedin C containing metal-chelating sequence.  
 XX KW  
 XX FT Misc-difference 12  
 XX FT /label= Mutated Asp to His  
 XX PN EP409814-A.  
 XX XX PD 23-JAN-1991.  
 XX PP 16-JUL-1990; 90EP-00870109.

XX  
PR 21-JUL-1989; 89US-00383778.  
XX  
PA (MONS ) MONSANTO CO.  
XX  
PT Haymore BL, Bild GS, Krivi GG;  
XX  
DR WPI; 1991-024364/04.  
XX  
PT Variant Proteins and Polypeptide(s) - have enhanced binding affinity for  
PT immobilised-metal affinity matrices.  
XX  
PS Claim 9; Page 23; 27pp; English.  
XX  
CC The two mutations introduce a metal-chelating sequence to tie the  
CC stromatemedin, enhancing the proteins ability to bind to immobilised-  
CC metal affinity matrix, useful in fractionating the variant proteins. DNA  
CC encoding the sequence is also claimed but not given in the specification.  
CC Wild type sequence was obtained from the International Journal of Peptide  
CC and Protein Resources 36(4)356-61. (Updated on 09-JAN-2003 to add missing  
CC OS field.)  
XX  
SQ Sequence 70 AA;

Query Match 30.2%; Score 26; DB 2; Length 70;  
Best Local Similarity 100.0%; Pred. No. 1.9e-19;  
Matches 26; Conservatve 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 RRAQQTGIVDECCFRSCDLRLLENYC 36  
Db 36 RRAQQTGIVDECCFRSCDLRLLENYC 61

Search completed: March 3, 2004, 12:01:19  
Job time : 55 secs